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Abstract 
Human papillomaviruses (HPVs) are the causative agent in cervical cancer and 
have been implicated in a rising number of head and neck cancers in both men 
and women. There are two licensed prophylactic vaccines, both target HPV 16 
and 18, the two most common, oncogenic types. However, there are no antiviral 
drugs for the treatment of HPV infection and disease. Papillomaviruses encode 
two DNA binding proteins, E1 and E2, which interact with host cell proteins to 
induce replication. Two essential cellular factors for viral transcription and 
replication are TopBP1 and Brd4. TopBP1 is a known interactor of HPV16 E2, and 
is essential for the initiation of DNA replication in eukaryotic cells. Previous 
studies with E2 mutants have shown that Brd4 is essential for transactivation 
properties of E2. Brd4 has also been implicated in the regulation of E1-E2 
mediated viral DNA replication. However, the role of E2 in regulating the host 
genome has been less well studied. As attempts at developing a therapeutic 
vaccine have failed, and current small molecule inhibitors which block the 
interaction of replication factors, E1 and E2, are not effective across all HPV 
types due to slight differences in E1-E2 interactions, Brd4 and TopBP1 may 
present themselves as pan-type specific targets. Blocking the interaction of the 
host proteins Brd4 and TopBP1 with viral E2 is a viable target for HPV related 
cancers. This thesis set out to understand how E2 interacts with TopBP1 and Brd4 
to regulate the cellular genome as well as the viral genome, to better 
understand how to terminate the viral life cycle. Two E2 mutants, E2-TopBP1 and 
E2-Brd4, which fail to bind TopBP1 and Brd4 respectively, were made to address 
this question. 
Functional assays with E2 wildtype and the two E2 mutants have enhanced our 
understanding of viral replication. TopBP1 and Brd4 are present at the viral 
origin of replication in an E1-E2 dependent manner, and optimal initiation of DNA 
replication is dependent on the interaction with E2. TopBP1 and Brd4 locate into 
E1-E2 foci and shRNA targeting these proteins destroys these replication foci. 
However, this has no effect on E1-E2 mediated levels of DNA replication. The 
results suggest a role for TopBP1 and Brd4 in the initiation of HPV16 E1-E2 DNA 
replication but not continuing replication, which may be mediated by alternative 
processes such as rolling circle amplification and/or homologous recombination. 
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To address the question of how E2 regulates the host, we stably expressed 
HPV16 and 18E2 wildtype, E2-TopBP1 and E2-Brd4, in U2OS cells, a p53 positive cell 
line that tolerates E2 expression. These cells were used in human exon array 
analysis, to determine which host cellular genes E2 regulates. We determined 
that HPV16 and 18E2 can regulate cellular genes and a failure to bind either 
TopBP1 or Brd4 increases the number of cellular genes altered. Overall the re-
sults suggest that the levels of TopBP1 and Brd4, which can interact, regulate E2 
function and therefore could regulate viral infection. 
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Chapter 1 – Introduction 
 History of HPV 
Papillomaviruses are small DNA viruses that infect the differentiating epithe-
lium, their characteristic double-stranded DNA structure has been known since 
1965 (Crawford 1965, KLUG, FINCH 1965). Papillomavirus genomes have been 
isolated and characterised from reptiles (Herbst, Lenz et al. 2009) , birds  (Te-
rai, DeSalle et al. 2002), marsupials   (Bennett, Reiss et al. 2010) and multiple 
other mammalian species (for recent review see  (Bernard, Burk et al. 2010) sug-
gesting an evolutionary history spanning more than 300 million years (Herbst, 
Lenz et al. 2009) .   
In the 1970’s it became apparent that there were various sub-types of papillo-
mavirus, due to the availability of molecular techniques. It was established that 
there were several HPV genotypes; some caused nongenital cutaneous warts 
(Gissman et al. 1977, Orth et al. 1977), skin lesions of epidermodysplasia verru-
ciformis (EV) (Orth, Jablonska et al. 1978), and other types were responsible for 
genital warts (Gissman and Zur Huasen 1988,(Orth, Favre et al. 1978)).The spec-
trum of HPV related diseases has accompanied humans throughout evolution, the 
HPV types we see in the human population today constitute a set of viral ge-
nomes that have co-evolved alongside us (Burk, Harari et al. 2013). Papilloma-
viruses manipulate the host enzymatic machinery to replicate their genomes, 
causing the lowest rate of mutations or errors possible. However, occasionally 
errors occur and these errors have been selected for over time, and are respon-
sible for the differences in papillomavirus genomes and the large heterogeneity 
of related viral variants detected today (Bernard, Calleja-Macias et al. 2006)  
(Gottschling, Stamatakis et al. 2007).  There are over 160 types of papilloma-
virus, and the differences in papillomaviruses can be classified by the varying ge-
netic distances between viral genomes (Bernard, Burk et al. 2010, de Villiers, 
Fauquet et al. 2004). Additionally, a distinct human papillomavirus (HPV) type is 
defined by at least a 10% difference in the DNA sequence of the L1 open reading 
frame (ORF) of that of any other characterised type (Bernard, Burk et al. 2010, 
de Villiers, Fauquet et al. 2004). 
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Italian physician, Rigoni-Stern (1842) made the first link between sexual contact 
and cervical cancer.  He observed a higher frequency of cervical cancer in mar-
ried women, widows and prostitutes, and an extremely rare occurrence in virgins 
and nuns (Rigoni-Stern 1842). 100 years later, Dr. George Papanicolaou estab-
lished the practice of pap smears in the 1940s as a screening method to detect 
precancerous and cancerous cervical lesions. However, it was unknown what the 
cause of cervical cancer was. In the early 1970’s the German virologist Harold 
zur Hausen gained knowledge from medical reports that documented rare events 
of malignant genital warts (condylomata acuminta) developing into squamous 
cell carcinomas (zur Hausen 1977). Previous research from Richard Shope in the 
1930’s showed that infection with papillomavirus caused warts and cancers in 
rabbits, leading Zur Hausen to believe a similar virus may be responsible for cer-
vical cancer (Shope, Hurst 1933). Originally, Herpes simplex virus type 2 was the 
viral candidate for the disease, until all attempts to find the viral DNA in cervi-
cal cancer biopsies were found to be negative (zur Hausen, Schulte-Holthausen 
et al. 1974), so this boosted the prospects of papillomavirus being the viral can-
didate (zur Hausen, Meinhof et al. 1974). Zur Hausen’s team began the search in 
human genital warts, and in 1982 HPV 6 was found in biopsies from three inva-
sively growing giant condylomata acuminta (Buschke-Lowenstein tumours), these 
tumours are non-metastasising. This was additionally backed up by work from 
Zachow et al in 1982 (Zachow, Ostrow et al. 1982). In the same year, endermo-
dyplasia verruciforms HPV-related bands were demonstrated in some cervical 
cancer biopsies. This was most likely HPV 10, and has not since been identified 
in cervical cancer biopsies (Green, Brackmann et al. 1982). HPV 6 was never 
found in any cervical cancer samples, but it did lead to the discovery of HPV 11. 
Southern blot hybridisations with HPV 11 DNA allowed for the detection of this 
DNA in one of 24 cervical cancer samples tested. Using HPV 11 as a probe it was 
then possible to identify a novel HPV type, HPV 16, which was found to be pre-
sent in almost half of all cervical cancers (Durst, Gissmann et al. 1983).  Closely 
following the discovery of HPV 16, HPV 18 DNA was identified from cervical can-
cer biopsies and additionally in cervical cancer derived cell lines, and was de-
tected in around one in five cervical cancer samples (Boshart, Gissmann et al. 
1984). Following these primary observations, it was possible to demonstrate 
HPV16 DNA in typical precursor lesions of anogenital cancer, (Ikenberg, 
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Gissmann et al. 1983) . A year later papillomavirus was also identified in intraep-
ithelial neoplasias (Crum, Ikenberg et al. 1984). 
In the next decade following these primary findings more HPV types were found 
in cervical cancer biopsies. In 1995 the International Biological Study on Cervical 
Cancer group was established to understand how the various HPV types affect 
the human population (Bosch, Manos et al. 1995). Cervical cancer samples were 
taken from a collective 22 countries; they found HPV in nine out of every ten 
cervical cancer samples (93%).  In 1999, all of the samples were re-tested and 
this percentage was amended to 99.7%. This gave the strongest evidence to date 
of a causal link and a specific cancer type (Walboomers, Jacobs et al. 1999). 
 HPV involvement in cancer  
HPV accounts for 30% of all cancers associated with infections (de Martel, Ferlay 
et al. 2012)  and are associated with cervical carcinoma head and neck cancers 
and other cancers. There are about 15 oncogenic/ high-risk types of HPV that in-
fect the genital tract. Two most common are HPV 16 and 18. (Stanley 2008). In 
many developed countries the prevalence of HPV infections in young women is as 
high as 40-80% and the lifetime probability of ever encountering HPV is as high 
as 80-90% (Bosch, Broker et al. 2013). Most women will naturally clear the infec-
tion, however middle aged women who still carry the virus are at higher risk of 
developing cancer. An estimated 4-10% of middle aged women are at highest 
risk. The time period between HPV infection and cancer is about 2 to 4 decades. 
This makes the initiating infections and precursor lesions of cervical cancer an 
appropriate target for screening and early detection of the disease. 
1.2.1 Cervical cancer  
As detailed in 1.1, HPV was found to be a causative agent in cervical cancer. 
There were more than 530,000 cases of cervical cancer in 2008, 85% of those 
were in developing countries. The mortality: incidence ratio was 52% and there 
were 275,000 deaths in 2008, 88% of them were in developing countries (Ag-
garwal, Batra et al. 2011) (International Agency for Research on Cancer, GLO-
BOCAN database, 2008). The prevention of cervical cancer requires a multi-
pronged approach involving primary, secondary and tertiary prevention. Primary 
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prevention includes better sex education about safe sexual practices, and human 
papillomavirus vaccination, which shall be discussed in more detail in Chapter 
1.3(Centres for Disease Control and Prevention).   
Secondary prevention involves screening asymptomatic patients or carrying out 
definitive tests in symptomatic patients or screen positive patients to pick up 
precancerous lesions before they turn into cancer. Implementing screening pro-
grammes reduces the incidence of invasive cervical cancer and cancer deaths.  
There are various screening methods for pre-invasive disease such as: cervical 
cytology (both conventional and liquid based); direct visual inspection (DVI); di-
rect visual inspection using 3-5% acetic acid (VIA), visual inspection using 3-5% 
acetic acid and magnification (VIAM), visual inspection using Lugol’s iodine 
(VILI); HPV DNA testing; speculoscopy; and polar probes. Cervical cytology is the 
most common and globally preferred method for screening. However, the down-
fall of this method is the frequency of testing and the coverage of the popula-
tion (Aggarwal 2014). For liquid based cytology (LBC) Pap smear, a cytobrush 
which rotates 360 degrees five times around the cervix exfoliates the cells. The 
exfoliated cells are then mixed in a proprietary solution which reduces specimen 
inadequacy by 80%. However, this proves to be more expensive than traditional 
Pap tests. 
HPV DNA testing is also now available for detecting the presence of HPV DNA. 
There are currently two types of tests available; one is a nucleic acid hybridisa-
tion assay with signal amplification for the qualitative detection of high risk HPV 
types in cervical specimens (Digene Hybrid Capture 2 High Risk DNA Test (Qi-
agen, Digene Corporation); Cervista HPV HR Test (Thirdwave Technologies)); the 
other test is a polymerase chain reaction based assay (HPV DNA Nested Polymer-
ase Chain Reaction Detection Kit (HiFi DNA Tech). 
More recently, another test is now becoming established which detects levels of 
HPV E6/E7 mRNA (PreTect HPV Proofer assay (Norchip) and APTIMA assay (Ho-
logic)). This is a useful assay for gauging the severity of a lesion and offers a pre-
dictive method of whether it is likely to progress to cancer. 
Tertiary prevention involves vital follow up screens and treatment of women 
who are in the precancerous stage. Cervical intraepithelial neoplasia (CIN) is a 
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premalignant lesion that can exist in three stages: CIN1, CIN2, or CIN3 (WHO 
treatment and prevention). CIN2 and CIN3 are collectively known as CIN2+, and 
every year 1-2% of women will have CIN2+ which has the potential to progress to 
cervical cancer. However, in women with HIV this rate is even higher, it in-
creases to 10%. When women test positive during routine Pap smears, the grade 
of CIN is then determined based on colposcopy, biopsy of suspicious lesions, and 
then treatment only when CIN2+ lesions have been confirmed. Treatment in-
volves cryotherapy or large loop excision of the transformation zone (LLETZ), 
which can both be performed in an out patient setting. LLETZ is the most effec-
tive treatment as it can remove the entire transformation zone as well as a le-
sion extending more than 1cm into the endocervical canal, which can be used 
for histological analysis. Studies have suggested that the deregulation of E6 and 
E7 expression may be a critical event in determining neoplastic grade, even in 
the absence of genome integration (Isaacson Wechsler, Wang et al. 2012). Neo-
plastic grade is determined by the extent of which basal-like cells extend into 
suprabasal epithelial layers (Jenkins 2007). 
In HPV related viral cancers, a characteristic of the cells is integration of the vi-
ral genome. Key characteristics of this integration are tandem repeats from sin-
gle copies to several hundreds of copies of the viral DNA at various random loca-
tions throughout the cellular genome. Only a small segment of the viral genome 
is integrated into the host, this segment contains the regulatory control region 
or alternatively known as the “Long Control Region” (LCR), and part of the early 
region, which includes the open reading frames of E6 and E7, which are the two 
main oncogenes of HPV.  These viral oncogenes are transcribed in at least two 
messenger RNAs initiated at a unique promoter contained within the viral regula-
tory region. The viral regulatory region for HPV16 and HPV31 is P97 and for 
HPV18 it is P105, given their names after the genomic sequence with number 
corresponding to 5’ end of the E6 and E7 messenger RNA. These regulatory re-
gions are located immediately upstream of the E6 open reading frame. In addi-
tion to this, another characteristic of integration is the disruption of the E1 
and/or E2 open reading frames which are downstream of E7. This integration 
event leads to a disruption of viral DNA replication. Disruption of E2 leads to 
transcriptional activation of E6 and E7 oncogenes in cervical cancer (Thierry, 
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Yaniv 1987).  The transcription of E6 and E7 in cervical carcinoma is controlled 
by cellular factors, due to this disruption in the viral transcription factor, E2. 
1.2.2 Head and neck cancer 
Men are also at risk of developing HPV positive cancers of the anogenital tract 
and oropharynx (Brown, White 2010). HPV 16 is the most common high-risk HPV 
detected in oropharyngeal squamous cell carcinoma (OSCC), this is the only head 
and neck site with a definite etiological association between persistent high-risk 
HPV infection. HPV in head and neck cancer probably utilises the same pathways 
in epithelial cell transformation as established for genital cancer (Rautava, Syr-
janen 2012) 
As early as the 1940s/50s reports of malignant conversion of recurrent laryngeal 
papillomas into squamous cell carcinomas (zur Hausen 1977). The demonstration 
of papillomavirus antigens in premalignant lesions of the oropharynx provided 
first hints for a possible role of papillomavirus infections in oral squamous cell 
carcinomas (Syrjanen, Pyrhonen et al. 1983). The first definitive evidence of the 
involvement of high risk HPV types in oropharyngeal carcinomas came about in 
1985 (Loning, Ikenberg et al. 1985). HPV16 was found in three out of 13 carcino-
mas tested, and one was found to be HPV 11 positive, and other contained HPV 
27 DNA. In 2006 Weinberger et al (Weinberger, Yu et al. 2006)     demonstrated 
that out of 61% of HPV 16-positive oropharyngeal carcinomas 23% had a similar 
expression pattern of p16 as observed in cervical cancers. It has been postulated 
that a conservative estimate of about 70% of oropharyngeal cancers are caused 
by high-risk HPV types (Figure 1.1). 
Patients who have HPV related head and neck cancers are generally younger 
than those with tobacco related cancers in a similar region.  Patients have the 
same risk factors as those associated with cervical cancer, which include a high 
number of sexual partners, an early age of first sexual encounter, and prior sex-
ually transmitted infections (D'Souza, Kreimer et al. 2007, Gillison, Koch et al. 
1999). In the United States, HNSCC is the sixth most common cancer (American 
cancer society). It has been shown in clinical trials that HPV+ patients respond 
better to treatment than those who have HPV- cancers (Rischin, Young et al. 
2010, Posner, Lorch et al. 2011, Nichols, Faquin et al. 2009, Hong, Dobbins et al. 
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2010, Ang, Harris et al. 2010). The differences in the responses to treatment 
may be in part due to molecular differences between the HPV+ and HPV- cancers 
(Strati, Pitot et al. 2006, Hafkamp, Speel et al. 2003, Boyle, Hakim et al. 1993). 
Currently the treatment given to patients with HPV+ and HPV- cancers is the 
same (Mehra, Ang et al. 2012, Mehanna, Olaleye et al. 2012). However, a change 
in the clinical treatment of the disease within clinical oncology will be tailored 
dependent on HPV status of the cancer. 
1.2.3 Anal cancer 
Anal cancer is uncommon, with age standard incidence rates mostly between 1 
and 2 per 100,000 per year. In approximately 80-90% of anal SCC cases high-risk 
HPV can be detected, HPV16 is accountable for about 90% of HPV positive cases 
of anal SCC (Figure 1.1) (Grulich, Poynten et al. 2012). Studies have revealed 
that women and men who have sex with men commonly have anal HPV infec-
tions, particularly in HIV-infected individuals. Clearance of this infection is com-
mon; however, indviduals who show persistant infection are generally those who 
are HIV-infected. HIV is strongly linked to the persistence and development of 
anal intraepithelial neoplasia (AIN). The studies that have been conducted in this 
field show that high-grade AIN is precursor to invasive anal cancer. Women, who 
have HPV-associated lesions, including CIN3+ and vulvar cancer, also have higher 
rates of anal cancer (Bosch, Broker et al. 2013).  
Anal cancer can be treated using electofulgaration, infrared coagulation, or la-
ser ablation. Those who have high-grade AIN where there may be microinvasive 
disease or cancer may be treated by excision. Clinical trials using topical thera-
pies for the treatment of high-grade AIN such as 5-fluoruracil (5-FU), imiquimod, 
and topical cidofvoir have all shown to be promising treatment options (Bosch, 
Broker et al. 2013). 
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1.2.4 Penile cancer 
Penile cancer is rare in developed nations. In the United States, the incidence is 
less than 1 per 1000,000 men per year (National Cancer Institute). HPV infection 
has been associated with penile cancer (Figure 1.1) (Del Mistro, Chieco Bianchi 
2001, Griffiths, Mellon 1999, Poblet, Alfaro et al. 1999, Frisch, van den Brule et 
al. 1996), and some observational studies have shown a lower prevalence in men 
who have been circumcised (Castellsague, Bosch et al. 2002). A higher number 
of sexual partners in a male’s lifetime contributes to the likelihood of being in-
fected with high-risk oncogenic HPV, the clearance of which decreases in men 
with higher numbers of sexual partners, and this is more rapid with increasing 
age. Surgical treatment is the best option for local disease, whereas regional dis-
ease is usually treated with radical inguinal lymphadenectomy if reselectable. In 
the case of nonreselectable regional disease and metastases, neoadjuvant cis-
platinum-based regimens are the best option. Topical chemotherapy agents such 
as 5-FU and imiquimod have also proven to be moderately effective first-line 
therapy for penile cancer. 
1.2.5 Vulvar cancer 
Vulvar cancer is rare. It is estimated that approximately 3,100 new cases of HPV-
associated vulvar cancer are diagnosed in the United States each year (Figure 
1.1) (Centers for Disease Control and Prevention). Vulvar squamous cell carci-
noma (VSCC) is responsible for greater than 90% of malignant tumours of the 
vulva (Judson, Habermann et al. 2006). Two atiopathogenic pathways for the de-
velopment of VSCC, one is associated with HPV and one is not (Toki, Kurman et 
al. 1991, Kurman, Toki et al. 1993, Fox, Wells 2003, McCluggage 2009) . These 
should be considered two distinct disease types as they both have different epi-
demiological, clinical, pathological and molecular characteristics. 
VSCCs originate in intraepithelial lesions, and precede the development of inva-
sive cancer. VSCC found adjacent to epithelial disorders in around 50-70% of pa-
tients. The association of HPV with cases of VSCC varies from 15%-79% in various 
clinical reports (van de Nieuwenhof, van Kempen et al. 2009, Alonso, Fuste et 
al. 2011, Riethdorf, Neffen et al. 2004, Pinto, Lin et al. 2000, Carter, Madeleine 
et al. 2001, Gargano, Wilkinson et al. 2012, Tsimplaki, Argyri et al. 2012, Monk, 
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Burger et al. 1995, Kim, Thomas et al. 1996, Kowalewska, Szkoda et al. 2010, 
Garland, Hernandez-Avila et al. 2007, Trimble, Hildesheim et al. 1996).  
Vuvlvar intraepithelial neoplasia (VIN) is a term used to designate precursors of 
VSCC. The presence of HPV DNA in VIN has been detected in 52-100% of the le-
sions (van de Nieuwenhof, van Kempen et al. 2009, Garland, Hernandez-Avila et 
al. 2007, Trimble, Hildesheim et al. 1996, Smith, Backes et al. 2009). It has been 
found that around one-fifth of all VSCCs and over four-fifths of VINs are associ-
ated with HPV infection. Despite the strong link with HPV and VINS, most VSCCs 
arise independently of viral infection. HPV16 is the most common HPV type 
found in both VIN and VSCCs, although other types are found too, such as 18, 31, 
33 and 45 (Santos, Landolfi et al. 2006, Bonvicini, Venturoli et al. 2005). The 
vaccine has played a vital role in reducing the incidence of VIN in young women 
(Garland, Hernandez-Avila et al. 2007). Additionally, there is evidence that a 
vaccination with synthetic long peptides from the HPV16 oncoproteins E6 and E7 
has a therapeutic effect on HPV16 positive VIN (Kenter, Welters et al. 2009). 
VIN is treated by surgical excision for unifocal disease and lesions which are 
likely to become invasive. However, this is not optimal for treating multifocal 
disease. Instead, topical agent imiquimod, and photodynamic therapy have both 
shown some useful efficacy (~50-60%) in the treatment of high-grade VIN. Vuvl-
var cancers are usually treated with surgery for localised disease and a combina-
tion of surgery and chemoradiation for nodal metastases. In the case of a very 
advanced vulval cancer, chemoradiation is the preferred therapy (Bosch, Broker 
et al. 2013). 
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Figure 1.1 
 
Figure 1.1: Incidence of HPV related cancers. 
The table presents the average number of cancers in sites where HPV is often 
found, and the percentage probably caused by HPV per year. 
The graph displays the probable number of HPV related cancer per year in various 
cancers sites. 
(Figure taken from CDC website- Data are all from States meeting USCS publication criteria 
for all years 2006-2010 and cover about 94.8% of the U.S population.) 
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 HPV vaccine 
Evidence from some of the earliest work carried out on papillomaviruses in the 
1930’s by Shope, showed that neautralisising antibodies were protective (Shope 
1937). In these experiments, Shope systematically infected rabbits with the cot-
tontail rabbit papillomavirus (CRPV) by directly injecting the virus into the mus-
cle, papillomas did not arise on the skin of the challenged rabbits and neutralis-
ing antibodies were generated. The rabbits in these experiments were com-
pletely resistant to further attempts for the papillomavirus to challenge the epi-
thelium by abrasion. This information suggested that generating neutralising an-
tibodies to viral capsid proteins would be an effective prophylactic vaccine 
strategy. 
Work was also done with the Bovine papillomavirus (BPV), both prophylactic and 
therapeutic vaccines were developed against BPV-4 (Campo 1994, Campo, Jar-
rett 1994) These vaccines prevent viral infection and induce early regression of 
papillomavirus respectively. It was shown that anti-L2 antibodies are responsible 
for virus neutralisation (Campo, O'Neil et al. 1997). The minor capsid protein L2 
and the N terminus of L2 (L2a, amino acids 11-200) are sufficient for protection 
against infection (Chandrachud, Grindlay et al. 1995). 
1.3.1 Clinical trials 
In 2002 a pilot controlled clinical trial of a HPV vaccine for HPV 16 only was car-
ried out (Koutsky, Ault et al. 2002). This gave evidence that the vaccine may 
prevent HPV16 related (cervical cancer) in women who have not come into con-
tact with the virus yet. The trial initially included 2392 women with a median 
age of 20 years old, 1194 of which received the vaccine and 1198 were given a 
placebo. Out of these original women included in the study, only 1533 (64 % of 
the original study cohort) were included in the primary analysis. This exclusion 
was due largely in part to evidence of HPV-16 infection at enrolment. Women in 
the study were monitored for approximately 17.4 months after receiving the full 
three doses of the vaccination. The data provided from this trial showed that 
this vaccine is a highly efficacious prophylactic against HPV infection. During the 
clinical trial, 41 women who received the placebo vaccine displayed new cases 
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of HPV-16 infection, including 9 cases HPV16-related cervical intraepithelial neo-
plasia. Therefore, the HPV16 vaccine was effective. 99.7 percent of the women 
in the vaccine study group seroconverted. The geometric mean titer of HPV16 
antibodies at month 7 of the trial was 58.7 times higher than the women with 
serological evidence of natural infection with HPV16 at enrolment. Overall, this 
study provided strong evidence that this vaccine reduces the incidence of HPV16 
infections and related cervical intraepithelial neoplasia, and that immunising 
HPV16 negative women may reduce their risk of cervical cancer. 
Subsequent to this initial study, two prophylactic vaccines were developed that 
offer protection against multiple HPV types. A bivalent vaccine called Cervarix 
(GlaxoSmithKline Biologicals, Rixensart, Belgium), which is a bivalent vaccine 
targeting HPV 16 and 18. A quadravalent vaccine called Gardasil (Merck and Co., 
Inc, Whitehouse Station, NJ, USA) targets low-risk HPV types, 6 and 11, in addi-
tion to high-risk HPV16 and 18. HPV 6 and 11 are responsible for around 90% of 
anogenital warts (AGW). The viral like particles for Cervarix are produced in in-
sect cells infected with L1 recombinant insect virus vectors (Inglis, Shaw et al. 
2006), and Gardasil VLPs are produced in bakers yeast (Saccharomyces ceravisae) 
expressing L1 (Shi, Sings et al. 2007). 
Two phase III studies, FUTUREI (Garland, Hernandez-Avila et al. 2007) and FU-
TURE II (FUTURE II Study Group 2007) , evaluated Gardasil. Two trials evaluated 
Cervarix, PATRICIA (Paavonen, Jenkins et al. 2007) and the Costa Rica HPV vac-
cine trial (CVT). Women in the trials were in the 15-26 age range, and all trials 
were of relatively large participant size (5,500-18,500 vaccinees), and blinded, 
randomised and controlled. The trials were company sponsored with the excep-
tion of the CVT, which was a U.S government sponsored community-based trial, 
centered in the Guanacaste province of Costa Rica (Herrero, Hildesheim et al. 
2008) . Company lead trials were carried out in Europe, North, Central and South 
America, and Asia Pacific, including Australia. Participants were restricted for 
selection criteria by their number of sexual partners in order to limit the number 
of women included in the trial who may have prevalent infections and/or preva-
lent genital lesions at enrolment. This was a key point as the vaccine trial set 
out to see if this was a valuable prophylactic for HPV related infection and can-
cer. The only exception to this was within the CVT and the Finnish participants 
in the PATRICIA trials, where no such restriction was placed upon the vacinees. 
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However, in these phase three trials women were not excluded for having a pre-
exisiting infection at enrolment, as measured by the presence of genital tract 
HPV DNA by sensitive PCR-based techniques. Nor were women excluded from the 
trial if they had been exposed to HPV prior to the trial, as measured by serum 
antibodies reactive to the VLPs, or in some cases by finding an abnormal cervical 
cytology at baseline. The reasoning behind this decision was to evaluate the 
prophylactic efficacy, safety and immunogenicity of the vaccine in women who 
had prior or current exposure to HPV, and also that the vaccine may have thera-
peutic activity. 
The trials of Gardasil and Cervarix provided evidence that they protected against 
HPV-16 related types (A9 species), (Brown, Kjaer et al. 2009, Wheeler, Cas-
tellsague et al. 2012) . Cervarix demonstrated significant efficacy against HPV31, 
33 and 52, whereas Gardasil only showed significant efficacy against HPV31. Cer-
varix also provided relatively strong protection against HPV45 (79.0%), a HPV18 –
related A7 species. Partial protection against HPV45 and HPV31 was also shown 
in the CVT trial of Cervarix (Herrero, Wacholder et al. 2011). The results gath-
ered by the CVT and PATRICIA trial were in agreement.  
Overall, from these clinical trials it was concluded that the vaccine is safe, with 
only minor injection-site symptoms. Both Gardasil and Cervarix are highly immu-
nogenic, inducing high peak titers of antibodies in virtually all vaccines, and 
measurable serum antibody responses that persist for years. They offer protec-
tion from anogenital infection and subsequent neoplastic disease by the types in 
the vaccine. The vaccines also induce-partial cross protection against non-vac-
cine types, which are phylogenitically related. The vaccines do not work thera-
peutically to induce regression or prevent progression of established infections. 
Currently, the duration of the protection offered by the vaccine is unknown. The 
Cervarix vaccine has shown continued persistence of serum antibodies for up to 
8.4 years (Roteli-Martins, Naud et al. 2012) without significant drop in titer af-
ter2 years gives hope for the vaccine having continued strong efficacy through 
the peal years of anogential HPV acquisition and perhaps lifelong. 
Work published by David et al has predicted that the mean HPV16 and 18 anti-
body levels will remain well above those associated with a natural HPV infection 
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for a minimum of 20 years for the bivalent vaccine (David, Van Herck et al. 
2009) . Another paper estimates that the duration of detection of vaccine-in-
duced anti-HPV 16 antibodies ranging from 12 years to near life-long in a major-
ity of women following vaccination with HPV16 vaccine (Fraser, Tomassini et al. 
2007). 
1.3.2 Biology of the HPV vaccine 
Since 2006, the bivalent and quadravalent vaccines have been licensed and 
available in over 100 countries. These vaccines are made of HPV L1 virus-like 
particle (VLP) that induce high concentrations of neutralising antibodies to L1 
(Harper, Franco et al. 2004)  (Villa, Costa et al. 2006). The HPV vaccine is deliv-
ered intramuscularly, as this leads to a rapid access to the local lymph nodes, 
which in turn circumvents the immune avoidance strategies of the viral intraepi-
thelial infectious cycle. VLPS induce potent antibody responses in the absence of 
adjuvant due to their ability to activate both the innate and adaptive immune 
responses. (Harro, Pang et al. 2001) VLPs are rapidly bound by myeloid DCs and 
B lymphocytes, and signal via the toll-like receptor (TLR) dependent pathway 
MYD88, which is essential for B-cell activation and antibody generation in mice 
and probably humans. (Yang, Murillo et al. 2004) (Yan, Peng et al. 2005). Both of 
the vaccines that are available commercially have been formulated with adju-
vants, these are compounds that enhance immunogenicity. In the quadravalent 
vaccine, there are VLPs for HPV 6, 11, 16 and 18 and additionally there is propri-
etry adjuvant amorphous aluminium hydroxysulfate (AAHS).  This proprietry ad-
juvant has been used in many vaccines already on the market without any side 
effects. The bivalent vaccine contains L1 VLP s for HPV 16 and 18. Plus the adju-
vant system AS04, which is composed of aluminium hydroxide and monophos-
phoryl lipid A (MPL), a modified endotoxin and agonist of TLR4. Immunity pro-
vided by vaccines depends largely on the activation of the appropriate antigen-
specific CD4+Th2 cells that “help” antigen primed B-cells differentiate into anti-
body secreting plasma cells and memory B-cells. Under normal circumstances 
with papillomaviruses infect the epithelium, the differentiation program de-
pends upon signals generated by the recognition of microbial products by pat-
tern recognition receptors such as TLRs expressed on the APCs. The vaccine 
works by triggering these signals via the adjuvants in them, the adjuvants trigger 
the innate immune responses that bias to an appropriate adaptive response. 
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1.3.3 Implementing HPV vaccination 
Within the U.S, the President’s Cancer Panel released a report urging for there 
to a greater uptake of the HPV vaccine. This letter to the president outlined 
three goals to make this possible within the U.S; (1) Reduce missed clinical op-
portunities to recommend and administer HPV vaccines, (2) Increase parents’, 
caregivers’, and adolescents’ acceptance of HPV vaccines, (3) Maximise access 
to HPV vaccination services (President’s cancer panel). 
All of these steps are in agreement with the published guidelines recommended 
for a greater communication and uptake of the vaccine published by WHO. At 
the end of 2012, 45 countries had introduced a HPV vaccination program (WHO). 
However, most of these countries are developed and have the finances to imple-
ment these vaccination programmes.  There is still a great need for developing 
countries to introduce HPV vaccine as part of a national public health strategy, 
as the greatest burden of cervical cancer is within these countries. 
In 2012, Europe saw a vast increase in the number of countries introducing the 
vaccine the number went from 3 in 2007 to 22 in the beginning of 2012. There 
are differences in how the vaccine is provided to the public, some countries of-
fer adolescent girls the vaccine at school, whereas other only provide it through 
health centres and primary care providers. The Global Alliance for Vaccines and 
Immunization (GAVI) decision to support HPV vaccination in low income coun-
tries should increase the implementation of the vaccine, as this is a very costly 
vaccination and not readily available otherwise. There are also benefits of vac-
cinating males with the HPV vaccine, such as direct benefits to the vaccinated 
males themselves as it will prevent male related HPV cancers, also indirect ben-
efits to non-vaccinated females and males via increased herd immunity, and also 
protection of men who have sex with men. 
The World Health Organisation (WHO) has published a second guidebook “Com-
prehensive cervical cancer control” in December 2014, which outlines the strate-
gies required to prevent and control cervical cancer. The main points highlighted 
to achieve this are; vaccinate 9 to 13 year old girls with two doses of HPV vac-
cine to prevent infection with HPV. Two doses of the vaccine have been shown 
to be just as effective as the three dose schedule, which will make the vaccine 
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more cost effective. HPV testing is recommended for screening women for the 
prevention of cervical cancer. Due to the discovery of a causal link between HPV 
and cervical cancer, molecular tests were developed to identify women who 
have HPV infections that may lead to cervical precancerious lesions. This testing 
method can reduce the incidence of cervical cancer within 4-5 years and reduce 
the mortality due to cervical cancer within 8 years, compared to cytological 
methods (Bosch, Broker et al. 2013). Following a negative result to testing, 
women are not required to be rescreened for at least five years, and this offers 
to be another cost saving method in the prevention of cervical cancer. Finally, 
WHO urge for there to a greater level of communication about cervical cancer, 
and reach women at all stages of life, from all levels of the health system. 
The vaccine works but it is only prophylactic. Therefore, we still need novel 
therapeutics. To do this we need a better understanding of the papilloma virus 
life cycle. 
 HPV life cycle  
High-risk HPV infects stratified squamous epithelia in the genital tract (Figure 
1.2). In normal stratified epithelium, cells located in the basal and parabasal 
layers, attached to the basal membrane, are the only cells that have the poten-
tial to proliferate. When these normal cells divide, one daughter cell becomes a 
new basal cell, while the other will migrate away from the basal layer and 
launches its differentiation process. The differentiated cells exit the cell cycle 
and change their gene expression pattern, which eventually results in cell death 
and desquamation (Jones, Simons et al. 2007). The HPV life cycle is closely 
linked to the differentiation program of infected epithelium. 
1.4.1 HPV genome 
The HPV genome can be divided into three different sections: the early region 
(E) which is approximately 4kb in size and encodes non-structural proteins, a 
late region (L) that encodes two capsid proteins and is about 3kb in size, and a 
1kb noncoding long control region (LCR) that contains a variety of cis elements, 
which regulate viral replication and gene expression (Figure 1.3) (Munger, Bald-
win et al. 2004). 
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Figure 1.2 
 
Figure 1.2: Viral life cycle. HPV infection occurs through microlesions in the ba-
sal layer of the stratified epithelium. Viral genomes are maintained as episomal 
DNA in the nuclei of infected cells. The viral lifecycle is closely linked to the differ-
entiation of host cells. As the infected host cells migrate towards the lumen of the 
cervix, viral proteins are expressed and viral DNA amplified. The late life cycle 
(productive lifecycle) occurs in the upper layers of the epethelia that are terminally 
differentiated, and the progenitor virions are released from the cornified keratino-
cytes. Figure adapted from Human Papillomavirus oncoproteins: pathways to 
transformation (Moody, Laimins 2010). 
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Figure 1.3 
 
 
Figure 1.3: Viral genome. Schematic linear representation of the HPV genome. 
The 8 ORF are shown. Figure adapted from Relevance of infection with human 
papillomavirus: The role of the p53 tumor suppressor protein and E6/E7 zinc finger 
proteins (Ruttkay-Nedecky, Jimenez Jimenez et al. 2013). 
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1.4.2 Viral entry  
Papillomavirus particles are small noneveloped icosaheadrons and are about 50-
55nm in diameter. 72 pentamers of the major structural protein L1 form the 
capsid in addition to the minor structural protein, L2, which can vary in amount 
up to 72 copies. (Buck, Cheng et al. 2008, Baker, Newcomb et al. 1991a). These 
viral particles mediate transmission and entry through mechanism not currently 
well understood. Several studies have suggested that virions bound to the cell 
surface may take several hours to be internalised by endocytic uptake of clathrin 
coated vesicles and the extended time until infection is established. (Christen-
sen, Cladel et al. 1995, Culp, Christensen 2004, Giroglou, Florin et al. 2001, 
Schelhaas, Shah et al. 2012, Smith, Campos et al. 2007) 
Current work is only beginning to understand the various steps in viral entry and 
how these steps are linked. Various in vitro systems can be utilised for the study 
of viral entry, by producing surrogate viral particles. Most of the current re-
search on viral entry utilises pseudovirions (PsV), which serve as viral pseudoge-
nomes as they harbour plasmid and encode reporter protein (Buck, Thompson 
2007). Expression of the PsV reporter indicates a successful “pseudoinfection”.  
The current model for viral entry suggests that PV initially binds to glycosamino-
glycan (GAG) chains of heparin sulphate proteoglycans (HSPG) on the cell surface 
or extracellular matrix (ECM). (Joyce, Tung et al. 1999). Mutational analysis and 
x-ray crystallography of L1 capsomers have shown that an interaction of PV with 
heparin at minimally four different sites ( (Dasgupta, Bienkowska-Haba et al. 
2011, Knappe, Bodevin et al. 2007), and that PV do not require a specific HSPG 
protein core for binding and infection (Shafti-Keramat, Handisurya et al. 2003, 
Huang, Lambert 2012).  
There may not be one single molecule responsible for the internalisation of the 
virus. Candidates for such receptors that are all expressed at high levels in the 
basal epithelium  include; CD151, alpha 6 integrin, annexin A2 heterotetramer 
and tetraspanin  (Culp, Budgeon et al. 2006b, Dziduszko, Ozbun 2013, Evander, 
Frazer et al. 1997, McMillan, Payne et al. 1999, Scheffer, Gawlitza et al. 2013, 
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Spoden, Kuhling et al. 2013, Woodham, Da Silva et al. 2012, Surviladze, Dzi-
duszko et al. 2012, Spoden, Freitag et al. 2008). All of these are known to asso-
ciate with HSPG complexes.  
The virus is then thought to be delivered to an endosomal compartment which 
allows for the shedding of L1 capsomers from a subviral particle, and then trans-
ported to the Trans-Golgi Network (TGN) where membrane penetration can oc-
cur. 
Papillomaviruses are trafficked through the endosomal system following endocy-
tosis. In live cells it has been shown that PV associate briefly with Rab5-positive 
structures (Schelhaas, Shah et al. 2012). It is then beleived that PVs follow the 
degredative arm of the endosomal system, as PV particles are detected in multi 
vesicular endosomes and late endosomes (LE)/lysosomes. (Schelhaas, Shah et al. 
2012). It is within the endosomes that further structural changes to the PV take 
place that result in partial uncoating.  
The mechanism by which PVs are imported into the nucleus is not yet under-
stood. The L2 protein harbours nuclear localisation signals for karyopherin-medi-
ated import, this may allow for import via nuclear pore complexes (Darshan, 
Lucchi et al. 2004a, Mamoor, Onder et al. 2012). Another proposed mechanism 
of entry involves the progression of the host cell through early mitosis, which is 
required for infection (Pyeon, Pearce et al. 2009). It is not clear which mecha-
nism allows for PV entry, but it is conceivable that the breakdown of the nuclear 
envelope aids in PV genomes accessing the nuclear lumen. Once PVs enter the 
nucleoplasm, L2 and the viral genome colocalise at ND10 domains. This is a criti-
cal step for the establishment of infection, as early transcription of the virus re-
lies on intact ND10 or expression of the PML protein (Day, Baker et al. 2004).  
Following infection and nuclear localisation the next step is to activate tran-
scription from the viral genome. This results in expression of viral genes and pro-
teins essential for the life cycle. 
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1.4.3 Transcriptional regulation of the HPV long control region 
(LCR) 
The LCR can be divided into three functionally distinct regions, called the 5’, 
the central, and the 3’ segment. The 5’ segment is about 300bp in size and it is 
bracketed by the termination codon of L1 and E2 binding sites. This segment 
contains transcription termination and polyadenylation sites for late transcripts 
and additionally a negative regulator element at the level of late mRNA stability 
(Furth, Baker 1991, Kennedy, Haddow et al. 1991). The central segment is 
flanked by two E2 binding sites (#1 and #2), has a size of about 400bp and has 
been shown to function as an epithelial specific enhancer in HPV 11, 16 and 18 
(Chin, Broker et al. 1989, Cripe, Haugen et al. 1987, Gloss, Bernard et al. 1987). 
The enhancer is also involved in modulating viral gene expression in response to 
the stage of differentiation the host keratinocyte is in within the different layers 
of stratified squamous epithelium.  These changes are facilitated by the differ-
ential binding of transcription factors to their cognate sites in the enhancer, and 
this in turn will be dependent upon the quantitative, and perhaps qualitative dif-
ferences in the these transcription factors in a particular cell environment. 
Many cellular transcription factors bind in vitro to more than 20 different sites of 
the HPV 16 enhancer. These include: AP1, cEBP, glucocorticoid receptor, proges-
terone receptor, NF1, NF-IL6, Oct-1, PEF-1, TEF-1, TEF-2 and YY1 (Chan, Klock 
et al. 1989) (Chin, Broker et al. 1989, Gloss, Bernard et al. 1987, Chong, Chan et 
al. 1990, Chong, Apt et al. 1991, Cuthill, Sibbet et al. 1993, Garcia-Carranca, 
Thierry et al. 1988, Gloss, Chong et al. 1989, Ishiji, Lace et al. 1992, Kyo, Inoue 
et al. 1993, O'Connor, Bernard 1995, Sibbet, Campo 1990). The 3’ side of the 
central LCR is flanked by the #2 E2 binding site, which is known to be involved in 
the initiation of replication  (Sibbet, Campo 1990, Chiang, Dong et al. 1992, Rus-
sell, Botchan 1995), and is also key for the modulation of the transcription of the 
viral oncogenes, E6 and E7 (Romanczuk, Thierry et al. 1990). 
The boundaries of the 3’ LCR are marked by the #2 E2 binding site and the E6 
gene. The 3’ LCR is approximately 140bp in size, and contains a single E1 binding 
site which identifies the origin of replication. About 5bp upstream of the ATG of 
E6, and 90bp downstream of the E1 binding site, lies the transcription start site. 
Within these 90bp a segment of about 45bp contains an SP1 transcription factor 
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binding site and two E2 binding sites, as well as a TATA box. These four sites are 
key players in the modulation of E6/E7 promoter activity. The TATA box is re-
quired for the binding of TFIID and the establishment of the pre-initiation com-
plex, and the SP1 factor for mediating the long range effect of the enhancer. 
The E2 sites overlap with the TATA box and with the AP1 site, such that the oc-
cupancy by E2 proteins displaces TFIID and the SP1 factor (Bouvard, Storey et al. 
1994)(Demeret, Yaniv et al. 1994, Dostatni, Lambert et al. 1991, Gloss, Bernard 
1990, Tan, Leong et al. 1994). 
It has been proposed from various studies of the HPV promoter that it can switch 
between transcription initiation and replication functions by depending on the 
concentrations of E2 available. Binding of SP1 to its site activates the E6/E7 pro-
moter, but not replication. This is due to SP1 blocking E2 binding which would 
enhance E1-dependent replication initiation.  When there are greater concentra-
tions of E2, SP1 is displaced, replication is activated and transcription is partially 
repressed (Demeret, Yaniv et al. 1994, Tan, Leong et al. 1994).  The binding of 
E2 to the promoter proximal site (site #4) would lead to TFIID displacement and 
further repression. 
1.4.3.1 Host transcription factors 
 
NFI was first identified through its role in the replication of the adenovirus ge-
nome, where it binds to the sequence TTGGC(N)6CCAA  (de Vries, van Driel et 
al. 1985, Nagata, Guggenheimer et al. 1983).  In HPVs NFI binds to only part of 
this sequence, TTGGC, however the NFI protein still binds as a dimer, which 
forms in solution (Mermod, O'Neill et al. 1989).  In epithelial cells, where the 
HPV enhancer is active, the major forms of NFI present consist of dimers made 
up of the three splice products from the NFI-C gene, CTF-1, CTF-2 and CTF-3. 
Every HPV LCR contains NFI sites. On average each LCR contains at least 4 sites. 
In genital HPVs all of these NFI sites occur within the central segment of the 
LCR, which is only 300-400bp long. The likelihood that this would happen by 
chance is negligible. 
All genital HPV LCRs contain at least one binding site for AP1, with most pos-
sessing 3 or 4.  Almost all of these sites lie within the central segment of the LCR 
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in the epithelial specific enhancer.  AP1 is heterodimers made up of proteins de-
rived from the Jun, Fos, ATF gene family, recognises DNA motifs related to the 
sequence TGANTCA and serves as a downstream target of intracellular signalling 
mechanisms (Vogt, Bos 1990). The AP1 sites that are present in the HPV enhanc-
ers may modulate viral gene expression in response to growth factors such as 
EGF, KRF and tumour growth factors via the protein kinase C pathway.  This has 
been shown through the use of phorbolesters which mimic the signalling path-
ways and strongly activate E6 and E7 expression. AP1 may also contribute to-
wards epithelial specific activation since the genes that give rise to its subunits 
are differentially expressed (Thierry, Spyrou et al. 1992). 
Oct-1 regulates a number of viral and cellular genes (Ruvkun, Finney 1991), and 
is a member of the POU factor family (Rosenfeld 1991).  All POU factors possess 
a highly homogenous, bi-partite DNA binding domain. Within this POU domain, 
an N-terminal POUS subdomain recognises the 5’ end of the recognition se-
quence, ATGCAAAT for Oct-1 (Verrijzer, Kal et al. 1990), and thus is separated 
by a linker, which varies in length and sequence in different POU factors. 
There is an epithelial enhancer and promoter which we don’t understand the 
specificity of. Overall, the effect of their function is to generate an epithelial 
specific enhancer. There seems to be no one function responsible; rather it can 
be hypothesized that a combination of functions or post-translational modifica-
tions accumulate to generate epithelial specificity. 
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1.4.4 Three stages of viral DNA replication 
There are three stages of viral DNA replication in the papillomavirus life cycle. 
The first stage is establishment which involves limited genome amplification 
when a viral particle first enters the host cell. The second phase is genome 
maintenance, where the viral genome is maintained at a constant copy number 
in the proliferating basal cells of a papilloma. The maintenance phase requires 
both genome replication and partitioning. In the third phase of replication, ge-
nomes are amplified in differentiated cells to produce progeny virions. 
1.4.4.1 Establishment 
  
HPV infection is thought to only be possible through wounds in the proliferative 
basal layer of stratified epithelium, allowing HPV to penetrate the physical bar-
rier of upper skin layers. Infections are established in the basal compartment of 
stratified epithelia as this is the only compartment of epithelium which contains 
cells progressing through the cell cycle. The results from studies also indicate 
that wound healing might increase efficiency with which the HPV DNA becomes 
established as a nuclear plasmid in the basal cells, because the basal cells are 
then in a hyperproliferative stage (Werner, Smola et al. 1994). 
Pyeon et al presented results using infectious wild type HPV16 virions that 
showed that events in early prophase segment of mitosis are critical for estab-
lishing HPV infection.  This was assayed by introduction and expression of HPV 
encapsidated DNA in nucleus. Pyeon et al propose that these events could in-
clude nuclear envelope breakdown, cytoskeleton restructuring, and sub-nuclear 
structure changes as well as the specific expression of one or more genes or 
gene in combinations in early mitosis (Pyeon, Pearce et al. 2009). 
Restructuring of PML oncogenic bodies (PODs) or ND10 and chromatin in early 
mitosis could be necessary for establishing HPV infection in the nucleus. After 
the initial steps of HPV infection, PODs are the final destination for HPV DNA, 
and this is approximately where HPV transcription and replication occurs (Day, 
Baker et al. 2004) (Van Tine, Dao et al. 2004). During S and M phases of the host 
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cell cycle, PODs are dynamically restructured, responding to changes in chroma-
tin organisation (Bernardi, Pandolfi 2007).  The structural changes of PODs in 
early mitosis could be essential for HPV DNA localisation to its POD destination 
during establishment of infection. Additionally, other host mechanisms involved 
in chromatin restructuring in early mitosis could contribute to viral gene expres-
sion. 
1.4.4.2 Genome maintenance  
 
Following establishment HPV is maintained at an episomal copy number of 
around 10-200 copies per cell and the early proteins (E1, E2, E6 and E7) are ex-
pressed at low level. (De Geest, Turyk et al. 1993, Stanley, Browne et al. 1989). 
E1 and E2 early viral genes cooperate to initiate viral DNA replication, whereas 
E6 and E7 modulate cell cycle regulators to maintain long term replication com-
petence (Frattini, Laimins 1994a, Sedman, Stenlund 1995). These genes are ex-
pressed at low levels in undifferentiated cells in order to evade the host immune 
response and for infection to persist. The low copy number of HPV in basal cell 
has been proposed based on studies in episomal cell lines derived from cervical 
lesions. Laser capture methods have been utilised in animal models, looking at 
benign oral papillomas, showing the copy number is as low as 50-100 copies per 
cell (Maglennon, McIntosh et al. 2011), but it is likely that there will be variation 
from lesion to lesion and between different sites. 
In order to maintain the viral DNA as an episome, E1 and E2 proteins are ex-
pressed (Wilson, West et al. 2002) and to facilitate correct segregation of ge-
nomes during cell division (You, Croyle et al. 2004). The establishment phase of 
the viral life cycle relies on the early proteins E1 and E2. Although, they may not 
be required for maintenance replication (Kim, Lambert 2002, Angeletti, Kim et 
al. 2002, Egawa, Nakahara et al. 2012). The E1 protein has been speculated to 
be able to keep viral DNA replication separate from cellular DNA replication dur-
ing genome establishment and cellular heli-amplification. (E1 helicase keeps 
separate from cellular helicases- MCM proteins) (Doorbar 2006, Blakaj, Fernan-
dez-Fuentes et al. 2009). 
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1.4.4.3 Genome amplification 
 
Throughout the maintenance phase in undifferentiated cells, the viral proteins 
are expressed at low levels in order to evade the immune response. However, 
once the HPV-infected cells leave the basal layer they undergo differentiation, 
which then leads to higher expression of the viral proteins. Higher expression of 
viral proteins is limited to highly differentiated layers of the epithelium as this 
circumvents the host immune response (Frazer 2009). 
As normal differentiating keratinocytes normally withdraw from the cell cycle, 
they down-regulate host replication factors (Munger, Baldwin et al. 2004), how-
ever, HPV does not encode its own DNA replication enzymes, so must force the 
cell to stay active to utilise its replication machinery. The viral protein responsi-
ble for this task is E7. E7 viral protein overrides pRb’s normal negative regula-
tion of the cell cycle that prevents progression to S-phase entry (this is done by 
associating with the transcription factor E2F). Instead E7 binds to pRb and dis-
places E2F, regardless of there being other growth factors present replication 
can take place as this leads to an increase in the expression of proteins needed 
for DNA replication. E7 can stimulate cell proliferation, but can only do so in a 
small subset of cells in the parabasal layers during productive infection. To 
counteract the effect of E7 causing unschedueled entry into S-phase, viral E6 
protein prevents the normal response of the cell to cause apoptosis. E6 interacts 
with p53 as well as other host proteins; such as another pro-apoptotic protein, 
Bak (Thomas, Banks 1998) and Bax (Li, Dou 2000).  
In order to produce infectious virions, papillomaviruses must amplify their ge-
nomes and package them into infectious particles. For high-risk types this hap-
pens in the mid or upper epithelial layers following the increase of activity of 
the late promoter. The late promoter resides within the E7 open reading frame. 
The up-regulation of the late promoter leads to increased expression of the viral 
proteins involved in viral DNA replication (E1, E2, E4 and E5) without directly af-
fecting expression of the E6 and E7 proteins that are necessary for S-phase entry 
(Middleton, Peh et al. 2003). In the proliferative compartment viral genome am-
plification take place, and this requires the expression of the viral early genes, 
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including E4 (Peh, Brandsma et al. 2004)  and E5 (Middleton, Peh et al. 2003), 
whose roles are not fully understood yet. 
In order for viral DNA replication to occur the early E2 protein must bind to the 
upstream regulatory region. E2 then in turns recruits the viral DNA helicase E1 to 
the viral origin of replication.  The complex that E1/E2 forms is similar to the 
host replicative complex of cdc6 and MCMs, and this viral complex allows for 
replication in the absence of these proteins. Throughout the virus life cycle, the 
levels of the viral proteins is regulated by promoter usage and by differential 
splice site selection, with an increase in the level of E1 and E2 allowing an in-
crease in viral copy number in the upper epithelial layers  (Ozbun, Meyers 
1998a).  A slight increase in promoter activation during differentiation may lead 
to an increase in the level of E1 and E2 (also E4 and E5), and a subsequent in-
crease in genome copy number. The newly replicated genomes serve as tem-
plates for the continued expression of E1 and E2, which allow for further ampli-
fication of viral genomes and in turn the further expression of additional E1 and 
E2 replication proteins (Middleton, Peh et al. 2003). 
1.4.4.4 Mode of DNA replication 
 
Papillomaviruses have regulated and uncontrolled replication phases during their 
life cycle. Flores and Lambert show in W12 cells a switch in the mode of replica-
tion at different stages of the cell cycle. W12 cell lines are naturally derived 
from infected cervical epithelium and harbour replicating HPV DNA episomes. 
When W12 cells were undifferentiated in a non-productive like state of the cell 
cycle, HPV16 DNA replicates primarily by theta structures in a bidirectional man-
ner. Replication was initiated within a bubble located at approximately at nucle-
otide 100, and terminates between nt 3437 and 4906, where two replication 
forks converge to a common site. When W12 cells were grown in conditions to 
promote differentiation the mode of replication switched from theta structure 
to a rolling circle mode of replication. This was concluded due to the absence of 
bubble and double-Y shaped DNA RIs, and only the presence of Y-shaped HPV16 
DNA RIs (Flores, Lambert 1997). 
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HPV16 rolling circle replication in epithelial cells relies on the origin of replica-
tion, E1 and E2, in the same manner as in bidirectional replication, suggesting 
that the two modes of replication share the same initiation mechanism. It was 
proposed that HPV16 rolling circle replication diverges from bidirectional repli-
cation by failure of replication termination. In the bidirectional mode of replica-
tion, two replication forks, moving from the origin, converge near the point an-
tipodal to the origin. The replication proteins at the forks then dissociate from 
the DNA to allow for completion of replication. Rolling circle DNA amplification 
is unidirectional, and one initiation event leads to the generation of multiple 
copies of the genome. A proposed mechanism for the initiation of rolling circle 
replication is that E1 fails to dissociate from the DNA on collision of two replica-
tion forks, which in turn would displace the 5’ end of DNA that has been synthe-
sised by the second replication fork, thus allowing a single stranded circular DNA 
to act as a continuous template for rolling circle replication (Kusumoto-Matsuo, 
Kanda et al. 2011). 
Alternatively, HPV may utilise homologous recombination (HR) to amplify the 
HPV genome. Homologous recombination is a DNA repair pathway, and a classi-
cal marker of this is Rad51, a recombinase that promotes strand invasion and ho-
mologous pairing. Other cellular factors include BRCA1 and pRPA. Recent work 
has shown Rad51 localised to the core of large replication foci in differentiated 
HPV31 containing cells (Sakakibara, Chen et al. 2013a, Gillespie, Mehta et al. 
2012).  The presence of Rad51 is suggestive that there is a switch to a recombi-
nation-directed mode of replication. E1 and E2 proteins are capable of inducing 
replication in these foci (Sakakibara, Chen et al. 2013a). These viral replication 
foci may contain stalled replication forks or abnormal replication intermediates. 
Therefore, the presence of HR is required for efficient high fidelity viral DNA 
synthesis upon differentiation. Or, HPV could utilise these factors to promote 
replication (Gillespie, Mehta et al. 2012). It has also been suggested that if viral 
genome amplification happens through rolling circle amplification, then HR may 
be needed for circularisation of HPV genomes upon cleavage of viral concatem-
ers to allow for packaging into virions.  
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1.4.5 Virus synthesis 
Once viral genome amplification is complete, the two structural proteins L1 and 
L2 are expressed in the upper layers of infected tissue (Ozbun, Meyers 1998b). 
The major capsid protein L1 is expressed after L2 allowing the assembly of infec-
tious particles in the upper layers of the epithelium (Florin, Sapp et al. 2002). 
During virus assembly the L2 protein locates to PML bodies, this may be in asso-
ciation with the transcription factor Daxx (Becker, Florin et al. 2004) and re-
cruits L1 to these nuclear domains. It has been proposed that the nuclear PML 
bodies may be sites of viral replication (Day, Roden et al. 1998) (Swindle, Zou et 
al. 1999) and that capsid proteins accumulate here to facilitate packaging. The 
L2 protein is thought to enhance packing (Stauffer, Raj et al. 1998, Zhou, Sten-
zel et al. 1993) and viral infectivity (Roden, Day et al. 2001) 
Papillomaviruses are not released until the infected cells reach the epithelial 
surface, their survival may be enhanced if they are shed within cornified squame 
(Bryan, Brown 2001). It is well documented that papillomaviruses avoid immune 
detection, by limiting the presentation of viral epitopes to the immune system in 
the lower epithelial layers (Ashrafi, Tsirimonaki et al. 2002, Marchetti, Ashrafi et 
al. 2002, Matthews, Leong et al. 2003). The expression of viral proteins can in-
hibit the expression of differentiation markers which can prevent the formation 
of normal cornified squames (Doorbar, Foo et al. 1997). A proposed role for the 
E4 protein is that it may contribute directly to virus egress in the upper layers of 
the epithelium by disturbing keratin integrity (Doorbar, Ely et al. 1991, Wang, 
Griffin et al. 2004) and by affecting the assembly of the cornified envelope 
(Bryan, Brown 2001)  (Lehr, Hohl et al. 2004). 
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 The viral oncoproteins 
High risk HPV types cause neoplasia, and there is a definite clear cut role for the 
Viral E6 and E7 proteins in cell transformation. These early viral proteins drive 
cell proliferation in the basal and parabsal cell layers (Doorbar 2006).  
E6 and E7 proteins are expressed by a bicistronic mRNA (Stacey, Jordan et al. 
2000)  expressed from the viral promoter (p97). Both of these proteins function 
to stimulate cell cycle progression (Munger, Basile et al. 2001). Human keratino-
cytes require both E6 and E7 to become efficiently immortalised ( (Hawley-Nel-
son, Vousden et al. 1989), however E6 alone can immortalise NIH 3T3 and human 
mammalian epithelial cells ((Joyce, Tung et al. 1999, Liu, Chen et al. 1999). It 
has been shown in transgenic mouse models that E6 plays an important role in 
cooperating with E7 in tumour induction at diverse anatomical sites (Lambert, 
Pan et al. 1993, Shai, Brake et al. 2007, Jabbar, Strati et al. 2010, Shai, Pitot et 
al. 2010). 
1.5.1 E7 protein  
E7 proteins are predominantly found in the nucleus and are 100 amino acids in 
size, and associate with the Rb family of proteins ((Dyson, Howley et al. 1989). 
The binding of E7 to Rb proteins is mediated through one of three conserved re-
gions, which can be found in all high risk E7 proteins: CR1 at the N terminus; 
CR2, which contains an LXCXE motif that binds the Rb protein; and CR3, which 
contains two zinc finger-like motifs. The Rb family of “pocket” proteins includes 
Rb, which is constitutively expressed throughout the cell cycle; p107, which is 
synthesised predominantly during the S phase, and p130 which initiates at G0 ( 
(Dyson, Howley et al. 1989, Berezutskaya, Yu et al. 1997, Classon, Dyson 2001). 
E7 viral protein overrides pRb’s normal negative regulation of the cell cycle that 
prevents progression to S-phase entry (this is done by associating with the tran-
scription factor E2F1). Instead E7 binds to pRb and displaces E2F1, regardless of 
there being other growth factors present, replication can take place as this leads 
to an increase in the expression of proteins needed for DNA replication. E7 pro-
tein binds to other host proteins as well as pRB; this includes other proteins re-
quired for proliferation, histone deacytelases (Longworth, Laimins 2004), compo-
nents of the AP-1 transcription complex (Antinore, Birrer et al. 1996) and p21 
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and p27 cyclin-dependent kinase inhibitors (Funk, Waga et al. 1997). E7 can 
stimulate cell proliferation, but can only do so in a small subset of cells in the 
parabasal layers during productive infection.  As a result of E7 expression and 
the disruption of E2F/pRb, cyclin E is expressed, which is necessary for progres-
sion into S-phase. In differentiating epithelial cells, the high levels of cyclin-de-
pendent kinase inhibitors (p21cip1 and p27kip1) can lead to inactive complexes 
of E7, cyclin E/cdk2 and either p21 or p27  (Noya, Chien et al. 2001). The pro-
gression into S-phase, stimulated by E7 protein is limited to a subset of differen-
tiated cell with low levels of p21/p27, or where there are high enough levels of 
E7 to overcome the block to S-phase entry. 
1.5.2 E6 protein 
The E6 protein is approximately 150 amino acids in size and contains two zinc 
binding domains with the motif Cys-X-X-cys. The E6 protein has been reported to 
bind to over 12 different proteins and can be found located in both the nucleus 
and the cytoplasm (zur Hausen 2002). E6 interacts with p53 as well as other host 
proteins; such as another pro-apoptotic protein, Bak (Thomas, Banks 1998)  and 
Bax (Li, Dou 2000).  E6 is also known to bind to other cellular proteins; these in-
clude paxillin, p300/CBP, the putative calcium binding protein E6-BP, and the 
interferon regulatory factor IRF-3 ((Patel, Huang et al. 1999, Ronco, Karpova et 
al. 1998, Zimmermann, Degenkolbe et al. 1999). 
To counteract the effect of E7 causing unschedueled entry into S-phase, viral E6 
protein prevents the normal response of the cell to cause apoptosis. When there 
is DNA damage p53 becomes activated and induces high levels of p21, this acti-
vation leads to cell cycle arrest and apoptosis (Ko, Prives 1996). Viruses have 
evolved mechanisms to evade the cells apoptotic response, and the activation of 
apoptotic pathways. This evasion can lead to malignancies, which is why the 
presence of E6 is a determining factor in the development of HPV related can-
cers, as this allows for the accumulation of unchecked errors in host DNA. Papil-
lomavirus evades these apoptotic pathways via E6 binding to p53 in a ternary 
complex with ubiquitin ligase called E6AP (Huibregtse, Scheffner et al. 1991). 
This leads to the ubiquitination of p53 and the degradation of p53 by the 26S 
proteasome. This degradation ultimately leads to a significantly shorter half-life 
of p53, which decreases from several hours to only 20 minutes in keratinocytes 
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(Hubbert, Sedman et al. 1992, Huibregtse, Scheffner et al. 1993). Alternatively 
E6 can also down regulate p53 through an interaction with p300/CBP, which is a 
co-activator of p53 (Zimmermann, Degenkolbe et al. 1999, Lechner, Laimins 
1994). This deregulation of p53 means it can no longer carry out its usual cell cy-
cle controls, p53 regulates G1/S and G2/M checkpoints of the cell cycle. This 
can lead to chromosomal duplications and centrosomal abnormalities (Foster, 
Demers et al. 1994, Kessis, Slebos et al. 1993, Thompson, Belinsky et al. 1997). 
E6 mutants in HPV 16 that are unable to degrade p53 retain the ability to immor-
talise mammary epithelial cells. Also, E6 mutants that retain the ability to de-
grade p53 have lost the ability to immortalise (Liu, Chen et al. 1999, Kiyono, Hi-
raiwa et al. 1997). 
E6 can also cause cell proliferation in the absensce of E7 through its c-terminal 
PDZ-ligand domain (Thomas, Laura et al. 2002). High risk E6 protein has a PDZ 
binding domain, which allows for its interaction with PDZ and in turn E6 can reg-
ulate many PDZ targets. Many of these targets are involved in regulation of cell 
polarity, proliferation and cell signalling. (Javier 2008, Culp, Cladel et al. 2006).  
The proliferation E6-PDZ binding causes may be sufficient to contribute to the 
development of metastatic tumours by disrupting normal cell adhesion. 
E6 proteins also activate expression of the catalytic subunit of telomerase, 
hTERT ((Klingelhutz, Foster et al. 1996, Meyerson, Counter et al. 1997, Naka-
mura, Morin et al. 1997). Telomerase is a four subunit enzyme that adds hex-
amer repeats to the telomeric ends of chromosomes. The lack of telomerase ac-
tivity results in a shortening of telomeres with successive cell divisions, which 
subsequently leads to sensessence (Liu 1999). So when hTERT is reactivated in 
cancer occurs it leads to reconstitution of telomerase activity (Liu 1999). E6 ac-
tivates hTERT transcription through Myc and Sp-1 (Greenberg, O'Hagan et al. 
1999, Kyo, Takakura et al. 2000, Oh, Kyo et al. 2001, Wang, Xie et al. 1998, Wu, 
Grandori et al. 1999). 
In conclusion, the combination of expression of E7 and E6 in abberant S phase 
entry and proteins of where cells from host defence mechanisms such as apopto-
sis. 
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 The roles of E1 and E2 in replication 
The two DNA binding proteins E1 and E2 are required for viral genome replica-
tion; E2 protein forms homodimers and binds to 12bp palindromic sequences sur-
rounding A/T rich origin of replication. The origin of replication also contains an 
E1 binding site (Ustav, Ustav et al. 1991, Ustav, Ustav et al. 1991). E2 recruits 
the replicative helicase E1 protein to the HPV origin via a protein-protein inter-
action (Mohr, Clark et al. 1990, Sanders, Stenlund 2001). E1 is the primary repli-
cation protein, however, E2 enhances and supports the functions of E1 (Frattini, 
Laimins 1994a, Mohr, Clark et al. 1990). The E1 helicase forms di-hexameric 
complex that replicates the viral genome via interaction with host proteins 
(Sanders, Stenlund 2001). E2 is then displaced, which also displaces nucleosomes 
from the origin of replication to alleviate repression (Li, Botchan 1994). 
1.6.1 Replication protein E1 
In 1982, the complete sequence of both HPV1 a and BPV1 genomes revealed a 
common genetic organisation that included several large open reading frames 
(Chen, Howley et al. 1982, Danos, Katinka et al. 1982). Following these studies, 
it was then demonstrated that the putative E1 proteins also shared homology 
with the SV40 large T antigen (Seif 1984). As the role of the T antigen in SV40 
replication initiation had already been established, a similar function for papil-
loma E1 was predicted (Clertant, Seif 1984). This was established in transfor-
mation studies with BPV1, which showed that an intact E1 ORF is required for 
stable maintenance of the BPV1 genome as a multicopy nuclear plasmid (Lusky, 
Botchan 1985, Sarver, Rabson et al. 1984, Rabson, Yee et al. 1986). 
Genomic E1 ORF sequences are available for over 170 human and  greater than 
112 non-human papillomaviruses, all of these E1 proteins are predicted to share 
numerous features with the well characterised BPV1 E1 protein and other hel-
icases (Patel, Picha 2000). E1 proteins vary in size between HPV types, they 
range from 593 (HPV48) to 681 (HPV10) amino acids with a molecular weight dis-
tribution from 67.5 (HPV47) to 76.2 kDa (HPV10). This range in size is due to the 
mucosal HPVs having additional residues in the N-terminal region, which in turn 
results in lower sequence similarity for the N-terminal third of E1 proteins than 
for the remaining C-terminal portion. 
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E1 proteins recognise the viral origin of replication and have ATPase and 3’-5’ 
helicase activities (Figure 1.4) (Hughes, Romanos 1993, Yang, Mohr et al. 
1993)(Seo, Muller et al. 1993). E1 recognises AT-rich sequences at the viral 
origin which are proximal to the start sites of early transcription (Frattini, 
Laimins 1994a, Frattini, Laimins 1994b, Muller, Giroglou et al. 1997). The bind-
ing of E1 onto the viral origin is facilitated by E2 (Frattini, Laimins 1994a, Dixon, 
Pahel et al. 2000, Lu, Sun et al. 1993, Sun, Lu et al. 1996). E1 then forms hex-
amers which have a high affinity for DNA (Sedman, Stenlund 1998), the viral DNA 
is able to pass through the centre of the E1 hexameric ring (Liu, Kuo et al. 
1998). With the aid of chaperone proteins, E1 is able to unwind supercoiled DNA. 
E1 binds to DNA polymerase α, and also help to recruit host cellular replication 
complexes to viral origin to aid in viral replication (Amin, Titolo et al. 2000, 
Conger, Liu et al. 1999, Masterson, Stanley et al. 1998). 
The crystal structure of the DNA binding domain of E1 has shown an extended 
loop and α-helix that are important for recognising DNA (Enemark, Chen et al. 
2000). The E1 protein has four cyclin kinase binding sites, and E1 binds to both 
cyclin A and E. When these sites are mutated it greatly impairs E1 replicative 
abilities (Ma, Zou et al. 1999).  
The P-loop of E1 proteins contains one or two prolines (consensus: G-P-P/A-N?D-
T-G-K-S) except for HPV16 E1 (GAANTGKS). The 16E1 protein binds ATP weakly, 
but binding is enhanced by the replacement of the two P-loop alanines with pro-
lines, again implicating this motif in ATP binding (Raj, Stanley 1995). Further to 
this role of binding ATP, mutational analysis of this motif in HPV11 E1 suggests 
that the P-loop is critical for both the interaction between E1 and the transcrip-
tional activation domain (TAD) of E2 (Titolo, Pelletier et al. 1999) and for E1-E1 
oligomerisation (Titolo, Pelletier et al. 2000). The P-loop may be offering an ar-
chitectural function for the interaction of E1 and E2, as this interaction does not 
require ATP (Titolo, Pelletier et al. 1999).Not much is known about the structure 
of HPV E1 beyond the primary sequence. No definitive information about the 
secondary structure or tertiary features are known, as E1 has never been crystal-
ised for diffraction analysis. However, there is a crystal structure for BPV1 E1. 
Due to the role of E1 in viral replication, it is no surprise it is located in the nu-
cleus of infected cells (Ustav, Ustav et al. 1991, Blitz, Laimins 1991, Santucci, 
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Androphy et al. 1990, Sun, Thorner et al. 1990). The nuclear localisation of E1 is 
driven by a sequence in the first 223 amino acids (Sun, Thorner et al. 1990). A 
small region of (BPV1) E1 (aa 84-166) containing the nuclear localisaiton se-
quence, KRKVLGSSQNSSGSEASETPVKRRK is necessary for the direct nuclear local-
isation of fusion proteins (Leng, Wilson 1994). 
In addition to its key role in viral replication as a helicase, E1 also plays a role in 
the regulation of viral transcription and transformation. This is thought to occur 
through binding to E2, E1 modulates E2s ability to activate certain viral promot-
ers. Studies in BPV1 have shown that E1 negatively regulates the activation of 
the major early promoter by E2 (Le Moal, Yaniv et al. 1994, Sandler, Vande Pol 
et al. 1993)  and this mechanism may be responsible for the suppression of trans-
formation by E1 (Lambert, Howley 1988, Schiller, Kleiner et al. 1989, Vande Pol, 
Howley 1995, Zemlo, Lohrbach et al. 1994). E1 also has a direct effect on the 
host cell cycle (Belyavskyi, Westerman et al. 1996, Belyavskyi, Miller et al. 
1994). Reinson et al have shown that E1 protein from expression constructs can 
induce cellular DNA damage when overexpressed. E1 induces double-stranded 
DNA breaks (DSBs) and activates the ATM-Chk2 pathway, leading to cell cycle ar-
rest in the S and G2 phases (Reinson, Toots et al. 2013). 
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Figure 1.4 
 
 
Figure 1.4: X-ray structure of the papillomavirus replication proteins E1 and 
E2 in complex.  
a) Schematic of HPV E1 and E2 ORFs indicating the amino acid bounda-
ries of key domains. E1 protein is approximately 650 amino acids in 
length. The N-terminal contains the nuclear localisation signal. The central 
portion of E1 contains the origin binding domain, which associates with a 
series of inverted-repeat sites at the viral origin. The C-terminal contains the 
helicase domain of E1. ATP stimulates the oligomerisation of E1 and en-
hances the helicase activity of E1. E1 also interacts with host cell replication 
factors such as polymerase α to promote bi-directional replication of the vi-
ral genome. E2 is approximately 370 amino acids in length. Locations of the 
functional domains of the E2 protein are indicated. TAD: transcriptional acti-
vation domain; DBD: DNA binding domain. The E2 ORF contains a con-
served N-terminal activation domain of approximately 200 amino acids. This 
domain is essential for transcription, replication, and viral DNA segregation. 
The TAD is connected to the DBD by a flexible proline-rich hinge domain. 
E2 is a homodimer and interacts with the “ACCGN4CGGT” DNA recogni-
tion site, which is conserved throughout the entire PV family. 
b) Cartoon representation of HPV18 E1 and E2 in complex.  E1 is shown in 
blue. The N-terminal helical domain of E2 is green, the β-strand structural 
domain is coloured in red, and the linker segment between the two domains 
is depicted in yellow. This Cartoon was adapted from(Abbate, Berger et al. 
2004) 
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1.6.2 Replication protein E2  
E2 is approximately 43kDa in size and functions as a dimer. The full-length E2 
protein is expressed from the entire E2 open reading frame (ORF) and has two 
functional domains which are separated by a hinge region. These are the N-ter-
minal transactivation domain (TAD) which is about 200 amino acids which is 
linked to the C-terminal DNA- binding/ dimerization domain of about 100 amino 
acids via a short hinge domain (Figure 1.4) (Giri, Yaniv 1988, McBride, Byrne et 
al. 1989). 
The length of the hinge region is variable between the E2s of different papillo-
mavirus genera, but similar within each genus. The E2 hinge region is rich in pro-
line, serine, threonine, glycine and arginine residues, and forms a flexible link 
between the transactivation and DNA binding domains (Gauthier, Dillner et al. 
1991). Although, the hinge region is not involved in transcriptional and replica-
tion functions (Winokur, McBride 1992). E2 hinge regions have auxiliary functions 
such as determinants of intracellular localisation, chromatin binding and protein 
stability. These functions are regulated by phosphorylation. 
The TAD is a protein interaction module that binds through one surface to the vi-
ral E1 helicase to promote replication of the genome, and through the opposite 
surface to cellular transcription factors, including Brd4, to regulate viral genome 
transcription(Gagnon, Joubert et al. 2009)(Chen, Stenlund 2000). Through crys-
talisation studies the N-terminus of E2 has been shown to consist of a glutamine 
rich α-helix packed against a β-sheet framework (Antson, Burns et al. 2000, Har-
ris, Botchan 1999). E2 dimers bind to E2 binding sites (E2BSs) which have the se-
quence ACCN6GGT (Androphy, Lowy et al. 1987, Bedrosian, Bastia 1990). In the 
URR there are 4 E2BSs, and three of these flank the E1 recognition sequences in 
the origin of replication (Androphy, Lowy et al. 1987, Hirochika, Hirochika et al. 
1988, Li, Knight et al. 1989). The C-terminal encodes a DNA binding domains and 
the crystal structure of this has shown that is has a dimeric β-barrel structure 
that bends DNA (Hegde, Grossman et al. 1992). 
The crystal structure of (HPV18) E2 activation domain bound to the helicase do-
main of E1 has been solved (Abbate, Berger et al. 2004). The E1-E2 complex can 
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be disrupted by mutations in the first N-terminal alpha-helix, or alternatively by 
antibodies that bind to this region of E2 (Baxter, McPhillips et al. 2005b). 
 Additional E2 functions and cellular partners 
1.7.1  Transcriptional repression 
E2 is a transcription factor, and is a specific DNA binding homodimer harbouring 
a classical modular structure in three distinct domains (Giri, Yaniv 1988, 
McBride, Byrne et al. 1989, Dostatni, Thierry et al. 1988).  As mentioned previ-
ously E2 binding sites are present in multiple copies in different papillomavirus 
regulatory regions, however, only 4 copies exist in mucosal types (Sanchez, Del-
larole et al. 2008). The distances between these sites is well conserved, there 
are 1 or 2 nucleotides between BS#1 and BS#2, these are the most proximal 
binding sites to the promoter, there are 64 nucleotides between BS#2 and BS#3 
and 320 nucleotides between BS#3 and BS#4. The E2 binding site location rela-
tive to the TATA box is also well conserved, involving 3 nucleotides for the ma-
jority of the mucosal HPV (Figure 1.5). 
The three sites proximal to the TATA box are involved in E2 transcriptional re-
pression of the early promoters. The two most proximal sites to the TATA box 
play the most prominent role (Romanczuk, Thierry et al. 1990, Thierry, Howley 
1991, Demeret, Desaintes et al. 1997) . Conversely, these sites are also crucial 
for the efficient replication of the virus, which involves the viral helicase E1 
(Demeret, Le Moal et al. 1995). 
Binding of E2 represses transcription through steric hindrance of the interaction 
with the transcriptional initiation factor TFIID at the proximal TATA box. The 
work that first described this transcriptional repression mechanism was done by  
transfecting cells in vivo  (Romanczuk, Thierry et al. 1990, Thierry, Howley 
1991) and in vitro in cell extract (Dostatni, Lambert et al. 1991), as well as in 
more recent years with purified transcription factors (Hou, Wu et al. 2000), this 
indicated that binding of E2 to the HPV regulatory region precludes binding of 
TBP to the adjacent site. 
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For transcriptional repression, there needs to be an intact DNA binding domain 
as well as in the involvement of a competent transactivation domain (Goodwin, 
Naeger et al. 1998, Nishimura, Ono et al. 2000). The involvement of an intact 
transactivation domain has been suggested to recruit transcriptional co-re-
pressors. However, this mechanism is not fully understood.  One such transcrip-
tional co-repressor is Brd4, which is known for its involvement in mitotic segre-
gation (You, Croyle et al. 2004), could be involved in transcriptional activation 
and repression, depending on the chromatin context (Schweiger, Ottinger et al. 
2007, Wu, Lee et al. 2006a). Another suggested mechanism for repression in-
volves the looping of the regulatory sequences through interaction of the E2 
amino-terminal domains, could also be involved in the mechanism of repression 
(Hernandez-Ramon, Burns et al. 2008)(Hernandez-Ramon, Burns et al. 2008).  
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Figure 1.5 
 
Figure 1.5: Schematic map of the long control region of HPV16. Transcrip-
tional activity is mainly controlled by the LCR. Within the LCR there is a transcrip-
tional enhancer which associates with various cellular transcription factors. Four 
E2 binding sites are found in the HPV16 LCR, and viral gene expression is regu-
lated by the occupancy status of these E2BSs. Figure adapted from (Muller, 
Demeret 2012) 
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1.7.2 Growth inhibition and E2-mediated apoptosis 
As well as playing roles in viral transcription and replication, there are a number 
of reports of additional functions for E2. The pro-apoptotic activity of E2 is one 
of the first described E2 functions independent of its binding to the viral genome 
(Desaintes, Demeret et al. 1997) . This role is specific to high risk E2 types. Vari-
ous assay systems have shown that an overexpression of E2 induces apoptosis, 
and some of this activity may be related to E2’s ability to repress viral gene ex-
pression in HPV transformed cells when it is highly expressed, resulting in a de-
crease in E6 expression and consequent increased levels of p53 (Desaintes, 
Demeret et al. 1997) . In addition, E2 has also been shown to induce growth ar-
rest in the G1 phase of the cell cycle (Goodwin, Naeger et al. 1998, Hwang, Nae-
ger et al. 1996), as well as to abrogate the mitotic checkpoint (Frattini, Hurst et 
al. 1997), through both p53 dependent and independent mechanisms. 
1.7.3 Mitosis and genome segregation 
Papillomavirus infections are usually long lived and the virus requires a specific 
mechanism to retain the episomal genomes within the dividing epithelial cells. 
HPV segregates its genome into daughter cells by tethering them to cellular mi-
totic chromosomes, which ensures that viral DNA is retained in the nucleus after 
cell division (Bastien, McBride 2000, Ilves, Kivi et al. 1999, Lehman, Botchan 
1998, Piirsoo, Ustav et al. 1996).  
The E2 protein was first implicated to be involved in segregation of the epi-
somally replicating genome when it was found that multiple E2 binding sites 
were required in cis with the replication origin for long-term genome mainte-
nance (Piirsoo, Ustav et al. 1996).  It was established that E2 and the extrachro-
masomal genome in dividing cells were both tethered to condensed mitotic chro-
mosomes (Skiadopoulos, McBride 1998). The transactivation domain of E2 is re-
sponsible for the tethering E2 to chromosomes (Bastien, McBride 2000), which 
forms a bridge between chromosomes and the genome (Ilves, Kivi et al. 1999). 
When this interaction is abrogated there is a dramatic loss of viral genomes from 
infected cells (Lehman, Botchan 1998).  
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Brd4 has a diffuse cloud like appearance around the condensed mitotic chromo-
somes (Dey, Chitsaz et al. 2003), however, when E2 is present, both proteins lo-
calise in punctate foci (McPhillips, Ozato et al. 2005) E2 stabilises the interac-
tion of Brd4 with host chromatin forming a stable anchor in interphase and mito-
sis (McPhillips, Ozato et al. 2005). Two conserved residues in the transactivation 
domain of E2 (R37 and I73) mediate the interaction with Brd4, and mutations in 
these residues abrogate the interaction of E2 with Brd4 and mitotic chromatin 
(Baxter, McPhillips et al. 2005a). The DNA binding domain of E2 is required to 
link the viral genomes to chromatin, but it is not required for the interaction 
with Brd4 (Abroi, Ilves et al. 2004). 
The mechanism of E2-mediated viral genome tethering and E2-Brd4 chromoso-
mal binding is still not fully understood. Alpha-PV E2 proteins only weakly inter-
act with Brd4, they also do not stabilise association of Brd4 with host chromatin 
and cannot be easily detected on mitotic chromsomes, except in late telophase 
(Oliveira, Colf et al. 2006, Donaldson, Boner et al. 2007). Due to this difficulty in 
seeing E2-Brd4 in alpha-papillomaviruses at mitotic foci, it has been proposed 
that there may be other targets such as the mitotic spindle (Dao, Duffy et al. 
2006), a mitotic kinesis-like protein, MK1p2 (Yu, Peng et al. 2007), Ch1R1 (an 
ATP-dependent DNA helicase important for sister chromatid cohesion) (Parish, 
Bean et al. 2006) and TopBP1 (Donaldson, Boner et al. 2007). 
Work by Stilla et al has shown that attachment to genomes alone is not enough 
(Silla, Mannik et al. 2010); chromatin binding and transactivation functions must 
cooperate to ensure proper plasmid segregation. BPV1 E2 have been shown to 
bind to transcriptionally active regions of chromatin through genome-wise ChIP-
on-chip studies. It has been proposed that the purpose of this is to ensure that 
the viral genome is localised to transcriptionally active regions in the nucleus 
(Jang, Kwon et al. 2009b). 
 
 
 
 
Chapter 1  61 
 
 HPV E2 interaction with host proteins 
E2 protein binds to a range of cellular proteins that are required for each of E2s 
functions. A detailed list of E2 associated proteins can be found in a recent re-
view by Alison McBride (McBride 2013). E2 associated proteins fall into several 
categories such as transcriptional regulation, RNA processing, apoptosis, cell cy-
cle, nuclear import and protein degredation. 
Transcriptional regulation represents the largest category of E2 interacting pro-
teins. E2 binds many basal transcriptional regulators (TAF, TBP, GTF2B) or regu-
latory transcription factors (SP1, HOXC9, NR4A1, C/EBP). E2 also interacts with 
co-activators (TMF), which suggests that the transcriptional properties of the vi-
rus may rely on the modulation of preinitation complex formation on specific 
promoters. The best characteristed interaction is between E2 and Brd4, which 
regulates transcription on the chromatin level.  Brd4 binds to acetylated his-
tones and stimulates RNA polymerase II-dependent transcription by recruiting 
distinct transcriptional regulators (Wu, Chiang 2007b). Failure to bind Brd4 abro-
gates the ability of E2 to activate transcription (Schweiger, You et al. 2006). 
E2 has also been found to regulate transcription through modification of the his-
tone code, by targeting histone-modification factors. E2 interacts with many his-
tone acetyltransferases such as PCAF, EP300, EP400 or CBP (Lee, Hwang et al. 
2002, Lee, Lee et al. 2000, Muller, Ritzkowsky et al. 2002, Cha, Seo 2011). Addi-
tionally, E2 also interacts with members of the chromatin remodelling com-
plexes, which are involved in the displacement of nucleosomes.  NAP1L1 and 
hSNF5 are both known E2 interactors (Cha, Seo 2011, Rehtanz, Schmidt et al. 
2004). 
1.8.1 E2 regulation of the host genome 
Previous studies of how E2 regulates the host genome to aid progression of the 
viral life cycle have focused on determining the effects of E2 on specific promot-
ers and biological processes. There is a gap in our understanding of how E2 regu-
lates cellular processes on a global scale. 
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Two complementary studies have shown that E2 binds to transcriptionally active 
cellular genes without significantly changing the mRNA levels of the E2-bound 
cellular genes. This suggests that the binding of E2 to transcriptionally active 
cellular genes does not have an effect on their activity (Vosa, Sudakov et al. 
2012, Jang, Kwon et al. 2009a). 
Vosa et al 2011 studied the occurrence and functionality of E2 binding sites 
(E2BS) in the human genome. Using a combination of computational analysis and 
genome-wide chromatin immunoprecipitation –on-chip analysis with human pro-
moter sequences, specific sites of E2 interaction were identified on chromatin.  
They found that E2 interacts with E2BSs located in active chromatin regions. E2 
and Brd4 were found bound on transcriptionally active promoters, and E2 binding 
did not correlate with the E2BS in the promoters. BPV1 E2 may bind to active re-
gions to escape silencing, giving an additional role for E2-mediated tethering of 
viral genomes to host chromatin; partitioning of viral genomes to daughter cells, 
ensure genomes are retained in the nucleus, and also to ensure that genomes 
are retained in functionally active nuclear domains to aid in the progression of 
the viral life cycle (Vosa, Sudakov et al. 2012). 
A study by Ramirez-Salazar et al overexpressed HPV16 E2 in HPV negative cells 
(C33a cells) using a recombinant adenoviral vector for use in microarray analysis 
studies to determine how E2 regulates biological processes (Ramirez-Salazar, 
Centeno et al. 2011). The main cellular pathway that was regulated by HPV16 E2 
expressing cells was WNT. The WNT pathway regulates genes involved in cellular 
processes such as, apoptosis, proliferation and cell differentiation. Additionally, 
16E2 overexpression was also shown to regulate genes from pathways such as 
PDFG, angiogenesis and cytokine and chemokines mediated inflammation. The 
cellular processes that were shown to be regulated by E2 expression provide a 
convenient environment for the replicative cycle of the virus (Ramirez-Salazar, 
Centeno et al. 2011). 
 E5 protein  
All α HPVs encode and express E5, however most β HPVs do not. The E5 ORF can 
be classified into four different groups depending on genera: alpha, beta, 
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gamma and delta (Bravo, Alonso 2004), these types correlate with different clin-
ical manifestations, in particular with oncogenic potential (Schiffman, Herrero 
et al. 2005). E5-aplha protein is encoded by HR αHPV and the E5-gamma and E5-
delta proteins are encoded by the low-risk genital HPVs (Garcia-Vallve, Alonso et 
al. 2005). However, the E5 ORF is often absent in the genome of many of the 
beta-, gamma- and mu-HPVs, which suggests that it is not an essential protein 
for the life cycle of HPVs, but may give some extra benefit to the virus with re-
gards to increasing the likelihood of oncogenic transformation following persis-
tent infections. In BPV-4 induced papillomas (Araibi, Marchetti et al. 2004) and 
HPV-16 induced cervix lesions (Chang, Tsao et al. 2001), E5 has been shown to 
be expressed in the basal and suprabasal layers. 
HPV16 E5 protein is 83 amino acids long. This protein is extremely hydrophobic 
and located within the membrane and expressed at very low levels. The HPV E5 
proteins display weak transforming activity in vitro. The first evidence of this 
transformation capability came from experiments with HPV-6 in mammalian 
cells, which showed that expression of HPV-6 E5 in established murine fibro-
blasts lead to anchorage independent growth (Chen, Mounts 1990). The E5 pro-
tein is known to interact with many cellular proteins and these interactions are 
important for the biological activity of E5 and evasion of the immune response. 
The transforming effects of E5 can be enhanced when it co-operates with other 
viral oncoproteins. When E5 interacts with E6 it can induce the formation of 
koilocytes, large cells with cleared cytoplasm and pyknotic nuclei with incon-
spicuous nucleoli, this is a morphological marker of HPV infection (Krawczyk, Su-
prynowicz et al. 2008).  
 E4 protein   
The primary E4 gene product is expressed from a spliced mRNA (E1^E4), in which 
the first five amino acids of E1 are spliced to the E4 ORF (Chow, Reilly et al. 
1987, Doorbar, Parton et al. 1990, Milligan, Veerapraditsin et al. 2007, Wang, 
Meyers et al. 2011, Ozbun, Meyers 1997). The E4 open reading frame varies in 
size between papillomavirus types. Although there is some sequence homology 
between E1^E4 proteins dictated by virus types of similar pathology, sequence 
homology is found within the amino and carboxy termini of the proteins (Rob-
erts, Ashmole et al. 1994, Roberts, Ashmole et al. 1997). 
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E4 was originally described as an early gene, although it is not clear that is has 
any function in the early stages of the life cycle.  This original distinction was 
given to E4 due to where it lies in the viral genome and it is found embedded in 
amongst early viral genes that are responsible for the regulation of cell cycle en-
try and genome maintenance (Chen, Howley et al. 1982, Danos, Katinka et al. 
1982). 
Though extensive studies have been made to investigate the role of E4 in the vi-
rus life cycle, its role still remains unclear. Most work focusing on high-risk E4 
proteins has come from studies in HPV16, 18 and 31. In these high-risk E4 pro-
teins there is a “leucine-cluster” motif close to their N-terminus, which is im-
portant (along with upstream amino acids) for keratin association.   This motif is 
thought to be largely unavailable for cytokeratin binding, and instead associates 
with the E4 multimerisation-motif located at the C-terminus of the protein 
(McIntosh, Martin et al. 2008, Bryan, Fife et al. 1998). Prior to the onset of ge-
nome amplification, the E1^E4 protein is not very apparent, however, it may be 
present at very low levels. The large increase in the presence of E1^E4 at around 
the onset of genome amplification, coincides with the activation of the differen-
tiation-dependent promoter (i.e p670 in HPV16) and subsequently an elevation in 
E1^E4 transcript levels. 
The first evidence of the role of E4 in amplification as opposed to early stages of 
infection came from work using mutant CRPV genomes that contain translation-
termination linkers in the E4 ORF (Peh, Brandsma et al. 2004). These mutant ge-
nomes with no E4 reduced the efficiency of genome amplification and the syn-
thesis of capsid proteins (Peh, Brandsma et al. 2004).  The role of E4 proteins in 
the amplification stage and additionally in the synthesis of capsid proteins was 
then later shown in HPV 16 (Nakahara, Peh et al. 2005), HPV 31 (Wilson, Fehr-
mann et al. 2005), and HPV 18 (Wilson, Ryan et al. 2007), using organotypic raft 
culture systems, the presence of which optomises life-cycle completion. The 
mechanism by which E4 achieves this is yet unknown. 
E1^ E4 has been linked to several biological functions within the viral life cycle, 
such as the disruption of normal cell division. (Davy, Jackson et al. 2002, Knight, 
Grainger et al. 2004, Nakahara, Nishimura et al. 2002). E1 ^E4 has also been 
shown to initiate the relocation of PML from multiple intranuclear speckles 
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(ND10 bodies) to the periphery of E4 inclusions (Roberts, Hillman et al. 2003) 
(Roberts 2002). Viral replication and virion assembly is proposed to be carried 
out within ND10 bodies. HPV1 E4 may disrupt of reorganise ND10 domains for ef-
ficient viral replication and ultimately increase the efficiency of HPV infection. 
Additionally, E1^E4 may aid in the release of newly synthesised virions from the 
upper cells in the epithelium, by a weakening of the cornified cell envelope 
(Bryan, Han et al. 2000) and also by disturbing the intermediate filament cyto-
skeleton (Doorbar, Ely et al. 1991, Roberts, Ashmole et al. 1993). 
E4 has been shown to be highly expressed in the mid and upper epithelial layers 
during productive infection (Maglennon, McIntosh et al. 2011, Doorbar, Foo et al. 
1997, Peh, Middleton et al. 2002). Due to the high expression of E4 in lesions, it 
has been suggested that E4 could be a valuable biomarker of active HPV disease 
(Middleton, Peh et al. 2003, Borgogna, Zavattaro et al. 2012), and at the cervix, 
E4 may serve as a marker for the severity of the disease (Griffin, Wu et al. 2012, 
Doorbar, Cubie 2005).  
 Capsid proteins 
The viral genome is packaged within the major (L1) and minor (L2) capsid pro-
teins that are produced through alternative-splicing  mechanisms, which regu-
lates the capsid-ORF transcriptional program (Buck, Cheng et al. 2008, Swindle, 
Zou et al. 1999, Doorbar, Gallimore 1987, Okun, Day et al. 2001, Buck, Thomp-
son et al. 2005, Kawana, Yoshikawa et al. 1998, Fligge, Schafer et al. 2001, 
Mole, Milligan et al. 2009).  
HPV caspids are composed of approximately 360 copies of the major capsid pro-
tein L1, which accounts for 80-90% of total viral protein (Favre 1975). Through 
hydrophobic interactions L1 proteins rapidly assemble into pentameric cap-
somers (Kirnbauer, Booy et al. 1992, Kirnbauer, Taub et al. 1993). 72 of these L1 
structures that form the capsid are arranged in a in a T=7 icosohedral array 
through a complex network of hydrophobic interactions and disulphide bonds 
(Baker, Newcomb et al. 1991a, Culp, Cladel et al. 2006, Trus, Roden et al. 1997, 
Baker, Drak et al. 1989, Belnap, Olson et al. 1996, Finnen, Erickson et al. 2003, 
Culp, Budgeon et al. 2006a, Modis, Trus et al. 2002, Ishii, Ozaki et al. 2005, 
Sapp, Fligge et al. 1998, Li, Beard et al. 1998). The localisation of L2 within this 
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structure is unknown, nor is its mechanism of assembly, although reports suggest 
that disulphide bonding may play a role (Belnap, Olson et al. 1996, Baker, New-
comb et al. 1991b). The capsid encases a single, circular, dsDNA genome of ap-
proximately 8kb, which associates with histones to form a chromatin-like struc-
ture (Fligge, Schafer et al. 2001, Belnap, Olson et al. 1996). The stability of the 
capsid is increased with the genome, increasing its resistance to environmental 
stresses such as proteolysis (Fligge, Schafer et al. 2001)  
L1 can accommodate up to 72 molecules of the L2, minor capsid protein.  Alt-
hough L1 is only minimally exposed at the surface of mature virion, it emerges 
from virion during the infectious entry process (Day, Baker et al. 2004)(Day, 
Gambhira et al. 2008). L1 is also transiently exposed in immature virions (Rich-
ards, Lowy et al. 2006). 
1.11.1 L1 protein 
The papillomavirus major capsid protein, L1, is approximately 55 kDa in size and 
has the ability to spontaneously self-assemble into a virus-like particle (VLPs). 
These VLPs make up the exterior surface, which is indistinguishable from the na-
tive 60nm non-enveloped papillomavirus virion. Due to the fact assembled VLPs 
are potent immunogens (Bachmann, Rohrer et al. 1993, von Bubnoff 2012), they 
have been used in the current VLP-based vaccines, which offer highly effective 
protection against HPV 16 and 18.  
The major protein L1 has a solved crystal structure (Chen, Garcea et al. 2000), 
which was used for predicting the localisation of L2 within the L1-pentameric 
shaft through Cluspro docking software (Lowe, Panda et al. 2008). The exterior 
surface of papillomavirus is made up of 72 knobs of pentameric L1 capsomer. 
The N- and C-termini of L1 are arranged as extended “invading arms” that form 
the floor between the capsomer knobs (Modis, Trus et al. 2002, Wolf, Garcea et 
al. 2010). 
1.11.2 L2 protein 
L2 is almost 500 amino acids in length, and has an estimated molecular mass of 
approximately 55kDa. However, when looking at L2 in SDS-PAGE analysis it ex-
hibits an apparent molecular weight of around 64-78kDa (Doorbar, Gallimore 
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1987) (Jin, Cowsert et al. 1989, Komly, Breitburd et al. 1986, Rippe, Meinke 
1989). The L2 protein has numerous functions and interacting partners. L2 facili-
tates in genome encapsidation, host cell entry, vesicular trafficking of the virus, 
vesicular escape during infection, nuclear entry and activities within the nu-
cleus. In silico analysis confirms interactions of L2 with β-actin (Yang, Yutzy et 
al. 2003) and the nuclear pore complex proteins (Holmgren, Patterson et al. 
2005, Florin, Becker et al. 2004, Fay, Yutzy et al. 2004, Bordeaux, Forte et al. 
2006, Darshan, Lucchi et al. 2004b), and that L2 is required for an infectious vi-
rion (Roden, Day et al. 2001). 
The amino terminus of the viral L2 protein contains highly conserved cysteine 
residues (C22 and C28) which are found in all PV types, and form an intra-molec-
ular disulphide hairpin loop rather than bridging with L1. No X-ray crystallo-
graphic structures are available for caspids containing L2. Studies have at-
tempted to look at high resolution three dimensional image reconstruction of 
cryo-electron micrographs of native BPV1, HPV1, or CRPV virions, HPV1 or HPV16 
VLPS to visualise the structure of L2 in the capsid (Buck, Cheng et al. 2008, Trus, 
Roden et al. 1997, Belnap, Olson et al. 1996, Baker, Phelps et al. 1987, Buck, 
Trus 2012, Hagensee, Olson et al. 1994). Cryo-EM has allowed for us to deduce 
L2s localisation within the L1 caspid, suggesting that L2 is localised within the L1 
caspid, which would be consistent with L2 functioning as a sub-scaffold within 
the intact virion (Buck, Cheng et al. 2008, Selinka, Florin et al. 2007). Possible 
reasons for these studies failing to visualise L2 are possibly due to L2 reflecting 
inadequate incorporation into the capsid, degredation, disorder or lack of sym-
metry.  
 E2 interactors TopBP1 and Brd4 
As the papillomavirus genome only encodes a small number of viral proteins, in 
order to maintain the viral life cycle within the host, each of these proteins in-
teracts with numerous cellular proteins to carry out its life cycle (Muller, 
Demeret 2012). In order for E2 to carry out transcription and replication roles in 
the viral life cycle, E2 must interact with host cellular proteins. Two such pro-
teins, TopBP1 and Brd4, are known to play roles in replication and transcription 
respectively (Schweiger, You et al. 2006, Kumagai, Shevchenko et al. 2010, 
Makiniemi, Hillukkala et al. 2001). 
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1.12.1 TopBP1 structure and function 
Human topoisomerase IIβ binding protein 1 (TopBP1) contains 9 BRCT (Breast 
Cancer Susceptibility Gene 1 [BRCA1] Carboxy Terminus domains (Yamane et al 
1999) which were originally identified within the carboxy terminus of BRCA1 
(Figure 1.6). TopBP1 was identified in a yeast two-hybrid screen for factors that 
interacted with Topoisomerase IIβ (Yamane, Kawabata et al. 1997). The TopBP1 
gene is comprised of 28 exons located on chromosome 3q22.1 and encodes for a 
1522 amino acid protein (180kDa) (Karppinen, Erkko et al. 2006, Xu, Leffak 2010, 
Yan, Michael 2009). TopBP1 is essential for maintenance of chromosomal integ-
rity and cell proliferation. TopBP1 also has many roles which involve; DNA dam-
age response, DNA replication checkpoint, chromosome replication and regula-
tion of transcription (Bang, Ko et al. 2011) (Garcia, Furuya et al. 2005, Jeon, Ko 
et al. 2011). The critical role of TopBP1 is evolutionary conserved between vari-
ous organisms including Drosophila and mouse. It has been shown that a TopBP1 
knockout mouse is embryonic lethal at the peri-implantation stage and TopBP1 
deficiency also induces cellular senescence in primary cells (Bang, Ko et al. 
2011, Jeon, Ko et al. 2011). 
TopBP1 is a scaffold protein capable of making numerous protein-protein inter-
actions through its constituent BRCT domains (Figure 1.6). These domains are 
found in pairs and their interactions are phosphor-specific. This allows for the 
regulation of their interactions via phosphorylation/dephosphorylation of their 
respective binding partners through the activity of distinct kinases and phos-
phates (Yu, Chini et al. 2003). BRCT domains of TopBP1 bring different proteins 
into temporal complexes, which in turn promote various cellular processes such 
as DNA replication initiation and checkpoint activation. Human TopBP1 was ini-
tially assigned 8 BRCT domains, with BRCT1+2, 4+5 and 7+8 forming pairs. Later 
an additional BRCT domain was identified (Garcia, Furuya et al. 2005), at the ex-
treme N-terminus. This new BRCT domain has been named BRCT 0, and has since 
been confirmed by structural studies (Rappas, Oliver et al. 2011). 
TopBP1 protein has a transcriptional –activation domain and two surrounding re-
pressor domains and can play a role in regulating transcription. Between amino 
acids 460-591 lays a transcriptional-activation domain, this region partly con-
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tains BRCT4. This is an essential region for transactivation and is rich in hydro-
phobic amino acids interspersed with acidic residues, this is typical characteris-
tic of transcriptional domains. A transcriptional repression domain located at 
BRCT2, lies within the transcriptional activation domain (Wright, Dornan et al. 
2006). A second repression domain exists within the C terminus of the activation 
domain, which requires amino acids 586-675. The carboxy-terminal of TopBP1 
contains two putative nuclear localisation signals (Going, Nixon et al. 2007, Liu, 
Lin et al. 2003, Sokka, Parkkinen et al. 2010) and deletion of BRCT7-8 and NLS 
region of TopBP1 induces cytoplasmic localisation of the protein.  
As previously mentioned, TopBP1 contains transactivational-repression domains, 
and has been proposed as a transcriptional repressor of E2F1 (Wright, Dornan et 
al. 2006, Liu, Luo et al. 2004), as well as a transcriptional co-activator with 
HPV16 E2 (Yoshida, Inoue 2004). TopBP1 interacts with E2F1 through the sixth 
BRCT motif of TopBP1 and N terminus of E2F1 (Liu, Lin et al. 2003, Leung, Kel-
logg et al. 2010). This induces the ATM-mediated phosphorylation of E2F1 at 
Ser31 upon DNA damage. E2F1’s transcriptional activity is repressed and E2F1 is 
recruited to DNA damaged nuclear foci (Liu, Lin et al. 2003). 
TopBP1 protein is also phosphorylated by Akt. Phosphorylation at Ser1159 in-
duces oligomerisation of TopBP1 through its seventh and eighth BRCT domains, 
which is important for the interaction with E2F1 and transcriptional repression 
(Liu, Paik et al. 2006). The E2F1 regulation of TopBP1 involves the phosphoinosi-
tide 3-kinase (PI3K)-Akt signalling pathways. This phosphorylation may also pre-
vent association of ATR with TopBP1 after DNA damage, thus inhibiting activa-
tion of ATR and G2/M checkpoint proficiency (Pedram, Razandi et al. 2009). Ad-
ditionally, Akt phosphorylation is also required for the interaction between 
TopBP1 and Miz1 or HPV16 E2. The interaction between Miz1 and TopBP1 re-
presses transcriptional activity, which implies TopBP1 plays a role in controlling 
transcriptional factors  
TopBP1 also recruits Brg1/BRM (Brahma-related gene 1/ Brahma protein), a cen-
tral subunit of the SWI/SNF (SWItch/sucrose nonfermentable) chromatin model-
ling complex, to specifically inhibit E2F1 transcriptional activity.  This is critical 
for E2F1 regulated apoptosis control during S phase and DNA damage.  TopBP1 
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expression is also induced by E2F1 and interacts with E2F1 during G1/S transi-
tion. These interactions form a feedback regulation to prevent apoptosis during 
DNA replication (Liu, Lin et al. 2003). 
1.12.2 TopBP1 and DNA damage response 
TopBP1 is a multifunctional protein, in response to DNA damage it has many 
roles such as checkpoint activation at G2/M in response to DNA damage and it 
also directly inhibits E2F1-mediated apoptosis. TopBP1 can be visualised as foci 
at sites of DNA damage or replication stress (Makiniemi, Hillukkala et al. 2001). 
TopBP1 plays a role in bringing DNA damage sensors, mediators and effectors to 
sites of DNA damage, and can also directly stimulate the kinase activity of ATR 
(Kumagai, Lee et al. 2006b). Cells have developed DNA damage pathways to 
maintain genomic stability in response to endogenous and exogenous stress 
(Aguilera, Gomez-Gonzalez 2008, Ciccia, Elledge 2010, Jackson, Bartek 2009, 
Branzei, Foiani 2010).  Two conserved PI3-kinase-like protein kinases, ATM 
(Ataxia telangiectasia mutated) and ATR (ATM- and Rad3-related) respond to 
DNA damage to control cell cycle progression and the regulation of other DNA 
damage responses such as DNA repair and apoptosis. ATM and ATR proteins are 
serine/threonine-specific kinases of about 300 kDa (Choi, Lindsey-Boltz et al. 
2009, Smits, Warmerdam et al. 2010). 
The induction of ATR is in response to single stranded DNA (ssDNA) occurring due 
to replication stress, resected double stranded breaks (DSBs) or other single 
strand lesions (Biton, Dar et al. 2006, Cimprich, Cortez 2008, Mavrou, Tsangaris 
et al. 2008, You, Shi et al. 2009). In eukaryotes, DNA damage-induced ssDNA is 
detected by ssDDNA binding protein complex RPA (Smits, Warmerdam et al. 
2010). Once bound to ssDNA, RPA is phosphorylated (Binz, Sheehan et al. 2004, 
Nasheuer 2010). RPA-coated ssDNA is a critical step for ATR activation. ATR asso-
ciates with ATRIP (ATR-interaction protein) an 85 kDa protein, which recruits 
ATR to RPA-coated ssDNA (Ball, Myers et al. 2005, Cortez, Guntuku et al. 2001, 
Mordes, Nam et al. 2008, Edwards, Bentley et al. 1999). This complex regulates 
the localisation of ATR to sites of replication stress and DNA damage. ATR acti-
vation also requires the activator protein TopBP1 (Mordes, Nam et al. 2008). Be-
fore ATR can be activated, the Rad17-RCF checkpoint clamp must be recruited 
to the junction of RPA-coated ssDNA and double stranded DNA (dsDNA), which 
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facilitates the loading of Rad9-Hus1-Rad1 (9-1-1) sliding clamp (Zou, Liu et al. 
2003). This co-recruitment of ATR and the 9-1-1 clamp establishes a platform for 
the activation of the ATR pathway (Liu, Shiotani et al. 2011, Lee, Kumagai et al. 
2007, Cotta-Ramusino, McDonald et al. 2011).  
In response to genotoxic stresses, TopBP1 colocalises and interacts with 
ATR/ATRIP.  The BRCT1 and BRCT2 domains in the amino terminal of TopBP1 
bind to phosphorylated Ser373 in the C-terminal of Rad9 (Rappas, Oliver et al. 
2011, Lee, Kumagai et al. 2007, Delacroix, Wagner et al. 2007, Kumagai, Lee et 
al. 2006a)(Smits, Warmerdam et al. 2010)(Takeishi, Ohashi et al. 2010). TopBP1 
then binds ATR through its ATR activation domain (AAD), which is located be-
tween the sixth and seventh BRCT repeats, in an ATRIP- dependent manner 
(Kumagai, Lee et al. 2006a)((Mordes, Nam et al. 2008)(Smits, Warmerdam et al. 
2010, Takeishi, Ohashi et al. 2010). ATRIP contains a conserved TopBP1 interact-
ing region, required for the association of TopBP1 and ATR and the subsequent 
TopBP1 mediated triggering of ATR activity (Mordes, Nam et al. 2008)(Smits, 
Warmerdam et al. 2010) 
TopBP1 protein also plays a direct and essential role in the pathway that con-
nects ATM to ATR, specifically in response to the occurrence of DSBs in a genome 
(Yoo, Kumagai et al. 2007).  
1.12.3 TopBP1 and DNA replication 
In budding yeast and Xenopus systems, replication initiation has been well stud-
ied. During G1 phase the pre-replicative complex (pre-RC) is assembled on the 
origin of replication. The pre-RC is composed of a number of proteins such as, 
ORC, Cdt1, Cdc6 components and MCM proteins. The pre-RC is activated at the 
onset of S-phase by S-phase dependent kinases (S-CDKs) and the Cdc7-Dbf4 pro-
tein kinase (DDK). This in turn results in the binding of Cdc45, the conversion of 
the pre-RC into a pre-initiation complex (Pre-IC), and also the unwinding of DNA 
at the origin of replication. This then leads to the recruitment of RPA, polα, and 
polε to form the initiation complex (IC). 
The TopBP1 family of proteins (Dpb11 in yeast, Rad4/Cut5 in S.pombe, Mus101 in 
Drosophila, and TopBP1 in metazoans) plays an essential role in the initiation of 
Chapter 1  72 
 
DNA replication (Masumoto, Sugino et al. 2000, Hashimoto, Takisawa 2003). De-
pletion experiments in Xenopus indicated that XCut5TopBP1 is not required for the 
loading of pre-replication components, but is needed for the loading of pre-initi-
ation complex components (Cdc45 and RPA) and the DNA polymerases (polα and 
polε). This is also seen in S.pombe (Dolan, Sherman et al. 2004) and S.cerivsiae 
(Araki, Ropp et al. 1992) homologues. In Saccharomyces cerivisiae, S-phase cy-
clin dependent kinase (CDK) promotes initaiton by phosphorylating Sld2 and 
Sld3, which enhances the binding of Dbp11. Dbp11 then binds origin chromatin 
and recruits the replisome together with the GINS complex and Cdc45, leading to 
replication initiation (reviewed in (Zegerman, Diffley 2009, Tanaka, Araki 
2010)). In humans, TopBP1 transcript and protein levels increase during S-phase 
(Makiniemi, Hillukkala et al. 2001, Liu, Luo et al. 2004, Yamane, Wu et al. 
2002), which indicates that it plays a role in the initiation of replication. Studies 
have indicated that the sixth BRCT domain is critical for TopBP1 replication ac-
tivity, possibly through an interaction with another replication factor 
(Makiniemi, Hillukkala et al. 2001). TopBP1 and its homologs do not directly bind 
the origin recognition complex or MCM helicase without recruitment by the phos-
phorylated RecQ4/Treslin (Kumagai, Shevchenko et al. 2010, Kumagai, 
Shevchenko et al. 2011) (Sld2/Sld3) (Im, Ki et al. 2009), which regulates replica-
tion initiation in a cell cycle controlled manner. 
TopBP1, and its Xenopus and yeast homologs, all bind to Polε when overex-
pressed (Makiniemi, Hillukkala et al. 2001, Mimura, Masuda et al. 2000). 
1.12.4 The role of TopBP1 in the viral life cycle 
For E2 to function it requires host protein interactions. The Morgan lab aimed to 
identify these cellular partners in order to provide targets for disruption of the 
viral life cycle, as well as gaining a better understanding of the viral life cycle, 
specifically transcription and replication mechanism (Boner, Morgan 2002a). In 
order to identify these cellular partners, yeast two-hybrid screening was uti-
lised, using the amino-terminus of the viral E2 protein that is essential for medi-
ating transcription and replication.  From this screen, TopBP1 was identified as a 
promising E2 interacting protein, due to its known roles in replication, cell cycle 
control and response to DNA damaging agents (Yamane, Kawabata et al. 1997, 
Yamane, Wu et al. 2002)(Makiniemi, Hillukkala et al. 2001). Subsequently, 
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TopBP1 was shown to interact in vitro and in vivo with E2 and can regulate the 
ability of E2 to control transcription and replication (Boner, Taylor et al. 2002). 
TopBP1 has been proposed to play a role as a transcriptional regulator. If TopBP1 
is overexpressed it co-activates transcription with the HPV16 E2 protein when E2 
is bound to target promoters (Boner, Taylor et al. 2002).  TopBP1 has also been 
implicated as being a transcriptional repressor; as TopBP1 can interact with the 
chromatin modification complex proteins Brg1 (BRM (Brahma)-related gene 
1)/BRM1 and represses the transcriptional and apoptotic function of E2F1 (Liu, 
Luo et al. 2004).  A feedback loop is formed as E2F1 positively regulates the 
TopBP1 promoter (Yoshida, Inoue 2004). 
TopBP1 binds to the human papillomavirus early protein E2, and modulates its 
transcriptional activation, as well as E2F1 transcription factor and the POZ do-
main factor Miz1 that can be co-regulated by c-Myc. The viral E2 protein regu-
lates viral transcription (Desaintes, Goyat et al. 1999) by binding to specific tar-
get sequences through its C-terminus and additionally it recruits transcriptional 
co-activators such as TBP, TFIIB and p300/CBP via interactions with its amino 
terminus (Boner, Morgan 2002b). The amino terminal region of TopBP1 has been 
shown to have transcriptional activation activity in yeast (Makiniemi, Hillukkala 
et al. 2001), and deletion of this region impairs E2 transcriptional activation. 
TopBP1 is proposed to be the mitotic chromatin acceptor for HPV16 E2, the asso-
ciation of E2 with chromatin may play a key role in mediating genome segrega-
tion and DNA replication functions of the E2 protein (Donaldson, Boner et al. 
2007). Donaldson et al showed that an absence of TopBP1 results in a redistribu-
tion of HPV 16 E2 into an alternative cellular protein complex, resulting in en-
hanced affinity for chromatin. This does not significantly alter the ability of E2 
to either activate or repress transcription. TopBP1 may also be the mitotic chro-
matin receptor for HPV16 E2 as it was shown to co-localise on chromatin at late 
stages of mitosis (Donaldson, Boner et al. 2007). 
A non-TopBP1 interacting 16E2 mutant (E2TopBP1), which is defective in replica-
tion but retains transcriptional function, has been identified (Donaldson, Mackin-
tosh et al. 2012) (amino acids responsible for the E2-TopBP1 interaction are 
highlighted in Figure 1.7). This mutant along with a non-Brd4 mutant shall form 
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the main focus of this thesis. The transcriptional function with the mutant is 
compromised at lower levels of input DNA. However, it can activate transcrip-
tion at almost WT levels when overexpressed. In the case of DNA replication, the 
optimal function of E2 cannot be regained at higher concentrations of DNA input. 
Due to the function of E2 not being dramatically impaired in transcription activa-
tion and repression function, it is believed that E2 is still binding to Brd4. Addi-
tonally, the defects in replication are not due to an altered stability of the E2-
TopBP1 protein. 
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Figure 1.6 
 
Figure 1.6: TopBP1 domain structure and BRCT domain protein interactions. 
The diagram of human TopBP1 displays the component domains, highlighting 
BRCT and AAD (ATR Activation) domains. Human TopBP1 has 9 BRCT domains 
which are found in pairs. TopBP1 is capable of making numerous protein-protein 
interactions though these BRCT domains. The table notes these protein-protein in-
teractions, which are colour coded related to function; red for checkpoint activa-
tion, blue for initiation of DNA replication, green for DNA repair and purple for tran-
scriptional regulation. This figure was adapted from (Wardlaw, Carr et al. 2014) 
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Figure 1.7 
 
Figure 1.7: TopBP1-E2 interaction. E2 amino acids 50-100 interact with three 
TopBP1 domains (as highlighted in the figure above, BRCT, 5 and 6). An E2 mu-
tant which fails to interact with TopBP1 has a mutation at amino acids 89-90 (high-
lighted in green on the E2 sequence). Possible phosphorylation sites (highlighted 
in red) may also be responsible for the impaired interaction. E2 cartoon was 
adapted from (Abbate, Berger et al. 2004). 
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 Bromodomain proteins and disease 
Proteins with two tandem bromodomains, followed by an additional extratermi-
nal (ET) domain, constitute the BET subfamily. The BET subfamily of proteins in-
clude; mammalian Brd2/Ring3/Fsrg1/Brd3/ Orfx/ Fsrg2/Brd4/MCAP, and 
Brd5/Brdt, Drosophila Fs(1)h, yeast Bdf1 and Bdf2, and corresponding homo-
logues in other species (Denis, Vaziri et al. 2000) (Dey, Ellenberg et al. 
2000)(Matangkasombut, Buratowski et al. 2000). 
Bromodomain containing proteins are of substantial biological interest, as com-
ponents of transcription factor complexes and determinants of epigenetic 
memory.  The mammalian bromodomains all display similar gene arrangements, 
domain organisations, and some functional properties. The bromodomain is a 
conserved region of approximately 110 amino acids that structurally forms 4 α-
helices (αz, αA, αB, αC) and 2 loops, linking αz and αA (ZA loop) and αB and αC (BC 
loop), these loops can bind acetyl-lysine residues in histones in addition to many 
other proteins (Zeng, Zhou 2002). The mammalian bromodomain proteins all 
have two conserved N-terminal bromodomains (BD1 and BD2), which are chroma-
tin interaction molecules that recognise lysine residues on histone tails and 
other nuclear proteins (You, Croyle et al. 2004, Dey, Chitsaz et al. 2003). They 
are chromatin “readers”; they recruit chromatin regulating enzymes, including 
“writers” and “erasers” of histone modification, to target promoters and regu-
late gene expression. The chromatin targeting activity of bromodomain contain-
ing proteins allows them to access chromatin and regulate gene activity through 
cell cycle progression. 
The best studied of these bromodomains is Bromodomain-containing protein 4 
(Brd4), which is recognized as a critical mediator of normal and disease func-
tions through it’s interaction with both cellular and viral factors. Brd4 is a known 
target for viral encoded regulators in both human papillomavirus and human im-
munodeficiency virus. This interaction allows the virus to hijack cellular machin-
ery to facilitate selective viral genom integration during mitosis (You, Croyle et 
al. 2004, Bisgrove, Mahmoudi et al. 2007). The deregulation of Brd4 is also asso-
ciated with a number of cancers (acute myeloid leukemia, multiple myeloma, 
Brukitt’s lymphoma. NUT midline carcinoma, colon cancer).  Cancer cells exploit 
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the host cell’s transcriptional and chromatin machinery to propogate their onco-
genic gene expression profiles (Wu, Donohoe 2015). Brd4 was initially identified 
via its association in NUT midline carcinoma (NMC) which is known to affect ad-
jacent parts of the respiratory tract (French, Miyoshi et al. 2003). 
The involvement of Brd4 in multiple cancers makes it a valuable therapeutic tar-
get. Pharmacological inhibition of BET bromodomain binding with small mole-
cules such as JQ1 and I-BET, interferes with Brd4’s requirement for enhancer 
function and transcriptional elongation in multiple cancers (glioblastoma, lung 
adenocarcinoma, ALL (acute lymphoblastic leukemia) and MLL (mixed-lineage 
leukemia (Delmore, Issa et al. 2011, Filippakopoulos, Qi et al. 2010, Rahl, Lin et 
al. 2010). 
1.13.1 Structure and function of Brd4 
The ubiquitously expressed Brd4 protein is approximately 200kDa, and was first 
identified in mouse as mitotic chromosome associated protein (MCAP) as it was 
first found associated with mitotic chromosomes (Dey, Chitsaz et al. 2003). Brd4 
contains two tandem bromodomains (BD1 and BD2) and an extraterminal (ET) 
domain (Florence, Faller 2001) (Figure 1.8). The structures of both Brd4 BD1 
and BD2 bromodomains have been solved and consist of 4 alpha helices and 2 
loops linking the alpha helices (Filippakopoulos, Picaud et al. 2012, Vollmuth, 
Blankenfeldt et al. 2009) (Figure 1.8). The BD1 domain binds to H3-K5ac, 
whereas BD2 binds to H4-K5ac and H4-K16ac (Vollmuth, Blankenfeldt et al. 
2009). The interactions of the two N-terminal bromodomains of Brd4 with lysine 
residues on histone tails, allows Brd4 to be retained on the chromatin during mi-
tosis in a range of cell types (Vollmuth, Blankenfeldt et al. 2009). The interac-
tion of bromodomains with acetylated chromatin result in the localisation of BET 
proteins to discrete locations along the chromosome, where they recruit other 
regulatory complexes to influence gene expression (Devaiah, Singer 2013).  
The association of Brd4 with chromatin persists throughout the cell cycle and is 
also implicated in cell cycle control (Dey, Chitsaz et al. 2003). The importance 
of Brd4 for regulating cell cycle control has been demonstrated in various ways, 
mouse studies injecting anti-Brd4 antibodies into proliferating cells lead to G2/M 
arrest, overexpression of Brd4 in cultured cells results in G1/S arrest, and severe 
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knockdown of Brd4 in human cultured cells significantly reduces cell growth 
(Dey, Ellenberg et al. 2000). 
Brd4 also has an extra-terminal domain (ET) which consists of 3 alpha helices 
and a loop.  The ET domain is thought to be a regulatory domain, it has been 
linked to transcriptional regulation by interacting with several histone modifiers, 
additionally the ET domain has been found to associate with ATP-dependent nu-
cleosome-remodeling enzymes SWI/SNF and CHD4  (Rahman, Sowa et al. 2011). 
These interactions imply that Brd4 alters chromatin structure at its occupied 
sites. 
In addition to binding acetylated chromatin, the BD1 and BD2 bromodomains also 
interact with nonhistone proteins to regulate transcription, DNA replication, cell 
cycle progression, and other cellular activities.  In mouse Brd4, the BD2-contain-
ing region has been shown to interact with several cellular proteins, including 
the cyclin T1 component of human positive transcription elongation factor b (P-
TEFb) (Jang, Mochizuki et al. 2005, Yang, Yik et al. 2005), the RCF-140 subunit 
of human replication factor C (Maruyama, Farina et al. 2002), signal-induced 
proliferation-associated protein (SPA-1)(Farina, Hattori et al. 2004), and HPV11 
E2 protein (Wu, Lee et al. 2006a). 
The C terminal domain contains polyserine stretches which are interspersed with 
glutamate and asprate (SEED) motifs and an unstructured region of about 500 
amino acids which is rich in proline and glutamine. This unstructured region of 
Brd4 is highly phosphorylatable and interacts with P-TEFb and papillomavirus E2 
protein. Brd4 promotes transcription by recruiting the transcriptional elongation 
factor, p-TEFb, to promoters to enhance phosphorylation of the CTD of RNA pol-
ymerase II promoters, and additionally by directly phosphorylating the RNA poly-
merase II CTD (Devaiah, Singer 2013, Jang, Mochizuki et al. 2005). 
A region of the Brd4 CTD, termed P-TEFb interacting domain (PID), mediates the 
activation of P-TEFb from the inactive ribonucleotide complex. The ribonucleo-
tide complex sequesters P-TEFb in a kinase inactive state. The interaction of 
Brd4 with P-TEFb can modulate the global level of P-TEFb activity in the cell 
(Wu, Donohoe 2015).  
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Figure 1.8 
 
Figure 1.8: Domain organisation of Brd4 and structure of the two bromo-
domains. Two N-terminal bromodomains (BD1 and BD2) are followed by an ex-
traterminal domain (ET). Protein-protein interactions with each of these domains 
are listed. Ribbon plot representation of BD1 and BD2 are also highlighted (Image 
adapted from (Vollmuth, Blankenfeldt et al. 2009)). 
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1.13.2 The role of Brd4 in the viral life cycle 
The cellular chromatin binding protein, Brd4, interacts with the viral E2 protein 
to function in many processes within the viral life cycle, including viral replica-
tion, genome maintenance, and gene transcription. The interaction between 
Brd4 and E2 was discovered through methods such as proteomic analysis (You, 
Croyle et al. 2004, Wu, Lee et al. 2006a) and yeast two hybrid screening 
(Olejnik-Schmidt, Schmidt et al. 2008). E2 was also investigated as a target be-
cause the analogous tethering protein in KSHV (LANA) interacts with Brd2 
(McPhillips, Ozato et al. 2005, Baxter, McPhillips et al. 2005a) (Platt, Simpson et 
al. 1999). Brd4 is an essential transcriptional co-activator for all E2 proteins, and 
is found ubiquitously in all proliferating cells (Houzelstein, Bullock et al. 2002). 
Brd4 is consistently found to be an interactor with E2 in many HPV types 
(16,18,31,1,6,8)  (Muller, Demeret 2012). When Brd4 interacts with HPV E2 pro-
tein it increases the stability of E2 (Lee, Chiang 2009), this interaction may en-
hance many of E2’s functions in the viral life cycle, as well as preventing proteo-
somal degradation by the E3 ligase cullin-3 (Gagnon, Joubert et al. 2009).  
One of the first known roles for Brd4 in papillomaviruses, was the binding of this 
cellular chromatin component to E2, allowing tethering of the viral episome to 
host chromosomes in order to facilitate its segregation to daughter cells during 
mitosis  (You, Croyle et al. 2004). Brd4 and other cellular proteins, such as Chr1 
(Parish, Bean et al. 2006), have been implicated as being involved in playing the 
role of chromatin adaptors that facilitate in viral genome segregation during mi-
tosis. Additionally, Brd4 may play an active role in cell cycle progression (Mochi-
zuki, Nishiyama et al. 2008) and cancer development (Crawford, Alsarraj et al. 
2008, French, Ramirez et al. 2008) , largely through its ability to modulate gene 
transcription by recruiting different transcription components to selective target 
genes.  
In luciferase reporter assays where E2 expression stimulates luciferase gene 
transcription, knocking down Brd4 disrupts the E2-Brd4 interaction and compro-
mises the transcription of the luciferase reporter (Schweiger, You et al. 2006, 
McPhillips, Oliveira et al. 2006, Senechal, Poirier et al. 2007). Disturbing the E2-
Brd4 interaction or knocking down Brd4 also affects the function of the Brd4-E2 
interaction to repress transcription in luciferase reporter based repression assays 
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(Wu, Lee et al. 2006a, Smith, White et al. 2010). Mutagenesis studies of the E2 
TAD have shown that substitutions of R37 and I73 affect the binding of HPV 16E2 
to Brd4, impairing the ability of E2 to activate transcription (Senechal, Poirier et 
al. 2007) (Figure 1.9).  It has also been shown that the E2-Brd4 interaction may 
be involved in E2 mediated transcriptional repression (Schweiger, Ottinger et al. 
2007). 
Additionally, in cervical cancer cells where the HPV genome is integrated into 
the cellular DNA, and subsequently E2 expression is disrupted/lost, Brd4 acti-
vates viral oncogene transcription independently of E2 by recruiting P-TEFb to 
the HPV early promoter. When E2 is reintroduced into the cervical cancer cells, 
E2 functions to repress viral oncogene expression by interacting with Brd4 and 
competitively inhibiting the Brd4-P-TEFb interaction (Yan, Li et al. 2010). Helfer 
et al use an E2-responsive reporter assay to demonstrate that Brd4 recruitment 
of P-TEFb is important for E2-dependent transactivation (Figure 1.10). P-TEFb is 
also recruited to the papillomavirus genome. They also show that Brd4 tethering 
of E2 to the cellular chromatin is necessary for the transactivation of the E2 re-
sponsive reporter. Treatment of cells carrying the papillomavirus genomes with 
JQ1(+), inhibits Brd4’s association with cellular chromatin and in turn reduces 
transcription of the viral early genes E1, E2, E6 and E7 (Helfer, Yan et al. 2014).  
Also more recently Brd4 is thought to play a role in viral replication and the for-
mation of small nuclear foci. In HPV16, Brd4 has been shown to be recruited to 
active replication origin foci with E2 and E1 and a number of other cellular repli-
cation factors (Wang, Helfer et al. 2013). The same R37A/I73A mutation respon-
sible for impairing the transcriptional activation regulatory function of E2 is also 
found to abrogate the formation of E1-E2 nuclear foci. Additionally, mutagenesis 
studies and siRNA silencing of Brd4, disrupting the interaction between Brd4 and 
E2, have both been shown to impair HPV16 replication ability (Wang, Helfer et 
al. 2013). There is also evidence that Brd4 may recruit DNA damage response 
proteins to these viral replication foci to aid in replication (shown in human 
keratinocytes for HPV16). All of these elements together suggest that an estab-
lished transcription factor may be involved in viral replication.  
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Figure 1.9 
 
Figure 1.9: Structure of E2-Brd4 complex.  
a) Cartoon of the E2-Brd4 complex. Brd4 is depicted in blue. The E2 N-ter-
minal α-helical domain is coloured green, the C-terminal β strand is col-
oured in red. The linker segment joining these two domains is yellow. 
b) As before, Brd4 is coloured blue. E2 is green with orange coloured side 
chains that make up the interaction surface. Highlighted on the diagram 
are important residues for the E2-Brd4 interaction (Phe1349 and Phe1357 
are there for orientation purposes). The R37A mutation in this thesis is 
marked with a yellow ring. Figure adapted from Abbate et al 2006. (Ab-
bate, Voitenleitner et al. 2006) 
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Figure 1.10 
 
Figure 1.10: Brd4 functions in E2-mediated viral transcription activation. The 
E2 protein binds to the E2 binding sites upstream of the early promoter as dimer. 
The C-terminus of E2 interacts with Brd4. The N-terminal bromodomains of Brd4 
direct E2 and the viral genome to transcriptionally active regions of the cellular ge-
nome. Brd4 forms homodimers and recruits P-TEFb to the viral promoter to phos-
phorylate the RNA pol II CTD to activate transcription elongation. Figure adapted 
from Helfer et al 2014. (Helfer, Yan et al. 2014) 
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 Purpose of study 
This thesis set out to understand how E2 regulates the viral and host genome by 
asking the following questions: 
(1) What are the effects of E2 mutants that fail to bind TopBP1 and Brd4 on 
the viral life cycle? 
(2) How does E2 regulate the host genome?  Do mutant E2 proteins that fail 
to bind TopBP1 and Brd4 have altered regulation of cellular genes? 
 
 
Overall, the essential role that E2 plays in the viral life cycle makes it a desira-
ble antiviral target; therefore, we need to fully understand the interaction of 
this protein with functional cellular pathways. Specifically, we need to gain a 
better understanding of the viral and cellular proteins utilised by papillomavirus 
at various stages of DNA replication. We propose targeting E1-E2 mediated viral 
DNA replication in association with cellular interaction proteins, TopBP1 and 
Brd4, may provide therapeutic benefits. TopBP1 is well documented for its in-
volvement in replication. However, the role of Brd4 in E1-E2 mediated DNA rep-
lication is more controversial. This study utilised two previously characterised E2 
mutants which fail to bind TopBP1 and Brd4, to further our understanding of vi-
ral replication and the viral life cycle.  
Additionally, we wanted to understand how E2 regulates host gene expression. 
Previous studies have focused on determining the effects of E2 on specific pro-
moters and biological processes. There is a gap in our understanding of how E2 
regulates cellular processes on a global scale. A few recent studies have been 
carried out in HPV negative C33a cells which have been transiently infected with 
adenovirus, to overexpress 16E2. This model does not tolerate E2 expression 
well. No study to date has fully investigated the regulation of the host genome 
by any E2 protein with physiologically tolerated levels of E2. In this study, I have 
used the U20S cell line for genome studies as it tolerates E2 expression. We hy-
pothesised that manipulation of host gene expression by E2 facilitates infection 
and the viral life cycle, and may inadvertently contribute to cancer develop-
ment. 
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Chapter 2 – Materials and Methods 
 Materials 
2.1.1 Antibodies 
Abcam Plc  
Anti-Sheep IgG horseradish peroxidase linked whole molecule (raised in donkey) 
- Catalogue Number: Ab6900 
Anti-TopBP1antibody, ChIP grade- Catalogue Number:  ab2402 
Anti-HPV16 E2 antibody (TVG261) 50µg- Catalogue Number: ab17185 
1X Goat Anti-Rabbit IgG H&L (Alexa Fluor 488) - Catalogue Number: ab150077 
1X Goat Anti-Mouse IgG H&L (Alexa Fluor 55) - Catalogue Number: ab150114 
Covance 
HA.11 clone 16B12 Monoclonal Antibody- Catalogue Number: MMS-101R-500 
Fisher 
Anti-mouse IgG peroxidase-linked whole antibody (from sheep) Secondary Anti-
body, GE Healthcare- Catalogue Number: 45000692 
Santa Cruz biotechnology, inc. 
Anti-TopBP1 antibody- Catalogue Number: sc-271043 
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2.1.2 Bacteriology 
Invitrogen Ltd  
Subcloning efficiency DH5αTM chemically competent cells- Catalogue Number: 18265 
Subcloning EfficiencyTM DH5α competent cells- Catalogue Number: 18265-017 
S. O. C Medium - Catalogue Number: 15544-034 
 
Novagen 
 
KOD Hot Start DNA polymerase- Cat no: 71086.3 
 
Sigma Chemical Co. Ltd  
Ampicillin- Catalogue Number: 10047 
Worldwide Medical 
Kanamycin Sulfate, 50mg/ml solution 20ml - Catalogue Number: 61132047 
2.1.3 Cell Lines 
C33a cells are derived from a 66 year old female with HPV negative cervical car-
cinoma, and are defective for both p53 and pRb function. The cells have an epi-
thelial morphology and are grown in continuous culture as a monolayer. C33a 
cells were obtained from Cancer Research UK (Cancer Research United Kingdom 
(CRUK), London). 
Human Embryonic Kidney 293T (HEK293T) cells are derived from the 293 cell 
line in which the SV40 T-antigen was inserted. They are p53+ and pRB+, pRB is 
present but abnormal size, and p53 is elevated. There is a point mutation at co-
don 273 resulting in an Arg to Cys substitution. Also, these cells are HPV nega-
tive. HEK293T cells were a kind gift from Dr. Brian Willet, University of Glasgow. 
U2OS cells were cultivated from the bone tissue of a 15 year old female suffer-
ing from osteosarcoma. U2OS cells exhibit epithelial adherent morphology, and 
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have no viruses present. The cells are p53 wildtype and were purchased from 
CRUK (CRUK, London, United Kingdom). 
2.1.4 Chemical and Reagents 
Invitrogen Ltd  
Agarose (ultrapure electrophoresis grade)- Catalogue Number: 41025 
Roche Biosystems   
Complete Protease Inhibitor Cocktail Tablets - Catalogue Number: 12481800 
Life Technologies  
RNaseOUTTM Recombinant ribonuclease inhibitor- Catalogue Number: 10777-019 
MicroAmp Fast Optical 96-Well Reaction Plate, 0.1mL- Catalogue Number: 4346907 
4-12% Tris Glycine gels- Catalogue Number: EC60355BOX 
TAQMAN TAMRA probe 6k PMoles- Catalogue Number: 450025 
RNase A (20mg/ml)- Catalogue Number: 12091021 
Sigma 
siRNA Universal Negative Control #1- Catalogue Number: SIC001-10NMOL 
Protein sepharose beads 5ml- Catalogue Number: P9424-5ml 
Protein A sepharose beads 5ml- Catalogue Number: P9424-5ml 
Formaldehyde solution- Catalogue Number: F8775-4X25ML 
CaCl2 Calcium chloride solution- Catalogue Number: 21115-250ml 
Chapter 2  89 
 
Bicinchonoinic Acid (BCA) solution- Catalogue Number: B9643 
Ethidium Bromide- Catalogue Number: E-1510 
 
Fisher 
10X Phospho buffer saline (PBS) 4L- Catalogue Number: BP3994 
Glycerol- Catalogue Number: BP2291 
VWR 
Phenol:Chloroform:Isoamyl Alcohol- Catalogue Number: 101174-118 
Ponceau S Stain Proteomics Grade 50ML - Catalogue Number: 97063-652 
Protein G Mag sepharose 500µl- Catalogue Number: 89129-076 
Protein A Mag sepharose 500µl- Catalogue Number: 89129-078 
Ethanol 200 proof- Catalogue Number: 89125172 
Greiner Cellstar T75 flask- Catalogue Number: 8205085 
Greiner Cellstar T175 flask- Catalogue Number: 82050878 
Methanol- Catalogue Number: BDH1135-4LP 
USB Affymetrix 
Water, RNase-free, DEPC treated, MB grade- Catalogue Number: 70783 100mL 
VectorLabs 
Vectashield Hardset Mounting Medium 10ml- Catalogue Number: H-1400 
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Agilent 
Brilliant III Ultra-Fast QPCR Master Mix- Catalogue Number: 60080 
Bioline 
Proteinase K, 100mg- Catalogue Number: 37037 
Alfa Aesar 
Triethanolamine- Catalogue Number: L04486 
Ethanolamine- Catalogue Number: A11697 
2.1.5 Enzymes 
New England Biosytems 
DpnI- Catalogue Number: R0176L 
Exonuclease (E.coli) - Catalogue Number: M0206L 
2.1.6 Kits 
Qiagen 
QIAprep Spin Miniprep Kit (50)- Catalogue Number: 27104 
QIAfilter Plasmid Midi Kit (25)- Catalogue Number: 12243 
Invitrogen 
 
 
PureLink Quick Plasmid DNA Maxiprep Kit- Catalogue Number: K2100-07  
 
PureLink Quick Plasmid DNA Miniprep Kit- Catalogue Number: K2100-10 
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2.1.7 Miscellaneous 
 
Genesee Scientific 
Olympus 10µl reach barrier tip- Catalogue Number: 24-401 
Olympus 200µl reach barrier tip- Catalogue Number: 24-412 
Genesee Scientific continued 
Olympus 1000µl reach barrier tip- Catalogue Number: 24-430 
VWR 
Mag rack 6- Catalogue Number: 89129-096  
Worldwide Medical 
1.5 ML Microcentrifuge tubes 500/pack- Catalogue Number: 41021009 
5X7 film- Catalogue Number: 41101002 
15ml Centrifuge tube flat top rim seal cap- Catalogue Number: 41101002 
Sigma 
Silicone grease bayer- Catalogue Number: 85403-1EA 
USA Scientific 
100mm cell culture dish 300/cs - Catalogue Number: CC7682-3394 
2.0ml Seal-Rite tubes, graduated, flat cap, natural- Catalogue Number: 16202700 
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Fisher 
Corning #4488 Pipette, 10ML, 200 per case- Catalogue Number: 7200574 
Corning #4489 Pipette, 25ML, 200 per case- Catalogue Number: 7200575 
 
2.1.8 Molecular Weight Markers 
Thermo Scientific 
Spectra MC BR protein ladder 6X250 µl- Catalogue Number: 26634 
2.1.9 Plasmids 
E2- described in (Bouvard, Storey et al. 1994) 
Ptk6E2- used previously in (Donaldson, Mackintosh et al. 2012) 
HPV18LCR- used previously in (Donaldson, Mackintosh et al. 2012) 
pOriM- described in (Taylor, Morgan 2003a) 
HA-E1 - a kind gift from Mart Ustav and described in (Kadaja, Sumerina et al. 
2007) 
Addgene 
P5188 pSUPER-shRNA-Brd4 (CT)- Catalogue Number: 24746 
2.1.9.1 shRNA 
 
Short hairpin RNA (shRNA) against TopBP1 and the appropriate negative control 
were expressed from the pBABE-puro plasmid and have been previously de-
scribed (Jurvansuu, Raj et al. 2005). shRNA against Brd4 was expressed from 
pSUPER and had the following targeting sequence: GCGGGAGCAGGAGCGAAGA 
(Addgene plasmid 24746) (Zheng, Schweiger et al. 2009)
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2.1.10 Cell Culture 
Gemini bioproducts 
G418 solution 20 mL (Geneticin) 50mg/mL- Catalogue Number: 400113 
Life Technologies  
Trypsin-EDTA .05% - Catalogue Number:  25300054 
Lipofectamine 2000 reagent 1.5 ML- Catalogue Number: 11669019 
Lipofectamine LTX, 1ML - Catalogue Number: 15338100 
DMEM 500ML - Catalogue Number: 11885092 
FBS- Catalogue Number: 10437028 
Ibidi 
25 Culture Inserts for self-insertion, sterile, in a 10cm transport dish- Catalogue 
Number: 80209 
VWR 
Greiner 6-well Tc treated polystyrene plare with lid, sterile, individually 
wrapped, 100/case- Catalogue Number: 82050-842 
145X20mm TC treated dish CS120- Catalogue Number: 82050-598 
Fisher 
Cloning cylinders 6X8 125/CSCL - Catalogue Number: 09-552-20 
Penicillin-streptomycin solution, 100X; 100mL- Catalogue Number: SV30010 
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Fisher continued 
Cell Scraper Small 23cm 50/pk- Catalogue Number: 1256558 
Neuvitro corporation 
German coverslip - Catalogue Number: GG-12-1.5-pre 
2.1.11 Primers 
Qiagen 
QuantiTech primer assay for the following genes: 
MAGEC1, ENG, FAR2, APBA2, SH3PXD2B, GDF15, RNF144B, TMPRSS15, NFE4, 
GTSF1, ADAMTSL1, C6orf15, CLDN4, HOXB2, LRRC15, SERPINA1, SLN, NRID2, 
ANO1, IFGL1, SPRR2A, EPHA4, SEMA6D, PBX1, TXNIP, DHRS2, ATP8B1, MFAP5, 
COL6A3, IFIH1, IFI35, DDX58, OAS2, CD14, IFTM1, IFIT3, OAS1, IL8, MX1, IFIT1, 
IFI44L, IFI27, IFNK. 
Invitrogen custom primers 
pOri Forward and Reverse primers 
Forward - 5’ ATCGGTTGAACCGAAACCG ‘3 
Reverse- 5’ TAACTTCTGGGTCGCTCCTG ‘3 
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Primers continued 
Integrated DNA Technologies 
Site directed mutagenesis primers: 
HPV18 E2 E94V  
Forward- 5’ GCACAAAGTGCATACAAAACCGTGGATTGGACACTGCAAGACAC 3' 
Reverse- 5’ GTGTCTTGCAGTGTCCAATCCACGGTTTTGTATGCACTTTGTGC 3’ 
HPV18 E2 R41A 
Forward- 5’ CAGTATTGGCAACTAATAGCTTGGGAAAATGCAATATTCTTTGC 3' 
Reverse- 5’ GCAAAGAATATTGCATTTTCCCAAGCTATTAGTTGCCAATACTG 3’ 
HPV16 E2 N89YE90V 
Forward- 5’ CAATATATAACTCACAATATAGTTATGTAAAGTGGACATTACAAG 3' 
Reverse- 5’ CTTGTAATGTCCACTTTACATAACTATATTGTGAGTTATATATTG 3’ 
HPV16 E2 R37A 
Forward- 5’ CAATATATAACTCACAATATAGTTATGTAAAGTGGACATTACAAG 3' 
Reverse- 5’ CTTGTAATGTCCACTTTACATAACTATATTGTGAGTTATATATTG 3’ 
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 Methods 
2.2.1 Molecular Biology 
2.2.1.1 Agarose Gel Electrophoresis 
 
1% agarose gels were prepared by dissolving 1g of agarose per 100ml of 0.5% TBE 
buffer (10 x TBE: 900mM Tris base, 900mM boric acid, 25mM EDTA, pH8.0) using 
heat. For 200ml solution 5µl (10mg/ml) ethidium bromide was added, and the 
solution cooled at room temperature, before pouring into the assembled gel cast 
containing the appropriate sized comb. When the gel had cooled and set it was 
then placed into the electrophoresis tank, and submerged in 0.5% x TBE buffer. 
For site directed mutagenesis, 5 μl of PCR product mixed with 5μl of 1 x loading 
buffer (10 x loading buffer : 65% (w/v) sucrose, 10mM Tris-HCl Ph 7.5, 10mM 
EDTA, 0.3% (w/v) bromophenol blue). For the confirmation of DNA shearing, 10 
μl of DNA and 5μl of loading buffer (as above) were mixed. Samples were loaded 
onto gel and run alongside a 1kb marker at 90V before gels were visualised by UV 
light and photographed on the GeneFlash system. 
2.2.1.2 DNA purification using phenol chloroform 
 
Restriction digests, sequencing, replication and ChIP assays were purified using 
phenol:chloroform to remove all residual contaminants. Equal volume of phe-
nol:chloroform:isoamyl alcohol (24:25:1 v/v/v) was added to sample and vor-
texed for 2 minutes until cloudy. The sample was then centrifuged for 15 
minutes at 3293 rcf at room temperature. This resulted in the separation of the 
aqueous and organic phases; the top aqueous phase was transferred to a fresh 
1.5 ml tube and the previous steps repeated. The bottom organic phase was dis-
carded. 
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2.2.1.3  Ethanol precipitation of DNA 
 
Following purification using phenol:choloroform DNA was precipitated using eth-
anol precipitation. 1/10 the sample volume 3M sodium acetate, pH 5.2, and 2 x 
the sample volume of 100% EtoH, was added to the sample and vortexed for 2 
minutes. Samples were then incubated at -20ºC for 2 hours or overnight. After 
samples were incubated they were centrifuged at 3293 rcf for 30 minutes to pel-
let the DNA. Supernatant was removed leaving the pellets remaining in the tube. 
Pellets were washed with 1 x the sample volume of 70% EtoH, centrifuged at 
3293 rcf for 15 minutes. Supernatant was then removed and pellets allowed to 
air dry. The precipitated DNA was then resuspended in distilled H2O. 
2.2.1.4 Site directed mutagenesis 
 
Site directed mutagenesis PCR was set up as follows. The PCR reaction contained 
5 μl of 10× KOD buffer with 5 μl of 2 mM deoxynucleoside triphosphates, 4 μl of 
25 mM MgSO4, 1 μl of dimethyl sulfoxide, forward primer, reverse primer, 50 ng 
of template DNA, 1 μl of KOD Hot-Start DNA polymerase (Novagen), and distilled 
H2O to 50 μl. Reactions were cycled as follows: 94°C for 4 min, followed by 18 
cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min, with a final 72°C for 4 
min. After completion of the mutagenic PCR, 10 μl of DpnI was added to the re-
action, followed by incubation for 90 min at 37°C. Then, 5 μl of the reaction was 
transformed into Escherichia coli DH5α (following manufacturer’s instructions- 
Invitrogen), and transformed cells were selected on Luria-Bertani/ampicillin 
plates (50μg/ml). Positive colonies were picked, and plasmids were recovered by 
using a miniprep procedure (Invitrogen Purelink Quick Plasmid DNA Miniprep kit) 
and sequenced to determine the mutation. Sequence analysis was carried out us-
ing Chromas Lite software and alignments were done using ClustalW. For samples 
containing the desired mutation the maxiprep procedure was followed to make 
working plasmid stocks. 100ml of LB broth plus ampicillin (50μg/ml) was inocu-
lated with one bacterial colony and incubated at 37ºC overnight with shaking. 
Maxiprep was carried out in accordance with Invitrogen PureLink Quick Plasmid 
DNA Maxiprep kit protocol. 
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Site directed mutagenesis continued 
 
The primers used for the generation of the N89YE90V mutant were as follows: 
forward, 5′-CAATATATAACTCACAATATAGTTATGTAAAGTGGACATTACAAG-3′; and 
reverse; 5′-CTTGTAATGTCCACTTTACATAACTATATTGTGAGTTATATATTG-3′. The 
primers used for the generation of the R37A mutant were as follows: forward, 5' 
GACTATTGGAAACACATGGCCCTAGAATGTGCTATTTATTACAAG 3'; and reverse; 5' 
CTTGTAATAAATAGCTCTAACTAGGGCCATGTGTTTCCAATAGTC 3'.  
2.2.1.5  BCA / CuSO4 Assay 
 
In preparation for the assay, bovine serum albumin (BSA) protein standard solu-
tions were made from a stock solution (2mg/ml) in the following concentrations: 
80, 100, 200, 400, 1000 and 2000µg/ml. 10µl of each protein standard and pro-
tein lysates were loaded onto a 96 well plate, along with 200µl of developing so-
lution (5ml BCA (Bicinchoninic Acid Sigma) 100µl Copper II Suplhate pentahy-
drate 4% w/v solution (Sigma)). After the protein and BCA solution was mixed it 
was incubated at 37ºC for 30-60 minutes (or until a change in colour was ob-
served). The absorbance was read using a plate reader to measure the absorb-
ance at 462nm. The absorbance readings of the BSA standards were used to de-
rive a standard curve, from which the sample concentrations were calculated. 
2.2.1.6 Western blots 
 
Cells were harvested by trypsinisation and pelleted by centrifugation. Cells were 
washed twice with phosphate buffered saline then resuspended in 100 µl of lysis 
buffer (0.5% Nonidet P-40, 50 mM Tris, pH 7.8, 150 mM NaCl with protease inhib-
itor cocktail (Roche Molecular Biochemicals) dissolved in the lysis buffer fresh 
prior to use) and lysed on ice for 30 min. Lysates were cleared by centrifugation 
(20,800 relative centrifugal force, 4˚C, 30 min). The supernatant was then re-
moved to a fresh 1.5 ml tube and the cell debris discarded. Protein levels were 
standardised using BCA Assay (Sigma).  
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Western blots continued 
 
60 µg of lysate was prepared for SDS-PAGE using the Invitrogen NuPage system (2 
µl 10x sample reducing reagent and 5µl 4 x LDS buffer). The lysates were run on 
4-12% gradient gels (Invitrogen) at 200 V for 1 hour and proteins were trans-
ferred onto nitrocellulose membranes using the wet-blot method (Biorad). 
ECL method: 
Nitrocellulose membranes were then blocked in blocking solution (PBS, 0.1% 
Tween, 5% nonfat milk powder) for 1 hour at room temperature. Membranes 
were incubated with TVG261 mouse monoclonal anti-HPV16 E2 (ab17185) at a di-
lution of 1:5,000, (anti-HA (1:1,000), Brd4 (1:500) or TopBP1 (1:5,000)) over-
night at 4 degrees and followed by a one hour incubation with secondary anti-
body (anti-Mouse Ig, Horseradish Peroxidase linked) (GE Healthcare) was then di-
luted to 1: 50,000 with PBS-T and 5% milk and added to the membrane which 
was incubated at room temperature for 90-120 minutes.  The membrane was 
then developed using ECL-Plus (Amersham Biosciences) to detect the horseradish 
peroxidase conjugate and the membrane exposed to film. 
Odyssey method: 
Membranes were blocked in Odyssey blocking buffer (1:1 diluted with PBS) for 
one hour at room temperature. After blocking the membranes were incubated 
with 1:1000 rabbit anti HA-tag antibody to detect E1 (ab9110), and 1:5000 
(1:1000 for shRNA blot) mouse TVG261 antibody to detect HPV 16E2 (ab17185), 
overnight at 4°C. Membranes were washed with 0.1% PBS-T before incubation 
with Odyssey secondary antibodies diluted 1:20,000 (Goat anti-mouse IRdye 
800cw, 827-08364 and Goat anti-rabbit IRdye 680RD, 926-68171) for one hour at 
room temperature. Following secondary incubation membranes were washed 5 
times for 5 minutes with 0.01% PBS-T before infrared scanning using the Odyssey 
Li-Cor imaging system. 
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2.2.1.7 Stripping membranes 
 
In order to reprobe a membrane with an antibody recognised by the same sec-
ondary antibody, membranes were stripped to remove all traces of the previous 
antiobody. The membrane was submerged in 0.2M NaOH and incubated for 10 
minutes at room temperature with gentle agitation.  The membrane was then 
washed twice with PBS-T (0.1% if using Li-Cor imaging system) for 10 minutes at 
room temperature, and then blocked for one hour in either 5% milk PBS-T or Od-
yssey blocking buffer, before adding the desired antibody. 
2.2.1.8 Crosslinking beads with antibody 
 
Agarose A beads were washed overnight in PBS at 4ºC. The following morning 
PBS was removed from the beads and replaced with one bead volume of dilution 
buffer (PBS+ 1mg/ml BSA) and rotated for 10 minutes at 4 ºC. Supernatant was 
then removed and replaced with 1 bead volume of TopBP1 rabbit antibody in di-
lution buffer (1µl of 1mg/ml stock in 1ml dilution buffer (1:1,000)), and rotated 
at 4 ºC for 1 hour. The supernatant was disgarded and beads washed in 1 volume 
of dilution buffer for 5 minutes at 4 ºC. Following this the incubation the super-
natant was disgarded and beads were washed in 1 volume PBS and the superna-
tant then disgarded. Cross-linking reagent was made fresh (13mg/ml DMP), 1ml 
of DMP stock was added to 1 ml wash buffer (0.2M triethanolamine in PBS) and 
vortexed. 1 volume of DMP solution was added to the beads and incubated for 30 
minutes at room temperature. Supernatant was then discarded and beads were 
washed in wash buffer for 5 minutes at room temperature. Supernatant was then 
discarded. DMP solution incubations were repeated two more times, including 
the wash step. Following this, 1 volume of quench buffer (50mM ethanolamine in 
PBS) was added to the beads and rotated for 5 minutes at room temperature. 
The supernatant was discarded and the quench buffer incubation step was re-
peated. Beads were then washed with PBS and supernatant discarded. Beads 
were then washed with 1 volume of elution buffer (1M glycine pH3) for 10 
minutes at room temperature.  
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Crosslinking beads with antibody continued 
 
Supernatant was discarded and elution buffer incubation step repeated. Finally, 
beads were then washed three times with NP40 lysis buffer supplemented with 
protease inhibitors. 
2.2.1.9 Co Immunoprecipitation  
 
For CoIP, 200µg of protein lysate (C33a cells) was incubated with cross-linked 
beads overnight at 4 ºC. The following morning the beads were washed 5 times 
with PBS. On the final wash all PBS was carefully removed from the beads with a 
fine tip pipette. The beads were then prepared for SDS-PAGE using the Invitro-
gen NuPage system (2 µl 10x sample reducing reagent, 5µl 4 x LDS buffer and 
10µl lysis buffer). The lysates were run on 4-12% gradient gels (Invitrogen) at 200 
V for 1 hour and proteins were transferred onto nitrocellulose membranes using 
the wet-blot method (Biorad). The membrane was then prepared for exposing 
using the ECL method. Western blots were probed with Brd4 and TopBP1 anti-
bodies (1:500 Brd4 antibody and 1:5,000 TopBP1 antibody). 
2.2.1.10 RNA extraction 
 
1x106 stably transfected U20S clones were plated out on 100mm plates. The fol-
lowing day cells were washed 2x with PBS. 600µl of buffer RLT from the Qiagen 
RNeasy kit was added to each plate and incubated at room temperature for 
about 5 minutes, cells were then scraped from the plate and buffer RLT/cell mix 
was added to a Qiashredder column (Qiagen) and centrifuged following the man-
ufacturers instructions to homogonize the sample. The Qiagen RNeasy protocol 
was then followed to extract RNA from the U2OS cells stably expressing E2. The 
DNA was removed using DNase treatment (Qiagen) on column. 
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2.2.1.11 cDNA synthesis 
 
cDNA was made using the Finnzymes (Thermo Scientific) DyNAmo SYBR Green 2-
Step qRT-PCR kit (F-430S, F-430L), following the protocol provided.  
2.2.1.12 Sybr Green qPCR 
 
 Sybr green real-time qPCR was used to validate the Human Exon array results 
(DyNAmo SYBR Green qPCR Kit with ROX, Cat no: F-400RL), using primers de-
signed by Qiagen, (Qiagen QuantiTech primer assay). The house keeping gene 
GAPDH was used as an endogenous control alongside the Vector, no E2 express-
ing U20S cell line to normalise the results, using the ΔΔct method.  
2.2.1.13 Transcription activation/ repression assay 
 
2X 105 C33a or 293T cells were plated out on a 60-mm plate and transfected 24 h 
later using the calcium phosphate technique. The next day cells were washed, 
and 24 h following the wash cells were harvested. The cell monolayers were 
washed twice with phosphate-buffered saline and then lysed with 300 µl of re-
porter lysis buffer (Promega) at room temperature for 10 minutes. After incuba-
tion plates were scraped and the lysate was transferred into a 1.5 ml Eppendorf 
tube and spun in a refrigerated microfuge for 10 minutes at 4 °C with 3293rcf to 
clear debris.  80 µl of the supernatant was assayed for luciferase activity using 
the luciferase assay system (Promega). To standardise for cell number a BCA 
protein assay was carried out, the RLU from the luciferase assay was divided by 
the protein concentration of that sample. All results were normalised to the 
ptk6E2 reporter plasmid and the final result expressed as fold difference com-
pared with ptk6E2 (or 18LCR for repression assay). pGL3CONT, which contains 
the SV40 promoter and enhancer driving expression of the luciferase gene, was 
always included in a parallel transfection to confirm efficient transfection. The 
assays shown are representative of at least three independent experiments car-
ried out in duplicate.  
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2.2.1.14 DNA replication assay 
 
DNA replication assays were carried out by plating out 6×105 C33a or 293T cells 
in 100-mm2 plates. The following day cells were CaPO4 transfected with 100 pg 
of pOriM, 1μg of E1 and 10ng- 1μg of E2 wild-type and mutant plasmids. For 
shRNA replication assays the same transfection process was followed expect for 
the addition of 1µg TopBP1 and Brd4 shRNA and control shRNA (plasmids from 
Addgene). The following morning cells were washed twice in PBS then 48 hours 
later low molecular weight DNA was harvested in Hirt solution (10mM EDTA, 0.5% 
SDS).  Samples were processed for qPCR-detected transient replication assay as 
previously described (Taylor, Morgan 2003b). 
2.2.1.15 Chromatin Immunoprecipitation (ChIP) assay 
 
A 100mm2 dish of 60% confluent C33a cells were transfected with 1µg of pOriM, 
1μg of E1 and 10ng- 100ng of E2 wild-type plasmid, using the CaPO4 method. The 
following day cells were washed twice with PBS and transferred to 150mm2 
dishes. 48 hours post transfection cells were cross linked with 1% formaldehyde 
at room temperature for 15 minutes. The cross linking reaction was stopped us-
ing 0.125M glycine. Cells were harvested by scraping and then lysed in 1.5X cell 
pellet volume cell lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% NP40, 
10mM sodium butyrate, 50 μg/ml PMSF, 1X complete protease inhibitor). Cells 
were incubated on ice for 10 minutes then nuclei collected by centrifugation at 
105 rcf at 4˚C. Cells were then resuspended in 1.2ml of nuclear lysis buffer (50 
mM Tris-HCl pH 8.1, 10 mM EDTA, 1% SDS, 10mM sodium butyrate, 50 μg/ml 
PMSF, 1X complete protease inhibitor) and incubated on ice for a further 10 
minutes, then diluted in 0.72ml of immunoprecipitation dilution buffer (IPDB)  
(20mM Tris-HCl pH 8.1, 150 mM NaCl, 2mM EDTA, 1% Triton X-100, 0.01% SDS, 
10mM sodium butyrate, 50 μg/ml PMSF, 1X complete protease inhibitor). The 
sample was sonicated using a water bath sonicator (Diagenode Bioruptor 300) till 
chromatin was sheared to <400bp. Shearing efficiency was tested by running 
10µl of sample from each cycle condition of sonication (18-24 cycles) on a 1% 
DNA gel. Prior to running the gel, each sample was treated with 100µg protein-
ase K overnight, and purified using phenol:chloroform extraction. 
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Chromatin Immunoprecipitation (ChIP) assay continued 
 
Figure 2.1: Sonication to shear chromatin. An example of a DNA gel (1%) 
showing the size of chromatin after shearing. Lane one is the DNA ladder, with 
500bp and 100bp highlighted. Lanes 2 to 5 display the product of 18, 20,22, and 
24 cycles of sonication respectively. Each cycle represents 30 seconds on (at full 
power) and 30 seconds off. 
Chromatin was measured using a nanodrop and 100µg of chromatin was used per 
antibodyexperiment. The antibodies used were as followed, per IP; 2l of a 
sheep anti-HPV16 E2 (amino acids 1-201) prepared and purified by Dundee Cell 
Products, UK; 2g of rabbit anti-HA for detecting HA-E1 (AbCam, ab9110); 2g 
rabbit anti-Brd4 (Bethyl, A301-985A1003); 2g of mouse anti-TopBP1 (Santa 
Cruz, sc-271043). The antibodies and chromatin were incubated along with 20µl 
of a slurry of A/G magnetic beads (washed in IPDB) (Thermofisher scientific; 
product number 26162). Chromatin, bead and antibody slurry was incubated ro-
tated at 4˚C overnight. The following day beads were washed with 750µl IP wash 
buffer 1 (x2) (20 mM Tris-HCl pH 8.1, 50 mM NaCl, 2 mM EDTA, 1% Triton X-100, 
0.1% SDS), then with IP wash buffer 2 (x2) (10 mM Tris-HCL pH 8.1, 250 mM LiCl, 
1 mM EDTA, 1% NP-40, 1% deoxycholic acid) and TE pH 8.0 (x1 or x2). Chromatin 
was then prepared for qPCR by eluting the immune complexes from the beads by 
adding 250µl IP Elution buffer (IPEB) (100 mM NaHC03, 1% SDS) and 10µg RNase 
A; and incubated at 65˚C for 30 mins; beads were separated from the superna-
tant leaving the ChIP DNA; DNA was incubated for 6 hours to overnight at 65˚C. 
100µg of proteinase K was added following this incubation and incubated for 2 
hours at 55˚C or overnight at 45˚C. Taqman qPCR using pOriM primer and probe 
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set was used to quantify the levels of E2, E1, TopBP1 and Brd4 at the HPV origin 
of replication (Taylor, Morgan 2003a).    
2.2.1.16 Immunofluorescence staining and imaging 
 
Cells were plated at a density of 2 X 105 cells/well on acid-washed coverslips 
and simultaneously transfected with the indicated plasmids (Lipofectamine 2000 
commercial protocol).  At 24h or 48h post-transfection, cells were fixed in 4% 
formaldehyde and permeablised with 0.2% Triton X-100. Cells were blocked in 1% 
FBS and then stained with the indicated primary and secondary antibodies. Co-
verslips were mounted in Vectashield mounting medium containing DAPI. Images 
were collected with a Zeiss LSM710 laser scanning confocal microscope and ana-
lyzed using Zen 2009 LE software.          
2.2.2 Tissue Culture 
2.2.2.1 General growth 
 
All cell culture work was conducted under strict sterile conditions inside a flow 
hood (Class II Microbiology Safety Cabinets, Gelaire BSB4). Cells were maintained 
in Dulbecco’s modified eagle medium (DMEM) with 10% Fetal Bovine Serum (FBS) 
and 1% (v/v) penicillin/streptomycin mixture (Invitrogen Life Technologies) at 
37°C in a 5% CO2/95% air atmosphere. Cells were passaged 1 in 10 every 3 days.  
2.2.2.2 Making stable cell lines 
 
4x 105 U2OS cells were plated onto 100mm2 plates. The following day cells were 
transfected using calcium phosphate, with 1µg of plasmid DNA, plasmid vectors 
encode neomycin resistance (G418) for selection in mammalian cells.  48 hours 
post transfection, cells were lysed with 0.5% trypsin EDTA (Invitrogen), and re-
plated at several dilutions (1:5, 1:20 and 1:50) and fed with DMEM media con-
taining G418 (Geneticin) at a concentration of 0.75mg/ml. Cells were monitored 
and re-fed every 3-4 days with fresh G418 media, for 14 days post the initial 
G418 treatment. Distinct “islands” of surviving cells are seen; drug resistant 
clones appear in 2-5 weeks. Clones were transferred using standard techniques, 
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using cloning cylinders, to 6 well plates, and cultures were maintained in G418 
medium. Candidate clones were then grown in 75cm2 flasks, and lysates made 
from pelleted cells using our cell lysis buffer with a protease inhibitor mixture 
(0.5% Nonidet P-40, 50 mM Tris, pH 7.8, 150 mM NaCl). The presence of E2 was 
tested using western blot technique. 
2.2.2.3 Growth Curve  
 
2 x 105 cells were seeded in 100mm plates in triplicate and grown in complete 
DMEM medium, cells were trypsinised and counted using a hemocytometer. This 
process was repeated three times in three day intervals. Growth curves of two 
separate sets of U20S vector and 16E2 wildtype clones were plotted on a log 
scale from the successive cell counts, 0, 3, 6 and 9 days. 
2.2.2.4 Wound healing assay 
 
To determine cell migration, “wound-healing” (scratch) assays were used. Cell 
culture inserts (Ibidi, cat # 80209) were attached to 6 well plates and seeded 
with 5 x 104 cells in each side of the cell insert divide. This was done in replicate 
for each Vector and 16E2-WT, E2-Brd4, and E2-TopBP1 U2OS clone. Cells were grown 
for 24 hours until each side of the chamber was confluent. The cell insert was 
the removed and pictures taken at time points 0, 16 and 24 hours (Zeiss, Axio-
vert 200M microscope and Axiocam). The width of the cell free gap was approxi-
mately 500 microns (+/- 50 microns) at time 0 hours. 
2.2.3 Genomics 
2.2.3.1 Human exon array 
 
Three independent polyA+ RNA preparations were made and converted to cDNA 
(as described in 2.2.1.11) and analysed using Affymetrix Human Exon Array. 
1.5µg of RNA was required to perform the array. The quantity and quality of the 
RNA was analysed using a 210000 Agilent bioanalyser (Jing Wang, SHWFGF). The 
Chapter 2  107 
 
DNA was prepared using GeneChip cDNA synthesis and amplification kit (Affy-
metrix) and analysed using Affymetrix Exon array software by Dr Pawel Herzyk. 
Analysis of the microarray core data was performed using Partek genomics suite. 
2.2.3.2 Ingenuity Pathway Analysis (IPA) 
 
Gene data sets from the human exon array with a fold-change of >1.5, were up-
loaded into Ingenuity Pathway Analysis software (IPA). IPA was used to analyse 
gene data sets from the human exon array to allow us to look at the functions 
and networks that E2 may be affecting.  List of the raw data uploaded into IPA 
can be found in the appendices section.
 
 Contributions 
Data by Mary Donaldson as follows: 
Figure 3.7.1 Localisation of E1 and E2 into nuclear foci 
Figure 3.7.2 TopBP1 and Brd4 are recruited to E1-E2 foci 
Figure 3.7.2 Knock down of TopBP1 and Brd4 disrupts E1-E2 DNA replication foci 
Plasmids and cell lines made by: 
 
Edward Dornan made HPV16 cell line sin U20S (bar second R37A clone). 
 
The Peter Howley lab kindly gave us the HPV18 E2 plasmid. 
 
TopBP1 and R41A single mutations made in HPV18 by Mary Donaldson and Edward 
Dornan. 
 
N89YE90V HPV16 E2 mutation made by Mary Donaldson. 
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Chapter 3 – Mutants of HPV16 and 18E2 compro-
mise viral transcription and replication. 
As discussed in Chapter 1.13, the viral protein E2 links most of its functions to 
direct interactions with host cellular factors, either to support viral genome ex-
pression, segregation, or replication cycle (Muller, Demeret 2012). TopBP1 has 
been shown to interact in vitro and in vivo with E2 and can regulate the ability 
of E2 to control transcription and replication (Boner, Taylor et al. 2002). Also, 
an essential transcriptional co-activator for all E2 proteins is Brd4, which is 
found ubiquitously in all proliferating cells (Houzelstein, Bullock et al. 2002).  
E2 mutants that impair the binding of both TopBP1 and Brd4 have been identi-
fied and shown to compromise the transcription ability of papillomavirus E2 
(Donaldson, Mackintosh et al. 2012)(Schweiger, You et al. 2006). A previous 
study in the Morgan lab showed that a non-TopBP1 interacting 16E2 mutant, E2-
TopBP1 has compromised replication potential but retains transcriptional ability 
(Donaldson, Mackintosh et al. 2012). The E2-TopBP1 mutant has an N89Y and an 
E90V mutation, amino acid 90 is a conserved glutamic acid in almost all E2 pro-
teins from all HPV types.  A Brd4 mutant (E2-Brd4) R37A (arginine to alanine at po-
sition 37) in E2 compromises interaction with Brd4 and transcriptional activation 
(Schweiger, You et al. 2006). The role of Brd4 in regulating viral replication is 
unclear. Reports have demonstrated two different phenotypes of the E2-Brd4 mu-
tant in replication; a 50% decrease in replication properties of the E2-Brd4 mutant 
(Wang, Helfer et al. 2013), or suggesting that Brd4 is not involved in DNA repli-
cation by E2 (Baxter, McBride 2005). Our current studies were designed to fur-
ther characterise these E2 mutants with our functional assays in various cell 
lines. 
3.1 Expression of HPV16 E2 and E2 mutants. 
Plasmids expressing HPV16 E2 had mutations successfully introduced using site-
directed mutagenesis (as described in Methods 2.2.1.4) so they could be used 
for functional analysis (primer sequences in Materials 2.1.11). These mutations 
were originally described in the following papers (Donaldson, Mackintosh et al. 
2012, Schweiger, You et al. 2006). From this point onwards the E2 mutants shall 
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be referred to as E2-TopBP1 and E2-Brd4. Figure 3.1 shows a western blot of the ex-
pression of all HPV16 E2 mutants created for this study in C33a keratinocytes. 
Lane 1 shows a non-E2 cell control, lane 2 shows that 16 E2-WT is more strongly 
expressed than either E2-TopBP1 or E2-Brd4, lanes 3 and 4 respectively. 
 
3.2 Transcription function of E2 and E2 mutants in 293T 
cells 
Transcriptional activation studies were carried out to determine the transcrip-
tional activation properties of the E2 mutants generated compared to wildtype 
E2. The 293T cell line was chosen for initial characterisation of the mutants.  
Figure 3.2 shows the transcriptional activation properties of E2-WT, E2-TopBP1 and 
E2-Brd4 in 293T cells. In lanes 1 and 2, it is clear that E2-WT induces transcription 
activation from a tk promoter with 6 E2 binding sites located upstream and that 
this activation becomes squelched at higher levels of E2 input (full description of 
plasmid in (Vance, Campo et al. 1999). Lanes 3 and 4 shows that the E2-TopBP1 
mutant has compromised transcriptional activation capabilities, 8% of E2-WTat 
lower levels of input DNA, but can recover to more than half of E2-WT levels of 
transcription activation with higher plasmid input. Finally, lanes 5 and 6 show 
that the E2-Brd4 mutant is severely compromised in transcriptional activation at 
all levels of input plasmid DNA, 22% with 10ng of E2 input and 11% at 1000ng, 
however it still has some transcriptional activity likely due to residual interac-
tion between E2 and Brd4. 
3.3 HPV16 E2-TopBP1 and E2-Brd4 display compromised repli-
cation in 293T cells 
To investigate whether E1–E2 mediated DNA replication is affected by point mu-
tations known to impair the ability of E2 to bind to either TopBP1 or Brd4, a 
real-time PCR detection method was used to measure E1-E2 mediated DNA repli-
cation in 293T cells. 
In Figure 3.3 results for the mock transfected, pOri only (plasmid containing vi-
ral origin of replication(Taylor, Morgan 2003b)) and HA-E1 expression plasmid 
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with pOri gives very little background signal in this assay, so only results with E2 
are presented. Lanes 1-3 shows that with increasing levels of E2-WT plasmid DNA 
(10ng, 100ng and 1000ng) the levels of replication also increase. For both E2-
TopBP1 and E2-Brd4 with 10ng of input plasmid (lanes 4 and 7) replication function is 
severely compromised, 28.7% and 35% respectively, at higher levels of plasmid 
DNA the E2-TopBP1 mutant recovers some replication ability, 65% compared to E2-
WT at the highest concentration, the E2-Brd4 also recovers replication capabilities 
at 100ng (130%) and 1000ng (76.5%) of input to a greater extent than the TopBP1 
mutant. 
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Figure 3.1 
       
  
Figure 3.1: Expression of HPV16 E2-WT, E2-TopBP1 and E2-Brd4. 
C33a cells were transfected with 1µg of each expression plasmid. Cells were har-
vested and protein prepared for western blot (as described in Methods section 
2.2.1.6). Western blot was carried out with 50µg of cellular protein extract. A non-
E2 expressing control (C33a cell lysate) was also included for comparison to E2 
transfected cells. E2 expression was detected using TVG261 antibody. Following 
E2 expression in the upper panel the membrane was stripped (as described in 
Methods section 2.2.1.7) and re-probed with actin (lower panel) to act as a load-
ing control. 
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Figure 3.2 
 
Plasmid 10ng 1000ng 
E2
-WT 15.7 6.8 
E2
-TopBP1 1.0 4.6 
E2
-Brd4 1.8 0.8 
 
Figure 3.2: 16E2 Transcription activation in 293T cells. Transcription assays 
were carried out in 293T cells with input levels of 10ng and 1000ng, along with 1µg 
of ptk6E2, an E2 reporter containing 6E2 DNA binding sites upstream from a tk 
promoter driving luciferase (Vance, Campo et al. 1999). Cells were harvested and 
luciferase and protein assays carried out (as described in Methods section 
2.2.1.5 and 2.2.1.13). The results are normalised to protein levels in each sample 
and are represented as fold increase over ptk6E2 levels in the absence of E2. The 
results are representative of three independent experiments done in duplicate. 
Bars represent standard error. Fold activation in transcription over that obtained 
when no E2 was co-expressed is shown in the table below. None of the above re-
sults were significant using a student T-test. 
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Figure 3.3 
 
 
 
 
Plasmid 10ng 100ng 1000ng 
E2-WT 0.08 0.5 1 
E2-TopBP1 0.02 0.3 0.7 
E2-Brd4 0.03 0.7 0.8 
 
 
Figure 3.3: 16E2 mediated replication in 293T cells. 293T cells were co-trans-
fected with various concentrations of E2 input DNA (10ng, 100ng and 1000ng) 
along with 100pg of the viral origin of replication (ori) and 1μg of HA-E1. Low mo-
lecular weight DNA was harvested using HIRT buffer, and fresh replication assays 
as described in Methods section 2.2.1.14. Results shown are expressed relative 
to the wild-type E2 levels equaling 1; and are representative of three independent 
experiments, numbers shown in table below. Bars represent standard error. Signif-
icant results from student T-test are displayed on the graph. * denotes p<0.05, ** 
p<0.01, *** p<0.001. 
  
 
 
 
 
 
 
* 
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3.4 Transcription function of E2 and mutant E2 in C33a 
cells 
To further determine whether TopBP1 or Brd4 could regulate E2 transcriptional 
activity, transcription assays were carried out in the C33a cell line. The C33a 
cell line was selected for studying transcriptional activation by E2 because they 
are keratinocytes which are derived from a cervical carcinoma devoid of HPV se-
quences. C33a cells are an extensively used model cell line for the study of HPV 
E2 protein function. This is the first report of the E2-TopBP1 transcriptional activity 
in C33a cells. 
Figure 3.4a shows the transcriptional activation properties of E2-WT, E2-TopBP1 and 
E2-Brd4 in C33a cells. A range of E2 plasmid concentrations were transiently co-
transfected in C33a cells with an E2-responsive reporter construct consisting of 
six E2 binding sites upstream of the minimal thymidine kinase promoter (ptk6E2) 
and firefly luciferase gene. The results were averaged and normalised to ptk6E2 
in the absence of E2 equalling 1. In Figure 3.4a it is clear to see E2-WT induces 
transcriptional activation from the ptk6E2 promoter in a concentration depend-
ent manner (lanes 1-3), activation increases as plasmid input increases (10ng, 
100ng and 1000ng).Lane 4 demonstrates that E2-TopBP1 activates transcription, 
although activation is significantly less than E2-WT (21.5%), lane 5 shows activa-
tion at 100ng is only 24.7% of E2-WT, however some function is regained when E2 
is overexpressed, at 1000ng activation recovers to 68.6% of E2-WT. E2-Brd4 activa-
tion is the most compromised (lanes 7-9), due to Brd4’s essential role in tran-
scription. Despite this highly compromised ability to activate transcription from 
the ptk6E2 promoter, there is still a notable 3-fold increase in transcription over 
background levels, despite the decrease in activation compared to E2-WT (only 
7.7% at highest E2 levels), this 3-fold increase may represent a residual interac-
tion with Brd4.  
E2 can also act as a transcriptional repressor of papillomavirus control regions, 
and the ability of E2-WT, E2-TopBP1 and E2-Brd4 to repress the HPV18 long control re-
gion (LCR) was determined (Figure 3.4b). The HPV18 LCR was used as it has 
some transcriptional activity, in our hands the 16 LCR doesn’t. In lane 1, E2-WT is 
shown to repress transcription from the HPV18 LCR as predicted, and in lanes 2 
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and 3 both E2 mutants, E2-TopBP1 and E2-Brd4 also repress transcription activation, 
although to a lesser extent than E2-WT. 
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Figure 3.4 
 
Plasmid 10ng 100ng 1000ng 
E2-WT 10.4 22.4 30.7 
E2-TopBP1 2.2 5.6 21.09 
E2-Brd4 1.6 2.6 2.4 
 
 
 
Plasmid Control 100ng 
18LCR 1   
E2-WT   0.2 
E2-TopBP1   0.5 
E2-Brd4   0.5 
 
Figure 3.4: Transcriptional function of 16E2 in C33a cells. 
a) Transcription assays were carried out in C33a cells with input levels of E2 
expression plasmids of 10ng, 100ng and 1000ng, along with an E2 reporter 
containing 6E2 DNA binding sites upstream from a tk promoter driving lucif-
erase. Cells were harvested and luciferase and protein assays carried out. 
The results are normalised to protein levels in each sample and are repre-
sented as fold increase over ptk6E2 out (as described in Methods section 
2.2.1.5 and 2.2.1.13). The results are representative of three independent 
experiments done in triplicate. Bars represent standard error. Fold activa-
tion in transcription over that obtained when no E2 was co-expressed is 
* 
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shown in the table below. Significant results from student T-test are dis-
played on the graph. * denotes p<0.05, ** p<0.01, *** p<0.001. 
b) Wild-type and mutant E2 plasmids were titrated into C33a cells along with 
1µg of pHPV18LCR-luc (long control region) reporter containing the origin 
of replication. Cells were harvested and luciferase and protein assays car-
ried out. The results are normalised to protein levels in each sample and 
are represented as fold increase over 18LCR. The results are representa-
tive of three independent experiments done in duplicate, numbers are rep-
resented in a table below. Bars represent standard error. No significant re-
sults. 
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3.5 HPV 16E2-TopBP1 and E2-Brd4 have compromised repli-
cation in C33a cells. 
 
To further investigate whether TopBP1 and Brd4 are required for E1-E2 mediated 
DNA replication, replication assays were carried out in the C33a cell line with 
both low and high levels of E2 input plasmid. Results are shown in Figure 3.5a 
(10ng E2) and 3.5b (1000ng E2), only results with E2 are presented as back-
ground was close to zero. Figure 3.5a replication results are presented on log-
scale and E2-WT levels set to 1 and the level of replication induced by mutants 
set relative to this. At low levels of E2 expression plasmid (10ng), E2-TopBP1 and 16 
E2-Brd4 levels of DNA replication are down compared to E2WT, levels of replication are 
reduced to 0.55% and 2.57% of E2-WT respectively. In Figure 3.5b the results ob-
tained with 1000ng of input plasmid are represented. At higher levels of E2 input 
the mutant phenotype can be overcome, however the mutants do not regain 100% of 
their replication function. Replication levels for E2-TopBP1 and E2-Brd4 (lanes 2 and 3) 
are 34.4% and 70.3% respectively when compared to E2-WT.  
Recent studies from the Morgan lab have demonstrated that an interaction be-
tween E2 and E1 stabilises the E2 protein, so therefore the expression levels of 
E2 proteins co-transfected with E1, with E2 input levels from 10ng, 100ng and 
1000ng were investigated and shown in Figure 3.5c. Lane 1 contains only C33a 
cell lysate (no E1 or E2 transfection) whereas lanes 2-10 all contain HA-E1 and 
E2. Lanes 2-4 are transfected with E2-WT increasing in concentration from left to 
right (10ng, 100ng and 1000ng), lanes 5-6 contain E2-TopBP1 increasing in concen-
tration, and lanes 8-10 contain E2-Brd4 also increasing in concentration from left 
to right. The blot shows that E2-WT is expressed at higher levels than either E2-
TopBP1 or E2-Brd4 mutant suggesting that there may be a contribution of E2 protein 
levels to the compromised DNA replication abilities of these mutants. It should 
be noted that the mutant expression does not appear stable in this blot and re-
sults merely give an indication of this conclusion. 
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Figure 3.5 
 
 
 
Plasmid 1000ng 
E2-WT 1 
E2-TopBP1 0.3 
E2-Brd4 0.7 
 
 
 
 
Figure 3.5: E1-E2 mediated DNA replication and expression in C33a cells. 
a)  C33a cells were transfected with 10ng of E2 input DNA along with 100pg of the 
viral origin of replication (ori) and 1μg of HA-E1. Low molecular weight DNA was 
harvested using HIRT buffer and fresh replication assays as described in Methods 
section 2.2.1.14. Results shown are expressed relative to the wild-type E2 levels 
equaling 1; and are representative of three independent experiments, numbers 
shown in table below. Bars represent standard error. 
b)  C33a cells were transfected with 1000ng of E2 input DNA along with 100pg of 
the viral origin of replication (ori) and 1μg of HA-E1. Low molecular weight DNA 
was harvested using HIRT buffer and fresh replication assays as described in 
Methods section 2.2.1.14.  Results shown are expressed relative to the wild-type 
E2 levels equaling 1; and are representative of three independent experiments, 
numbers shown in table below. Bars represent standard error. 
Plasmid 10ng 
E2-WT 1 
E2-TopBP1 5.5E-03 
E2-Brd4 2.3E-02 
42 kDa 
42 kDa 
72 kDa 
10ng   100ng   1µg 10ng        100ng     1µg 10ng   100ng   1µg 
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c)  C33a cells were co-transfected with 1ug of E1 and E2-WT, E2-TopBP1 or E2-Brd4, 
titrated at 10ng, 100ng or 1000ng (concentration of plasmid input increases from 
left to right). Cells were harvested and protein prepared for western blot (as de-
scribed in Methods section 2.2.1.6). Western blot was carried out with 50µg of 
cellular protein extract. A non-E2 expressing control (C33a cell lysate) was also in-
cluded for comparison to E2 transfected cells. Actin is shown as a loading control. 
Following E2 expression in the upper panel the membrane was stripped (as de-
scribed in Methods section 2.2.1.7) and re-probed with actin (lower panel) to act 
as a loading control. The E2 mutants to appear to be unstable and this may affect 
the quality of the blot. Therefore, these results present an indication of their ex-
pression. 
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3.6 Brd4 and TopBP1 proteins are recruited to the viral 
origin of replication in an E1-E2 dependent manner. 
Results in Figures 3.5 a and b suggest TopBP1 and Brd4 are required for opti-
mum DNA replication by E2 in association with E1 in C33a cells. To test whether 
these host proteins interact with the HPV viral origin of replication directly, ChIP 
assays were carried out with chromatin prepared from C33a cells that had been 
transfected with the HPV16 origin of replication along with HA-E1 and E2 (100ng) 
expression vectors (as described in Methods section 2.2.1.13). Averaged results 
from replicate ChIP experiments are presented on a log-scale as the levels of 
pOri detected in the control conditions are orders of magnitude lower than when 
the viral origin is transfected alongside both E1 and E2 plasmids.  
The results are graphed in Figure 3.6. In Figure 3.6a, the results of the ChIP ex-
periment carried out with an HA antibody that recognises the HA-E1 protein is 
displayed (graphed on a log scale). In lane 1 the result with non-transfected cells 
is shown, lane 2 has the origin plasmid only transfected while lanes 3 and 4 have 
the HA-E1 and E2 expression plasmids transfected respectively. Transfecting ei-
ther HA-E1 or E2 with the origin of replication alone (lanes 3 and 4) gives no sig-
nal, and highlights both E1 and E2 are required together at the viral origin of 
replication. Neither are present in the absence of the other. In lane 5, cells 
were co-transfected with pOri, E1 and E2 plasmid DNA. This condition clearly 
shows an increase in signal of several orders of magnitude. Figure 3.6b shows 
ChIP carried out with an E2 antibody; again only a signal is detected when pOri 
plus HA-E1 plus E2 expression plasmids are transfected, E2 is located at the 
origin in an E1 dependent manner (lane 5). This result demonstrates that E2 re-
cruitment and/ or stabilisation at the viral origin of replication is assisted by the 
presence of E1. Figure 3.6c shows TopBP1 at the origin in an E1-E2 dependent 
manner when ChIP is performed with a TopBP1 antibody (lane 5). This is also 
true for Brd4, results shown in Figure 3.6d, lane 5. When the viral origin is com-
bined with HA-E1 and E2 the level of signal increases. 
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Figure 3.6 
 
Figure 3.6: ChIP of TopBP1 and Brd4 at the viral origin in an E1-E2 depend-
ent manner. Cells were transfected with nothing (lane 1); 1µg of the viral origin of 
replication by itself (pOri) (lane 2); along with 1µg of HA-E1 expression plasmid 
(lane 3); 1µg of pOri plus 1µg of HA-E1 expression plasmid (lane 4); 1µg of pOri 
plus 1µg of HA-E1 expression plasmid plus 1µg of E2 expression plasmid (100ng) 
(lane 5). Approximately 1x107 cells were cross linked and chromatin prepared 
<400bp using sonication method (as described in Methods section 2.2.1.15).  
100µg of chromatin was immunoprecipitated with 2µg of the appropriate antibody 
(HA (recognises E1), E2, TopBP1 or Brd4) and the resulting DNA quantified using 
our pOri taqman qPCR to quantify the levels of pOri DNA in the presence of our 
proteins of interest. This experiment was done in triplicate and results averaged. 
Error bars represent standard error. Pg of Pori detected is also shown in a table 
below. 
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3.7 TopBP1 and Brd4 are present in E1-E2 induced nu-
clear foci 
E1 and E2 have previously been shown to locate to nuclear foci when co-ex-
pressed and some reports suggest this is enhanced by the presence of the viral 
origin. Figure 3.7.1a shows a random example of C33a cells transfected with 
HA-E1, E2 and pOri. The left panel is HA staining (to detect HA-E1), the middle 
panel is E2 and the right panel is a merge with a DAPI stained image (all immu-
nofluorescence done by Mary Donaldson). Three distinct staining patterns were 
observed; large foci (i), punctate foci (ii) and a dispersed appearance (iii) that 
also looked like co-localisation was occurring. In order to distinguish whether 
pOri influences the distribution of these nuclear foci three independent experi-
ments and 50 random images were taken.  Large, punctate and diffuse patterns 
were counted in these images and the results shown for E2 in Figure 3.7.1b and 
for HA-E1 in Figure 3.7.1c; cells that displayed expression of both proteins were 
counted. The results showed that the presence of pOri enhanced the numbers of 
large foci containing cells and a reduced number of cells with a dispersed pheno-
type. This is suggestive that the large foci are replication foci.  
To determine whether TopBP1 and Brd4 are located in these foci, they were 
stained for either TopBP1 or Brd4 and co-stained for E1 as a marker for the E1-
E2-pOri replication foci. Figure 3.7.2a shows images of TopBP1 and Figure 
3.7.2b shows images of Brd4; which show that both of these proteins are located 
in the replication foci containing E1 and E2. Additionally, both proteins in the 
absence of E1-E2-pOri has dispersed nuclear expression patter (No image 
shown). 
3.8 shRNA knockdown of TopBP1 and Brd4 destroys E1-
E2-pOri nuclear foci but has no effect on DNA replication. 
Mary Donaldson investigated whether knocking down TopBP1 or Brd4 would have 
an effect on the formation of nuclear foci. Figure 3.8.1a shows co-transfection 
with shTopBP1 (i) and co-transfection with shBrd4 expressing plasmids (ii), which 
shows no replication foci are formed when TopBP1 or Brd4 is knocked down. In 
this experiment only HA-E1 was stained for but E2 and the pOri plasmids were 
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co-transfected and there is no TopBP1 detected in foci of any cell. Figure 
3.8.1b shows that no replication foci were formed and Brd4 cannot be detected. 
These experiments were repeated multiple times with no change in results and 
the absence of foci was observed after only 24 hours post transfection. 
As TopBP1 and Brd4 are present at the origin of replication, we hypothesized 
that knocking down the expression of these proteins may effect E1-E2 mediated 
DNA replication. To test this replication assays were carried out with increasing 
concentrations of E2 input plasmids (10ng, 100ng and 1000ng) in the presence 
and absence of shRNA plasmids targeting either TopBP1(as described in Methods 
section 2.2.1.14, details of shRNA in Materials section 2.1.9.1) (Figure 3.8.2a) 
or Brd4 (Figure 3.8.2b). There does not appear to be any change between the 
control and TopBP1/Brd4 shRNA. 
Figure 3.8.2c shows a western blot demonstrating shRNA knockdown of Brd4 
(TopBP1 shRNA knockdown has been shown in a previous publication (Donaldson, 
Boner et al. 2007). Lane 2 shows Brd4 expression in the absence of shRNA and 
lane 1 clearly shows a reduced level of Brd4 expression when cells are treated 
with 1µg Brd4 shRNA. Lane 3 is a cell control. This shows us our shRNA works and 
the replication result is true, knockdown of TopBP1 and Brd4 has little to no ef-
fect. 
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Figure 3.7.1
 
Figure 3.7.1. Localization of E1 and E2 into nuclear foci.  
a) The panel of images demonstrates examples of three types of staining: i) Large; 
ii) Punctate; iii) dispersed. All staining was carried out in C33a cells transfected 
with 1µg pOri, 1µg HA-E1 and 1µg E2. HA-E1 or E2 by themselves did not form 
foci and showed a dispersed nuclear appearance (not shown). 
 b)  Cells staining positive for both E1 and E2 were scored for the types of cell 
staining observed for E2 in both the absence and presence of pOri. The table dis-
plays a summary of three experiments with standard error bars shown. 
c) Cells staining positive for both E1 and E2 were scored for the types of cell stain-
ing observed for HA E1 in both the absence and presence of pOri. The table dis-
plays a summary of three experiments with standard error bars shown. These re-
sults are the work of Mary Donaldson. 
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Figure 3.7.2 
 
Figure 3.7.2. TopBP1 and Brd4 are recruited to E1-E2 foci. 
 a) C33a cells were transfected with 1µg pOri, 1µg HA E1, 1µg E2 then stained for 
TopBP1 (left panel) or HA (to detect HA E1, middle panel); the presence of E1 foci 
indicated co-expression of E2 (as described in Methods section 2.2.1.16). Stain-
ing is shown in the context of DAPI staining (right panel). All cells with E1 foci 
demonstrated recruitment of TopBP1 to these foci, two example panels are 
shown.  
b) C33a cells were transfected with 1µg pOri, 1µg HA E1, 1µg E2 then stained for 
Brd4 (left panels) or HA (to detect HA E1, middle panels); the presence of E1 foci 
indicated co-expression of E2 (as described in Methods section 2.2.1.16). Stain-
ing is shown in the context of DAPI staining (right panels). All cells with E1 foci 
demonstrated recruitment of Brd4 to these foci, two example panels are shown. 
This experiment was repeated with identical results at least three times. 
These results are the work of Mary Donaldson. 
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Figure 3.8.1 
 
 
Figure 3.8.1. Knock down of TopBP1 and Brd4 disrupts E1-E2 DNA replica-
tion foci.  
a) C33a cells were transfected with 1µg pOri, 1µg HA E1, 1µg E2 and 1µg of 
pShTopBP1 (i) or 1µg pShBrd4 (ii) then stained for TopBP1 (left panels) or HA (to 
detect HA E1, middle panels) (as described in Methods section 2.2.1.16, details 
of shRNA in Materials section 2.1.9.1); staining is shown in the context of DAPI 
staining (right panels). 
 b) C33a cells were transfected with 1µg pOri, 1µg HA E1, 1µg E2 and 1µg of 
pShTopBP1 (i) or 1µg pShBrd4 (ii) then stained for Brd4 (left panels) or HA (to de-
tect HA E1, middle panels) (as described in Methods section 2.2.1.16, details of 
shRNA in Materials section 2.1.9.1); staining is shown in the context of DAPI 
staining (right panels). This experiment was carried out two times with identical re-
sults, the knock down of TopBP1 or Brd4 always ablated the E1-E2-pOri induced 
foci. 
These results are the work of Mary Donaldson. 
 
 
 
Chapter 3  128 
 
Figure 3.8.2 
 
 
     
 
 
 
                                        
 
 
 
Figure 3.8.2: shRNA against TopBP1 and Brd4 has no effect on replication. 
a) C33a cells were co-transfected with various concentrations of E2 input DNA 
(10ng, 100ng and 1000ng) along with 100pg of the viral origin of replication (ori) 
and 1μg of HA-E1, also 1ug of TopBP1 shRNA or vector shRNA control (as de-
scribed in Methods section 2.2.1.14). HPV16 E2 and mutants DNA replication 
was tested by quantifying pOri levels, results shown are expressed relative to the 
wild-type E2 levels equalling 1; and are representative of three independent exper-
iments. Bars represent standard error. Significant results from student T-test are 
displayed on the graph. * denotes p<0.05, ** p<0.01, *** p<0.001. 
b) C33a cells were co-transfected with various concentrations of E2 input DNA 
(10ng, 100ng and 1000ng) along with 100pg of the viral origin of replication (ori) 
and 1μg of HA-E1, also 1ug of Brd4 shRNA or vector shRNA control (as described 
in Methods section 2.2.1.14). HPV16 E2 and mutants DNA replication was tested 
by quantifying pOri levels, results shown are expressed relative to the wild-type E2 
levels equalling 1; and are representative of three independent experiments. Bars 
represent standard error. Significant results from student T-test are displayed on 
the graph. * denotes p<0.05, ** p<0.01, *** p<0.001. 
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c) Brd4 shRNA western blot. C33a cells were transfected with 1µg of either a con-
trol vector for Brd4 shRNA or Brd4 shRNA and harvested 48 hours post transfec-
tion, and pellets lysed using NP40 buffer (as described in Method section 
2.2.1.6). The knockdown of Brd4 using shRNA was examined using western blot. 
TopBP1 shRNA has been previously shown in a western blot in (Donaldson, 
Boner et al. 2007). 
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3.9 The role of Brd4 and TopBP1 in HPV18 E2 transcrip-
tion and replication functions 
Plasmids expressing HPV18E2 (HA-tagged) had mutations successfully introduced 
using site-directed mutagenesis so they may be used for functional analysis (pri-
mer sequences shown in Materials section 2.1.11). Amino acid 90 is a conserved 
glutamic acid in almost all E2 proteins from all HPV species, mutating either 
amino acid 90 or 89 has been shown to disrupt the E2-TopBP1 interaction (Don-
aldson 2012). Mutations made in HPV18 E2 correspond to the mutants made in 
HPV16 E2, as 18E2 has an extra 4 amino acids at the beginning of its sequence 
compared to 16E2 (Figure 3.9), the R37A mutant becomes R41A in HPV18, and 
the N89YE90V mutant becomes T93YE94V. Ed Dornan made a T93YE94V mutant 
in 18E2 to make a comparison to the N89YE90V 16E2 mutant. T93YE94V was 
shown to replicate poorly, thus, we decided to analyse whether making a single 
mutation in 18E2 (E94V) would have the same functional consequence as “E” 
glutamic acid is a conserved amino acid.  
Figure 3.10 demonstrates that all of the plasmids made express E2 successfully 
when transfected into C33a cells. 
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Figure 3.9 
 
 
 
Figure 3.9: HPV18 has 4 extra amino acids at the beginning of its sequence 
compared to HPV16. Sequences of both HPV16 and 18 were put into Clustal W 
to align the sequences based on similarity. The red box highlights the 4 amino acid 
difference between 16 and 18. E2-TopBP1 and E2-Brd4 mutants of both HPV16 
and 18 are indicated by green and yellow boxes respectively. 
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Figure 3.10 
 
 
 
 
 
Figure 3.10: Expression of HPV18 E2-WT, E2-TopBP1 and E2-Brd4. C33a cells were 
transfected with 2µg of each expression plasmid. Cells were harvested and protein 
prepared for western blot (as described in Methods section 2.2.1.6). Western blot 
was carried out with 50µg of cellular protein extract. A non-E2 expressing control 
(C33a cell lysate) was also included for comparison to E2 transfected cells. 
HPV18 E2 was detected using anti HA antibody. Following E2 expression in the 
upper panel the membrane was stripped (as described in Methods section 
2.2.1.7) and re-probed with actin (lower panel) to act as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 kDa 
72 kDa 
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3.10 Transcription properties of 18E2 in 293T and C33a 
cells. 
Plasmids expressing each protein were transiently co-transfected into 293T and 
C33a cells with an E2-responsive reporter construct consisting of six E2 binding 
sites upstream of the minimal thymidine kinase promoter (ptk6E2) and firefly lu-
ciferase gene. The results from three independent experiments were averaged 
and normalised to ptk6E2, which in the absence of an E2 expression vector there 
is very little reporter activity. 
Figure 3.11a shows 18E2 mediated transcription activation from the tk6E2 pro-
moter in 293T cells and Figure 3.11b shows HPV18 E2 mediated transcription in 
C33a cells. In both 293T and C33a cells, 18E2-WT induces transcriptional activa-
tion from a tk promoter (lanes 1-3), and this activation increases as the concen-
tration of E2 input increases (500ng, 1000ng and 2000ng). Unlike 16E2-WT, higher 
concentrations of input DNA do not “squelch” activation of 18E2-WT. The ability 
of the two E2 mutants to activate transcription is severely compromised com-
pared to E2-WT, although Brd4 is slightly more compromised than TopBP1. This 
defect is more pronounced with increasing levels of E2. In Figure 3.11a, E2-TopBP1 
(lanes 4-6) has compromised replication at lower levels of E2, 26.8% of E2-WT and 
does not regain transcriptional activation at higher levels of E2 input as there is 
decrease to 19% of E2-WT at 1000ng. E2-Brd4 (lanes 7-9) can activate transcription 
to 19% of what E2-WT levels at low concentrations of E2 and this activation de-
creases to 14% at higher concentrations (1000ng). In Figure 3.11b, E2-TopBP1 repli-
cation (lanes 4-6) drops from 31% of E2-WT at 10ng to 15% at 1000ng. The same is 
true for E2-Brd4 (lanes 7-9) which drops from 34% compared to E2-WT at 10ng to 
12.6 % at 1000ng of E2 input. 
3.11 18E2 wild-type and mutants cannot repress tran-
scription 
HPV E2 can act as a transcriptional repressor of papillomavirus control regions, 
and the ability of 18E2 and mutants to repress the HPV18 long control region 
(18LCR) was tested in Figure 3.12. Repression assays were carried out in C33a 
cells, and the results were averaged and normalised to 18LCR. 18E2 wildtype 
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and mutants cannot repress transcription from the HPV18 LCR (lanes 1-9). 18E2 
does work in C33a cells as transcriptional activation in this cell line is similar to 
results seen in 293T cells, so these results are valid. 
 
3.12 18 E2-TopBP1 has compromised replication and 18 E2-
Brd4 replicates better than 18 E2-WT in 293T and C33a cells 
Replication assays were carried out in 293T and C33a cells to investigate the role 
of TopBP1 and Brd4 on HPV18 E2 replication function (Figure 3.13). Results are 
presented on a log-scale and E2-WT levels set to 1 and the level of replication in-
duced by mutants set relative to this. In Figure 3.13a and Figure 3.13b, E2-WT 
replication levels increase as the concentration of E2 input increases (10ng, 
100ng and 1000ng, lanes 1,2 and 3 respectively). In Figure 3.13a, at all concen-
trations of E2 expression plasmid (10ng, 100ng and 1000ng), E2-TopBP1 is severely 
compromised in replication abilities compared to E2-WT, 4.7% of E2-WT at 10ng and 
0.1% at 1000ng. However, unlike the results seen with 16E2-Brd4, 18E2-Brd4 replica-
tion is similar to E2-WT at all concentrations of input plasmid, 66% at 10ng com-
pared to E2-WT and optimal replication ability of the E2-Brd4 mutant are observed 
at 100ng, 145% of E2-WT. In Figure 3.13b, lanes 4-6 show replication ability of 
the E2-TopBP1 mutant, which displays compromised replication at all levels of E2 
input compared to E2-WT at all concentrations of E2 input, this defect is more 
pronounced in C33a cells compared to 293T. Similarly the E2-Brd4 phenotype is 
more pronounced in C33a cells, at the optimal level of E2 for replication with 
this mutant (100ng), E2-Brd4 replicates 664.8% greater than E2-WT. 
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Figure 3.11 
 
 
  
 
Plasmid 500ng 1000ng 2000ng 
E2-WT 6.5 12.5 20.7 
E2-TopBP1 1.7 1.9 4.0 
E2-Brd4 1.2 1.3 3.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid 10ng 100ng 1000ng 
E2-WT 5.0 11.6 37.5 
E2-TopBP1 1.6 2.7 5.7 
E2-Brd4 1.7 2.3 4.7 
 
Figure 3.11: HPV18 E2 transcription activation in 293T and C33a cells. Tran-
scription assays were carried out in 293T (a) and C33a cells (b) with input levels of 
wild-type 18E2 and mutant E2 of 500ng, 1000ng and 2000ng, along with 1µg of 
ptk6E2, an E2 reporter containing 6E2 DNA binding sites upstream from a tk pro-
moter driving luciferase (Vance, Campo et al. 1999). Cells were harvested and lu-
ciferase and protein assays carried out (as described in Methods section 2.2.1.5 
and 2.2.1.13). The results are normalised to protein levels in each sample and are 
represented as fold increase over ptk6E2 levels in the absence of E2. The results 
are representative of three independent experiments done in duplicate. Bars rep-
resent standard error. Fold activation in transcription over that obtained when no 
E2 was co-expressed is shown in the table below. Significant results from student 
T-test are displayed on the graph. * denotes p<0.05, ** p<0.01, *** p<0.001. 
* * ** * ** ** 
* * * * * 
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Figure 3.12 
 
 
 
 
 
Figure 3.12: 18E2 cannot repress transcription in C33a cells. Wild-type and 
mutant E2 plasmids were titrated into C33a cells along with 1µg of pHPV18LCR-
luc (long control region) reporter containing the origin of replication (as described 
in Methods section 2.2.1.13). Cells were harvested and luciferase and protein as-
says carried out. The results are normalised to protein levels in each sample and 
are represented as fold increase over 18LCR. The results are representative of 
three independent experiments done in duplicate, values shown in table below. 
Bars represent standard error. No significant results. 
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Figure 3.13 
 
 
 
Figure 3.13:  E1-E2 mediated DNA replication of 18E2 in 293T cells. 293T cells 
were co-transfected with various concentrations of E2 input DNA (10ng, 100ng 
and 1000ng) along with 100pg of the viral origin of replication (ori) and 1μg of HA-
E1. Low molecular weight DNA was harvested using HIRT buffer and fresh repli-
cation assays as described in Methods section 2.2.1.14. Results shown are ex-
pressed relative to the wild-type E2 levels equaling 1; and are representative of 
three independent experiments, numbers shown in table below. Bars represent 
standard error. No significant results. 
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3.13 Chapter summary and discussion 
As described in Chapter 1 the viral E2 protein regulates transcription from and 
replication of the viral genome, in association with viral and cellular factors. 
This is an essential for the continuation of the viral life cycle, making E2 a desir-
able antiviral target. Two essential host cellular factors that E2 interacts with to 
promote viral transcription and replication are TopBP1 and Brd4. 
TopBP1 has been shown to interact in vitro and in vivo with E2 and can regulate 
the ability of E2 to control transcription and replication (Boner, Taylor et al. 
2002). Previously our lab characterised a mutant of 16E2 which does not bind 
TopBP1 (E2-TopBP1) which has compromised replication in association with E1 but 
retains the ability to activate transcription, demonstrating that this mutant can 
bind target sequences and is correctly folded and functionally active in mamma-
lian cells (Donaldson, Mackintosh et al. 2012). The model proposed by the Mor-
gan lab is that the DNA binding proteins E1 and E2 both form a complex with 
TopBP1, and TopBP1 is involved in loading DNA polymerases onto the E1 helicase 
in mammalian cells resulting in replication initiation. Brd4 is also known to inter-
act with E2, and this interaction is present in many HPV types (16,18,31,6,8). 
Brd4 is believed to be part of a “transcription core”, made up of a number of 
host cellular genes, which are essential for transcriptional functions of all E2 
proteins. Brd4’s involvement in HPV transcription is well documented (Schwei-
ger, You et al. 2006, Schweiger, Ottinger et al. 2007), and its key role in the 
HPV viral life cycle makes it a valuable target for antiviral therapies.  
In this report I determine the functional effects of two E2 mutants, E2-TopBP1 and 
E2-Brd4, which fail to bind to TopBP1 and Brd4 respectively. The previous reports 
investigating the role of Brd4 in viral replication, have failed to keep experi-
mental conditions similar. Different cell types, different E2 proteins, and differ-
ent expression vectors were all used to quantify DNA replication.  
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3.13.1 Mutants of HPV16 E2 compromise viral transcription 
In Chapter 3.2 and 3.4, the effects of two E2 mutants were determined, E2-
TopBP1 and E2-Brd4, which fail to bind TopBP1 and Brd4 respectively, on HPV 16 
transcription in two model cell lines. 
Transcription results in 293T cells for HPV16 E2 and mutants are in agreement 
with previous publications (Donaldson, Mackintosh et al. 2012, Schweiger, You et 
al. 2006), E2-TopBP1 and E2-Brd4 are compromised in activating transcription, as 
they only activate transcription from the ptK6E2 promoter 8% and 22% respec-
tively (Figure 3.2). When E2-TopBP1 is overexpressed it regains almost wildtype ac-
tivation, 54% of E2-WT. This suggests that the E2-TopBP1 mutant can still interact 
with Brd4, which is known to be essential for transcriptional function of HPV16 
E2 in 293T cells (Schweiger, You et al. 2006). E2-Brd4 does not regain this function 
when overexpressed, which is expected due to its essential role in viral tran-
scription, 11.4% of E2-WT. This also confirms that Brd4 plays the more dominant 
role out of the proteins in the complex for this function. 
Results in the C33a cell line show a similar defect, whereas at higher concentra-
tions of E2 input E2-Brd4 shows a more severe phenotype compared to E2-TopBP1, 
E2-Brd4 only activates transcription by 7.7% of what is seen in E2-WT. conditions, 
compared to 68.7% for E2-TopBP1 (Figure 3.4a). The defect displayed by E2-Brd4 in 
transcription activation abilities can be supported by various studies that show 
the E2 stability is enhanced by Brd4 (Li, Li et al. 2014) and inhibiting the interac-
tion of E2-Brd4 with Brd4-CTD or knocking down Brd4 with siRNA for Brd4 re-
duces the E2 dependent transcription activation (Schweiger, You et al. 2006), 
additionally JQ1 (+) treatment (dissociates E2-Brd4 complexes from chromatin) 
potently reduces transcription (Helfer, Yan et al. 2014). 
HPV E2 is known to mediate transcriptional repression as well as activation. The 
repression of HPV LCR by E2-TopBP1 and E2-Brd4 is lessened by the failure of E2 to 
interact with these host proteins. Previously published results from the Morgan 
lab showed no difference in E2-mediated repression of the E2-TopBP1 mutant in 
293T cells (Donaldson, Mackintosh et al. 2012). However, the slight differences 
in repression found in this study may be explained by the use of C33a cells. 
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Studies from other labs have shown the knockdown of Brd4 in human cells has 
been shown to alleviate E2-mediated repression of HPV transcription (Wu, Lee et 
al. 2006b). This is somewhat in agreement with the results observed in C33a 
cells. It is proposed that there is an acetylation-dependent role of Brd4 in the 
recruitment of E2 for transcriptional silencing of HPV gene activity (Wu, Lee et 
al. 2006b). 
3.13.2 Mutants of HPV16 E2 compromise viral replication 
Previous replication studies have employed a Southern blot technique to quan-
tify levels of replication, which is limited in its ability to measure E1-E2 medi-
ated DNA replication. In this study a more sensitive real-time PCR assay for the 
detection of E1-E2 replication was utilised, which can detect a wider range of 
levels of replication than the traditional Southern blot technique. 
Previous work from the Morgan lab has shown that the interaction between E2 
and the host protein TopBP1 is essential for E1-E2 replication in 293T cells (Don-
aldson, Mackintosh et al. 2012). The results from assays conducted in this thesis 
are in agreement with this original finding. E2-TopBP1 displays compromised repli-
cation compared to E2-WT and this defect is more pronounced at lower levels of 
E2 input, at 10ng E2-TopBP1 only has 28.7% replicative function as E2-WT. Function 
is regained by both mutants when E2 is overexpressed but not to E2-WT levels. 
This was also seen in C33a cells. 
Additionally, in this thesis work, the role of Brd4 in HPV replication was investi-
gated. As well as the known role of Brd4 in viral transcription, new evidence sug-
gests that an interaction between E2 and Brd4 may be required for E1-E2 medi-
ated DNA replication (Wang, Helfer et al. 2013). In HPV16, Brd4 has been shown 
to be recruited to active replication origin foci with E2 and E1 and a number of 
other cellular replication factors (Wang, Helfer et al. 2013). Additionally, muta-
genesis disrupting the interaction between E2 and Brd4, and siRNA silencing of 
Brd4, have both been shown to impair HPV16 replication ability (Wang, Helfer et 
al. 2013).  
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E2-Brd4 was similarly compromised in its ability to replicate at 10ng of input DNA, as 
the E2-TopBP1 mutant. However, at the higher input concentration of 100ng, the abil-
ity of the E2-Brd4 mutant was greater than E2-WT. Due to the highly sensitive nature 
of our replication assay, we are able to see this defect in E2-Brd4 replication, at 
lower concentrations of DNA input. It should be noted that at higher levels of in-
put DNA, the defect is not so defined and less sensitive techniques such as 
southern blots will not be able to detect the replication defect.  
3.13.3 Brd4 and TopBP1 proteins are recruited to the viral origin 
of replication in an E1-E2 dependent manner 
In our replication assay experiments, the interaction between TopBP1/Brd4 with 
HPV16 E2 was shown to be required for viral replication. However, it was un-
known whether these host cellular factors are recruited to the viral origin of 
replication along E1 and E2. The interaction of the “complex” at the viral origin 
of replication was investigated using chromatin immunoprecipitation. 
A few novel observations were made about HPV replication using this technique: 
The first notable feature of HPV replication is that E1 and E2 require each other 
to be present at the origin of replication, neither one is expressed in the ab-
sence of the other. Previously, it was believed that E2 would recruit E1 to the vi-
ral origin of replication (Ustav, Ustav et al. 1991). Perhaps, E2 does not bind the 
viral replication origin until it is complexed with E1. Alternatively, it could be 
suggested that once E1 is recruited to the viral origin there is an enhanced inter-
action of E2 with viral DNA. The mechanism by which these proteins are re-
cruited the viral origin remains unclear. 
The second novel finding from ChIP experiments is that TopBP1 and Brd4 locate 
to the viral origin of replication in an E1-E2 dependent manner. This result con-
firms that both TopBP1 and Brd4 are required for HPV replication. It may also 
suggest that TopBP1/Brd4 complex could act as a chaperone to bring the viral 
E1-E2 proteins to the viral origin. Further optimisation of the ChIP technique is 
required to test whether this is true for the E2 mutants, E2-TopBP1 and E2-Brd4. 
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3.13.4 shRNA knockdown of TopBP1 and Brd4 destroys E1-E2 nu-
clear foci but has no effect on DNA replication 
In Chapter 3.7 Mary Donaldson showed that TopBP1 and Brd4 are present in E1-
E2 induced nuclear foci when co-expressed with the viral origin of replication, in 
C33a cells. The E2 mutants, E2-TopBP1 and E2-Brd4 were then tested for their ability 
to form nuclear foci in Chapter 3.8. Mary Donaldson clearly demonstrated that 
the ability of these E2 mutants to form nuclear structures was compromised. 
This defect is particularly noticeable at lower concentrations of E2 expression, 
giving a correlation between nuclear foci formation and DNA replication (as seen 
in Figure 3.5a). 
To follow up from this finding of TopBP1 and Brd4 being present in these replica-
tion foci, it was decided to see if the role these host proteins is critical for the 
initiation of viral replication. E1-E2 mediated DNA replication initiated in con-
junction with the host proteins TopBP1 and Brd4 is not affected by shRNA knock-
down of either TopBP1 or Brd4. However, knocking down TopBP1 or Brd4 com-
pletely destroyed the formation of E1-E2-pOri nuclear foci formation. Perhaps 
the interaction of TopBP1 and Brd4 are required for the initiation of replication 
but once initiated they are no longer needed, which would explain by knocking 
down TopBP1 and Brd4 after initiation of replication had no effect. 
Supporting evidence for this argument comes from a recent report by (Sa-
kakibara, Chen et al. 2013a) who demonstrated that Brd4 is in the heart of repli-
cation foci induced by E1-E2 but after initiation Brd4 becomes peripheral to the 
foci.  
3.13.5 Conclusions 
Novel findings were made that enhance our understanding of DNA replication by 
human papillomavirus 16 E1 and E2. (1) Our replication assays showed that E2-
Brd4 is severely compromised in DNA replication ability which suggests that Brd4 
is required for efficient initiation of E1-E2 mediated DNA replication. (2) E1 and 
E2 co-operate to interact at the viral origin as neither is present at the origin in 
the absence of the other. Previously it was thought that E2 could bind to the 
origin of replication independently of E1, but this was not reflected in the ChIP 
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assay results. We propose that E1 may stabilise the interaction of E2 with the 
origin allowing for detection in ChIP assays, similar to how E1 stabilises the E2 
protein (King, Dornan et al. 2011). (3) ChIP was used to demonstrate the pres-
ence of both TopBP1 and Brd4 at the viral origin of replication in an E1-E2 de-
pendent manner. (4) TopBP1 and Brd4 were also shown within E1-E2 foci and 
shRNA targeting the expression of the cellular proteins destroys these replication 
foci. (5) Although the replication foci are destroyed by shRNA targeting the ex-
pression of TopBP1 and Brd4, the levels of DNA replication are not affected, sug-
gesting that replication is not dependent upon these foci.  
Overall, these initial findings indicate that TopBP1 and Brd4 are located in the 
same cellular complex, and that the TopBP1-Brd4 complex may recruit E2 and 
the HPV genomes to areas of host chromatin that would stimulate viral replica-
tion following entry into S phase. Previous work from the McBride group has 
shown that E2 and Brd4 are located on similar host regions of chromatin, known 
for viral genome replication, implicating Brd4 in E1-E2 mediated DNA replication 
(Jang, Shen et al. 2014). Additionally, E2 also co-localises with TopBP1 in late 
mitosis, allowing the HPV genome to interact with a number of host replication 
factors (Donaldson, Boner et al. 2007). 
The co-localisation of the E1-E2-TopBP1-Brd4 complex is required for the initia-
tion of replication. If this failed perhaps there would be a mislocalisation of the 
viral genome to inappropriate locations in the host chromatin, which could af-
fect the quality of the replication. We currently do not understand what will 
happen to the quality of the replication in these conditions and further work is 
needed in this area. Also, we do not fully understand the mechanisms of replica-
tion used by the virus at different stages within the life cycle. As was demon-
strated in Figure 3.8.2, the complex is not required for the continuation of rep-
lication, only for initiation, this suggests the mode of replication switches.  
As described in Chapter 1, homologous recombination is the proposed method of 
viral amplification throughout the lifecycle (Gillespie, Mehta et al. 2012) (Sa-
kakibara, Chen et al. 2013b), and the virus promotes DNA damage response to 
promote amplification of the viral genome (Moody, Laimins 2009).The results 
support this model as it has been shown that both TopBP1 and Brd4 are required 
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for initiation for viral replication, but not the continuation. Suggesting that Brd4 
and TopBP1 are not required for the homologous recombination mechanism of 
replication. Although, it should be noted TopBP1 has been suggested to be in-
volved in this process (Morishima, Sakamoto et al. 2007) (Germann, Oestergaard 
et al. 2011). 
3.14 HPV18 replication and transcription 
A study from the Bodily lab showed that the Brd4 mutant in HPV31 could main-
tain viral episomes, whereas the same mutant in HPV16 failed to do so (Gauson, 
Donaldson et al. 2015). This result suggests that there are differences between 
HPV types and their requirement for Brd4, and possibly TopBP1, for genome rep-
lication and establishment. This highlights the need to address questions about 
viral replication of a specific HPV type in a consistent manner. 
As past studies have focused on 16E2, not much work has been done to under-
stand the transcription and replication function of HPV18 E2, in relation to E2’s 
ability to bind TopBP1 and Brd4. Due to the differences seen with HPV31, it was 
expected that HPV18 may also demonstrate key differences. 
3.14.1 Mutants of HPV18 E2 compromise viral transcription 
Activation defects are similar for both E2-TopBP1 and E2-Brd4 mutants in HPV18, E2-
Brd4 is less compromised in HPV18 than HPV16, this is true at all levels of E2 in-
put, and both model cell lines. This would suggest that Brd4 may not play the 
most dominant role in HPV18 transcriptional activation. Perhaps HPV18 is com-
plexed with other transcription factors to facilitate effective transcription. 
A novel difference between HPV16 and HPV18 is that HPV18 E2 cannot repress 
transcription, unlike HPV 16E2 which does repress transcription. In HPV18 the 
failure to repress transcription is independent of its interaction with TopBP1 and 
Brd4. The differences in the mechanism used by HPV 18 is not yet understood an 
further studies are required. 
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3.14.2 Mutants of HPV18 E2 compromise viral replication 
As with HPV18 transcription, there have been no previous studies on the effect 
of 18 E2 mutants on viral replication. These assays were carried out in both 293T 
and C33a cells. 
In HPV18, the E2-TopBP1 mutant exhibited severely compromised replication com-
pared to 16 E2-TopBP1. As seen in Figure 3.10, E2-TopBP1 fails to replicate at all lev-
els of E2 input, the defect worsens as the concentration increases, the replica-
tive ability goes from 4.7% at with 10ng of input and drops to 0.1% with 1000ng 
of input (in 293T cells). However, in contrast to this 16 E2-TopBP1 can still repli-
cate, although at lower levels than E2-WT. Perhaps 18E2 relies solely on the inter-
action with TopBP1 for viral replication, whereas 16E2 may interact with other 
host proteins to aid in replicative function, such as Brd4. E2 is known to interact 
with a number of host proteins, however the roles these interactions play is cur-
rently understudied. The interaction of E2 with TopBP1 stabilises E2 in S phase 
explaining the replication defect seen in our assays (Donaldson, Boner et al. 2007). 
Despite E2-TopBP1 being extremely compromised in HPV18, E2-Brd4 can replicate 
better than E2-WT (Figure 3.13), this phenotype is more apparent at higher con-
centrations of E2, in both 293T and C33a cells. Replication of E2-Brd4 is optimal at 
100ng of DNA input in both cell lines, 154% in 293T and 664.7% in C33a cells com-
pared to E2-WT. 
All of these differences seen between HPV16 and 18 E2 transcription and replica-
tion function indicates that they interact with host proteins in a different man-
ner to carry out the viral life cycle. 
3.14.3 Summary of HPV18 results 
Major differences between HPV16 E2 and 18 E2 have been observed in this study; 
(1) 18E2-TopBP1 mediated DNA replication is severely compromised compared to 16 
E2-TopBP1. (2) 18E2-Brd4 can activate transcription stronger activation of transcrip-
tion than 16E2-Brd4. (3) 18E2 does not repress transcription unlike 16E2 which 
does repress transcription. (4) 16 E2-Brd4   is compromised in DNA replication 
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function in a cell type specific manner. (5) 18 E2-Brd4    is not compromised in 
DNA replication in any cell type.  
Further experiments similar to those done with 16 E2 and mutants are required 
to investigate whether these host cellular factors are playing a different role in 
viral replication. This emphasises the need to make conclusions about viral repli-
cation in a very consistent manner, using the same HPV type, assays, and even 
concentrations of plasmid in each assay. This also emphasises the need to gain 
an antiviral target that is pan-type specific to many HPV types. Perhaps TopBP1 
offers to be this target? 
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Chapter 4 – Regulation of human genome expres-
sion by HPV16 E2 
 
4.1 Wildtype E2 regulates host genes 
Following the findings of the previous chapter which focused on how TopBP1 and 
Brd4 interact with E2 to regulate the viral genome, further investigation of how 
these host proteins interact with viral E2 to regulate the host genome was car-
ried out. The proposed hypothesis is that E2 manipulates host gene expression to 
facilitate infection and the viral life cycle. 
4.1.1 Generation of U20S cells expressing HPV16 E2 
To address this question, U20S cells which are derived from an osteosarcoma 
were chosen as a model system. These cells provide a good model for the inves-
tigation of the regulation of the host genome by E2. U20S cells are p53 wildtype 
and tolerate E2 expression. Similar stable clones expressing E2 have been made 
previously using the U20S cell line, and are therefore known to tolerate physio-
logical levels of HPV16 E2 (Taylor, Boner et al. 2003). The Ustav lab have also 
used U20S cells as a model to study the replication of low and high-risk cutane-
ous HPV (Reinson, Toots et al. 2013, Geimanen, Isok-Paas et al. 2011), as well as 
analyse the transcriptome of HPV18. They did not observe any changes in the 
promoter, splice site, or polyadenylation usage in U20S when compared to keri-
tinocytes (Wang, Meyers et al. 2011). U20S cells are a valuable tool for investi-
gating the E2 interaction with the host chromatin and histone modifications, as 
ENCODE data is readily available for this cell line. 
U20S cell lines that stably express 16E2-WT were generated for use in gene ex-
pression studies, using a similar protocol to that previously published (Taylor, 
Boner et al. 2003) (as described in Methods section 2.2.2.2). Stable colonies 
following transfection were isolated and expanded and screened for E2 expres-
sion (Figure 4.1.1a). Growth of these E2 expressing clones was monitored and 
recorded by carrying out growth curves with two separate clones, which show no 
difference in the growth rates of non-E2 and E2 expressing U20S cells (Figure 
4.1.1b). 
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Figure 4.1.1 
 
Figure 4.1.1: Generating and characterising stably expressing E2 clones. 
a) Potential E2 expressing clones were screened by making lysates for western 
blot analysis (as described in Methods section 2.2.1.6). Lanes 1 and 3 show cells 
which stably express HPV 16E2 protein and lanes 2 and 4 show non-E2 express-
ing vector controls. 
b) 4x105 cells were seeded and counted every 3 days, growth curves were gener-
ated from the numbers of cells from each count (as described in Methods section 
2.2.2.3). The growth curve displays no difference in the growth rate between the 
E2 and non-E2 expressing clones. 
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4.1.2 Identifying differentially expressed host genes induced by 
E2 
To investigate the regulation of the host genome by viral E2, three independent 
polyA+ RNA preparations were made and converted into cDNA (as described in 
Methods section 2.2.1.10 and 2.2.1.11) and analysed using Affymetrix Human 
Exon Array (as described in Methods section 2.2.3.1). From this point forward 
this shall be known as “array 1”. The aim of this study was to identify the cellu-
lar genes E2 regulates in the host genome and whether mutations in E2 alter this 
regulation. Analysis of the array was carried out by Pawel Herzyk using Partek 
genomics suite software, lists of the top 50 up and down regulated genes can be 
found in the tables below (Table 4.1.1). (Supplementary Table S.1 displays full 
list of genes regulated by 16 E2 wildtype ≥ 1.5-fold). 
From the analysis; 74 genes were found to be differentially regulated 2 fold or 
greater (p-value ≤0.05) when E2 was compared with the vector control (non-E2 
expressing); 33 up-regulated and 41 down-regulated. Of the list of 74 E2 regu-
lated genes, ten of the altered genes were selected to validate the array results 
in two independent clones of E2 (Table 4.1.2 displays validation). Sybr green 
real-tume qPCR was used to validate the array gene expression results. The 
house keeping gene GAPDH was used as an endogenous control alongside the 
vector, no E2 expressing U20S cell line to normalise the results using the ∆∆ct 
method. In clone 1, 7 out of 10 gene changes validated while in clone 2, 10 out 
of 10 tested validated. This demonstrates that the results generated from the 
exon array screen were predictive of actual fold gene changes. 
Ingenuity Pathway Analysis (IPA) was used to further analyse the 74 genes (as de-
scribed in Methods section 2.2.3.2). 5 networks were found and the functions 
were associated with the presence of cancer, reproductive system disease, gene 
expression and DNA replication and repair (Table 4.1.3). 
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Table 4.1.1 
 
Up-regulated by E2 Fold-change Down-regulated by E2 Fold-change
HIST1H2BM 71.9508 GTSF1 -302.705
HIST1H3H 70.7304 NFE4 -24.794
MAGEC1 40.1869 TMPRSS15 -11.624
SLN 14.5889 SLC14A1 -5.94492
HOXB2 10.631 C1orf85 -4.48436
TNFAIP6 4.86318 CD33 -4.1363
ENG 4.85397 CLIC2 -3.9316
GNG11 4.11702 FBXL13 -3.60857
FAR2 3.70124 PTGFR -3.59376
ZNF788 3.3983 CSTA -3.49077
APBA2 2.99782 NLRP5 -3.33859
SERPINA3 2.74046 DNAJC18 -3.31614
C10orf72 2.5905 BMPER -3.27652
GFPT2 2.53867 HBE1 -3.07671
SH3PXD2B 2.50361 RNF144B -3.04874
FAP 2.47498 GDF15 -2.98979
LRRCC1 2.36516 LOC79015 -2.97446
ARHGDIB 2.35827 HSD17B8 -2.75366
SNTB1 2.25035 HIST1H3E -2.69962
EML1 2.23335 MLH3 -2.64666
ARHGAP11A 2.23306 NLRP4 -2.60899
CCDC99 2.16172 TRIML2 -2.55713
FGD4 2.1616 CD68 -2.47599
ZNF271 2.15217 ACYP1 -2.43839
MTMR10 2.11787 PSG9 -2.41357
CALHM2 2.11199 HLA-DPA1 -2.38118
HNMT 2.09265 GNGT2 -2.37174
GOLGA8B 2.08224 FST -2.35479
AQR 2.05191 GCNT2 -2.3148
NFIA 2.02545 GRAMD3 -2.29601
ZNF770 2.02363 PGAP2 -2.20441
ZADH2 2.01373 RPL23 -2.20367
RTKN2 2.00087 IL1RAPL1 -2.18097
CLEC2B 1.98705 OR10A3 -2.14773
RAB27B 1.97895 GPR65 -2.14222
MYO5B 1.97609 AURKC -2.13613
TMEM55A 1.96272 ZNF300P1 -2.10876
IMPACT 1.92209 ME3 -2.06315
ZNF738 1.90705 ADRB2 -2.05351
TRPS1 1.88341 PSG4 -2.04519
TTC39C 1.87129 ZFP90 -2.02583
ATPBD4 1.86744 DPYSL4 -1.9764
FAN1 1.86327 TOX -1.96981
B4GALNT3 1.85095 LTBP2 -1.96341
STK38L 1.83674 IL6 -1.95904
ZNF365 1.82942 CARS -1.90807
CASC5 1.81003 EIF2B2 -1.89313
FAM60A 1.79363 AOC2 -1.88615
C8orf40 1.79137 MDGA2 -1.88515
NUP210 1.78893 WNT2B -1.87542
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Table 4.1.1: Genes regulated by HPV16 E2 in U20S cells. Human exon array 
analysis was used to generate lists of genes regulated by HPV16 E2-WT. Pawel 
Herzyk carried out Partek analysis to sort the raw data into lists of genes that had 
a fold-change (F.C) of ≥ 1.5 and a p-value of ≤0.05. The genes represented in this 
table display a transcriptional level which has been increased or decreased by the 
levels indicated. The results are validated in the same clone used for the microar-
ray study, as well as an additional clone to verify the findings. 
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Table 4.1.2 
Gene 
Name 
Fold-change in Ar-
ray 
Fold-change clone 
1 
Fold-change clone 
2 
MAGEC1 40.19 190.7 ± 197.63 594.2 ± 522.29 
ENG 4.85 11.7 ± 3.90 6.61 ± 11.79 
FAR2 3.7 3.78 ± 1.26 2.81 ± 1.28 
APBA2 2.99 6.83 ± 11.15 27.09 ± 33.27 
SH3PXD2B 2.5 1.93 ± 0.27 3.9 ± 4.43 
GDF15 -2.99 -1.24 ± 0.53 -3.47 ± 2.44 
RNF144B -3.05 -1.29 ± 1.10 -6.81 ± 0.84 
TMPRSS15 -11.62 -6.22 ± 2.75 -14.32 ± 5.25 
NFE4 -24.79 -16.22 ± 6.97 -10.31 ± 3.37 
GSTF1 -302.71 
-2413.91 ± 
1449.10 -2,723.91 ± 1940.0 
 
Table 4.1.2: Validation of genes regulated by HPV16 E2. The table displays the 
fold-change relative vector (no E2) of 5 up and 5 down-regulated genes that were 
regulated by 16 E2-WT in the human exon array.  Validation was done in two sepa-
rate clones in triplicate, standard error is shown. Sybr Green qPCR validation is 
described in Methods section 2.2.1.12. 
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Table 4.1.3 
Network Associated network functions 
1 Protein synthesis; protein degradation; hereditary disorders 
2 Tissue morphology; cancer; reproductive system disease 
3 Gene expression; cancer; renal and urological disease 
4 Hematological system development and function; organismal development; cell morphology 
5 Cellular assembly and organization; DNA replication, recombination, repair; gene expression 
 
Table 4.1.3: Top 5 16E2 regulated pathways from Ingenuity Pathway analy-
sis. The 74 E2-WT regulated genes (≥ 2-fold) were subjected to IPA and 5 networks 
of genes were identified. The table lists the predicted functions with the IPA gener-
ated networks. (Genes associated with this table are shown in Supplementary 
Table S.2 and p-values associated with functions can be found in Supple-
mentary Table S.13). 
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4.1.3 Regulation of cell motility by E2 
A number of genes from the microarray gene expression analysis are implicated 
in cell movement and motility (Table 4.1.1). SH3PXD2B, FDG4, FAP and ARHG-
DIB were all up-regulated in the microarray analysis (Table 4.1.1) and may mod-
ulate the migration of E2 expressing cells.SH3PXD2B encodes for an adapter pro-
tein that is required for podosome formation and is involved in cell adhesion and 
migration of various cell types (Bogel, Gujdar et al. 2012). FDG4 is involved in 
the regulation of of the actin cytoskeleton and cell shape, and promotes migra-
tion of nasopharyngeal carcinoma cells infected with EBV (Liu, Chen et al. 2012). 
FAP is thought to be involved in the control of fibroblast growth or epithelial-
mesenchymal interactions during development, tissue repair, and epithelial car-
cinogenesis (Kelly, Huang et al. 2012). ARHGDIB is a RhoGDP dissociation inhibi-
tor that can regulate metastasis, potentially by downregulating adhesion 
(Griner, Theodorescu 2012). 
To investigate how E2 effects cell movement, wound healing assays were carried 
out over a 24 hour time period in two separate E2 and non-E2 expressing clones. 
After 24 hours of wound healing only the non-E2 expressing cells had successfully 
closed the wound, whereas the cells expressing E2 struggled to do so (Figure 
4.1.2), despite there being no difference in the rates of cell growth, as seen in 
Figure 4.1.1a. To further understand the differences in cell movement, videos 
were made to monitor the movement over 24 hours, also with two separate 
clones (available to view online in the following paper (Gauson, Windle et al. 
2014)) From the videos it is clear to see that E2 expressing cells have impaired 
movement, they move in large sheets of cells and do not move unidirectional 
like non-E2 expressing cells. This accounts for their inability to close the wound 
in the same time frame as the non-E2 cells. 
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Figure 4.1.2 
 
 
 
Figure 4.1.2: Wound healing and cell movement of HPV16 E2. 5x104 cells were 
seeded into cell chambers and grown for 24 hours. 24 hours after seeding the 
chambers were removed and movement of E2 expressing cells vs non E2-ex-
pressing cells was monitored by microscopy and images were collected at 0, 16 
and 24 hour time points (as described in Methods section 2.2.2.4). Two separate 
clones for each condition were monitored. Both E2-WT clones clearly show a defect 
in movement and their ability to close the gap in the 24 hour time period, whereas 
both no E2 clones have closed the gap by the 24 hour time point.  
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Figure 4.1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.3: Still images of E2 and non-E2 expressing cells movement.  
a) Cell movement by U2OS Vec (No E2 expression) cells. A monolayer of 
U2OS cells was scratched with a 20µl pipette tip to create a “wound”. The 
movement of the cells to heal the “wound” was followed over a 24 hour pe-
riod. There is random movement of the cells at the leading edge to move 
forward into the empty space created by the scratch. 
b) Cell movement by U2OS E2 expressing cells.  A monolayer of U2OS cells 
was scratched with a 20µl pipette tip to create a “wound”. The movement of 
the cells to heal the “wound” was followed for 24 hours as before. The E2 
expressing cells are more coordinated and tend to move into the gap cre-
ated by the scratch together in sheets. Note this assay did not measure the 
size of the “wound”, but only demonstated the mechanism of movement of 
these cell lines. 
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  The role of Brd4 in E2 regulation of host genes 
As demonstrated in Chapter 3, Brd4 is a key player in HPV transcription and E2 
mutants that fail to bind Brd4 have severely compromised transcription activa-
tion capabilities, in both 293T and C33a cells. Additionally, Brd4 is also involved 
in HPV16 E1-E2 mediated replication, and is likely required for the efficient initi-
ation of viral replication. As Brd4 plays key roles in the viral life cycle we 
wanted to address the question of how E2 regulates the host genome in conjunc-
tion with Brd4, and would E2’s regulation of the host genome change if it fails to 
interact with Brd4. This may allow us to better understand how E2 regulates the 
viral life cycle as well as how E2 regulates viral and host gene regulation. 
4.2.1 E2-Brd4 fails to activate transcription in U20S cells 
To address this question a human exon array study that mirrors the previous 
study in 16E2-WT was set up, this shall be known as “array 2” from this point for-
ward. Firstly, the ability of the E2-Brd4 mutant to activate transcription in U20S 
cells was tested. The results demonstrate that E2-Brd4 is severely compromised in 
its ability to activate transcription from the ptk6E2 promoter, at all levels of E2 
DNA plasmid input (Figure 4.2.1). This is similar to the results previously ob-
tained in 293T and C33a cells in Chapter 3 (Figure 3.2 and 3.4). 
4.2.2 Generation of U20S cells expressing 16E2-Brd4 
This allowed us to utilise the U20S model to answer the question of how the in-
teraction of Brd4 and E2 affects the regulation of the host genome. To do this, 
U20S cells that stably express E2-Brd4 were generated in the same way as E2-WT 
cells (as described in Methods section 2.2.2.2). Expression of potential clones 
was tested using western blot analysis, as seen in Figure 4.2.2a.  The growth of 
these cells was also monitored by a growth curve, and no significant difference 
in growth rate was seen between E2-Brd4, E2-WT and non-E2 expressing U20S cells 
(Figure 4.2.2b). 
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Figure 4.2.1 
 
Figure 4.2.1: 16E2-Brd4 Transcription activation in U20S cells. Transcription as-
says were carried out in U20S cells with input levels of 10ng, 100ng and 1000ng, 
along with an E2 reporter containing 6E2 DNA binding sites upstream from a tk 
promoter driving luciferase (Vance, Campo et al. 1999). Cells were harvested and 
luciferase and protein assays carried out (as described in Methods section 
2.2.1.5 and 2.2.1.13). The results are normalised to protein levels in each sample 
and are represented as fold increase over ptk6E2 levels in the absence of E2. The 
results are representative of three independent experiments done in duplicate. 
Bars represent standard error. Fold activation in transcription over that obtained 
when no E2 was co-expressed is shown in the table below. No significant results. 
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Figure 4.2.2 
 
Figure 4.2.2: Generating and characterising stably expressing E2-Brd4 clones. 
a) Colonies were picked and expanded after G418 selection. Potential E2 ex-
pressing clones were screened by making lysates from the cells and tested 
for E2 expression using standard western blot procedure (as described in 
Methods section 2.2.1.6).  
b) 4x105 cells were seeded and counted every 3 days, growth curves were 
generated from the numbers of cells from each count (as described in 
Methods section 2.2.2.3). The growth curve displays no difference in the 
growth rate between the E2 and non-E2 expressing clones, E2-Brd4 is also 
similar. This was done in two individual clones. Only one clone is graphed 
as the clones grow similarly. 
 
 
42 kDa 
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4.2.3 Identifying differentially expressed host genes induced by 
E2-Brd4 
A Human exon array study was carried out to look at the differences between 
non-E2 expressing cells, E2-WT and E2-Brd4 (“array 2”). 16E2 was shown to regulate 
879 genes, of these genes 407 are up-regulated ≥1.5 fold and 472 are down-regu-
lated ≥1.5 fold. The E2-Brd4 mutant, that does not bind Brd4, regulates about 
1884 host genes (≥ 1.5 fold), 956 up-regulated and 928 down-regulated (Table 
4.2.4 displays top 50 +/- regulated genes ≥ 2-fold for E2-WT). (Supplementary Ta-
ble S.3 and S.5 displays the full list of genes regulated by 16 E2-WT and 16E2-
Brd4 ≥ 1.5-fold respectively). 
When E2 fails to interact with Brd4 there is a notable increase in the number of 
genes E2 is able to regulate in the host genome. It should also be noted that in 
“array 2” 16 E2-WT regulates the gene expression of more genes than in “array 
1”, this is most likely due to the RNA being prepared at different times and con-
ditions may have varied slightly. The overlap of the E2-WT regulated genes from 
array 1 and 2 corresponds to 58% of the top 50 up-regulated genes in array 1 (Ta-
ble 4.1.1) were similarly regulated in array 2 (Table 4.3.2), and 54% of the top 
50 down-regulated E2-WT genes in array 1 were similarly regulated in array 2 . 
This difference may also be contributed to the experiments being carried out at 
different times. 
4.2.4 Validation of E2-WT and E2-Brd4 regulated genes 
The microarray was validated with primer sets for genes which were up or down-
regulated greater than two-fold by both E2-WT and E2-Brd4 (Table 4.2.1 and 
4.2.2). Seven out of 8 and 6 out of 8 genes validated for E2-WT clones 1 and 2 re-
spectively, and 7 out of 7 genes validated for both E2-Brd4 clones.  
4.2.5 Specific E2-WT genes not regulated by E2-Brd4 
An additional 6 genes were selected to further validate the array. These genes 
are specifically regulated by E2-WT (≥ 2-fold). Three out of the 6 E2-WT specific 
genes screened validated successfully, and are presented on a graph to highlight 
the difference in regulation between no E2 control, and E2-Brd4 expressing clones 
(Table 4.2.3 and Figure 4.2.3).  E2-Brd4 Clone 1 validated for all six genes, but 
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E2-Brd4 Clone 2 only validated 3 out of six genes (Table 4.2.3). This shows that 
the genes regulated by E2-WT only in the array are specific to E2-WT. The figure to 
accompany the three validated genes demonstrates this (Figure 4.2.3).  
4.2.6 Similarities between E2-WT and E2-Brd4 regulated genes 
A table of the top 50 E2-WT +/- regulated genes ≥ 2-fold highlights genes similarly 
regulated by E2-Brd4 (grey= similarly regulated in top 50 genes, and green= simi-
larly regulated but not in the top 50 genes) (Table 4.2.4). Interestingly, out of 
the top 50 E2-WT up-regulated genes (≥ 2-fold change), E2-Brd4 regulates approxi-
mately 14% of these genes. Comparatively, out of the top 50 E2-WT down-regu-
lated genes (≥ 2-fold change), E2-Brd4 regulates about 50% of these E2-WT genes. 
When this comparison is extended to look at all of the genes regulated ≥ 1.5 
fold, 42% of the up-regulated 16 E2-WT genes are regulated in a similar manner to 
E2-Brd4. The number of down-regulated genes shared between 16 E2-WT and E2-Brd4 
is 92%. In this array we have demonstrated that both E2-WT and E2-Brd4 are down-
regulating the same subset of genes.  
Additionally, IPA analysis was carried out to investigate the pathways regulated 
by the sets of genes found from the analysis of the second array, for both 16E2-WT 
and E2-Brd4 (as described in Methods section 2.2.3.2). Tables 4.2.4 and 4.2.5 
display the top 5 biological functions associated with the top 100 genes regu-
lated by E2-WT and E2-Brd4 respetively. Some similarities between E2-WT and E2-Brd4 
functions are an involvement in cancer, cellular movement, and immune cell 
trafficking. 
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Table 4.2.1 
Gene 
Name Fold-change in array Fold-change clone 1 Fold-change clone 2 
MAGEC1 30.25 541.85 ± 178.85 1964 ± 813.94 
APBA2 2.69 33.59 ± 4.52  42.61 ± 15.92  
ENG 2.63 10.29 ± 4.99 6.58 ± 2.16 
FAR2 2.19 3.02 ± 0.75                  2.6 ± 0.26 
RNF144B -3.05 -4.32 ± 2.38               -6.03 ± 5.02 
TMPRSS15 -9.06 -1463 ± 697 -981.84 ± 481.84 
NFE4 -33.27 -50 ± 8.37 -21.76 ± 2.43 
GTSF1 -219.71 -1735.49 ± 218.59 -174188 ± 87637 
 
Table 4.2.1: Validation of E2-WT regulated genes. The table displays the fold-
change of 8 up and down-regulated genes that were regulated by 16 E2-WT, the 
fold-change corresponds to array 2. Validation was done in two separate clones in 
triplicate, and fold-change was calculated relative to VEC1:1.Standard error is 
shown. Sybr Green qPCR validation is described in Methods section 2.2.1.12. 
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Table 4.2.2 
 
Gene 
Name 
Fold-change in array Fold-change clone 1 Fold-change clone 2 
MAGEC1 35.05 615.05 ± 226.68 1009.61 ± 219.75 
ENG 2.67 13.23 ± 5.64 18.52 ± 5.66 
APBA2 2.28 29.66 ± 2.58 62.10 ± 32.80 
ATP8B1 -2.28 -3111 ± 2627 -2.77 ± 1.13 
TMPRSS15 -7.4 -674.80 ± 325 -19177 ± 6507.25 
ADAMTSL1 -8.82 -5.53 ± 0.67 -7.23  ± 0.86 
GTSF1 -291.81 -5962 ± 3550 -53282 ± 27525 
 
 
Table 4.2.2: Validation of E2-Brd4 regulated genes. The table displays the fold-
change of 7 up and down-regulated genes that were regulated by 16 E2-Brd4, the 
fold-change corresponds to array 2. Validation was done in two separate clones in 
triplicate, and fold-change was calculated relative to VEC1:1. Standard error is 
shown. Sybr Green qPCR validation is described in Methods section 2.2.1.12. 
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Table 4.2.3 
 
Gene 
Name 
Fold-change 
in Array  E2-WT clone 1  E2-WT clone 2 
E2-Brd4 clone 
1 
E2-Brd4 clone 2 
c6orf15 7.11 3.52  ± 2.3 12.16 ± 3.7 0.39 ± 0.1 7.08 ± 5.2 
CLDN4 6.72 28.91 ± 20.2 
1704.06 ± 
1662.6 
0.62 ± 0.1 29.67 ± 28.3 
HOXB2 9.14 63.59 ± 34.0 97.77 ± 56.4 1.48 ± 0.5 97.20 ± 58.2 
LRRC15 6.62 9.00 ± 3.7 5.76 ± 2.1 0.45 ± 0.1 2.77 ± 1.8 
SERPINA1 5.93 4.49 ± 0.3 4.80 ± 0.8 1.36 ± 0.2 1.61 ± 0.3 
SLN 20.23 15.84 ± 1.2 11.41 ± 2.7 0.25 ± 0.02 0.69 ± 0.2 
 
Table 4.2.3: Validation of E2-WT regulated genes. The table displays the fold-
change of 6 up-regulated genes that were regulated by 16 E2-WT exclusively in the 
second array. Validation was done in two separate clones of E2-WT and E2-Brd4. 
Fold-change is calculated relative to vector (no E2 control) and standard error is 
shown. Sybr Green qPCR validation is described in Methods section 2.2.1.12. 
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Figure 4.2.3 
 
 
 
 
 
Figure 4.2.3: Graph of the validation of 16 E2-WT regulated genes. Three genes 
exclusively regulated by E2-WT were successfully validated using SYBR green 
qPCR in two separate clones, in triplicate (as described in Methods section 
2.2.1.12). The fold-change (over vector control (VEC 1:1)) is indicated below the 
graph, standard error can be found in Table 4.2.3 above. The graph clearly shows 
that these genes are E2-WT regulated genes. 
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Table 4.2.4 
 
Up-regulated by E2 Fold-change Down-regulated by E2 Fold-change
HIST1H3H 90.7546 GTSF1 -219.713
HIST1H2BM 46.231 NFE4 -33.2709
MAGEC1 30.2533 BGN -22.9955
SLN 20.2274 KCNIP1 -21.732
HOXB2 9.13427 MIR31 -18.8279
C6orf15 7.1056 MGP -18.0495
FAM198B 7.06128 KRT75 -17.2035
CLDN4 6.71694 FGF5 -14.8293
LRRC15 6.61625 RIMS1 -14.4025
SERPINA1 5.93304 SEMA3A -12.5742
LRRC17 5.67212 SULT1B1 -12.5642
CXCL14 5.30661 ESM1 -12.2765
CDK15 4.91096 IL1RL1 -9.54772
SPTLC3 4.61896 CCL2 -8.46037
IL2RB 4.54159 HHIP -8.32544
LIPH 4.41975 PDCD1LG2 -7.53008
TRIM16 4.35329 CD274 -7.42495
PLAC8 4.3376 MC5R -7.17821
MGST1 4.26395 DCHS2 -7.10103
UNC13D 4.13402 SEMA3E -6.75657
CA12 4.07438 ADAMTSL1 -6.52013
SLC12A8 4.00346 KRTAP4-1 -6.49334
LUM 3.96639 ST6GALNAC3 -6.15485
LIMCH1 3.91481 TMEM154 -6.04587
3.67791 TMPRSS15 -6.0099
LCP1 3.51652 CLDN1 -5.66267
CALHM2 3.42559 MTAP -5.63307
IGFBP5 3.42263 SLITRK6 -5.55367
KCNJ8 3.41959 VLDLR -5.38956
GFPT2 3.38769 RAB38 -5.2863
KLK6 3.33344 LPAR1 -5.20042
PAGE2 3.29191 KIAA1797 -5.17872
GPR56 3.26354 KITLG -4.94164
SPP1 3.22762 KRT34 -4.93765
CDO1 3.20934 FBXL13 -4.75785
PTP4A3 3.20919 FAM180A -4.7544
TNNC1 3.16845 KCNB2 -4.63984
SERPINF1 3.14816 KIAA1432 -4.60797
GPR45 3.12373 EGLN3 -4.43062
KRT86 3.09044 DENND4C -4.40059
RASD2 3.0506 AK3 -4.38385
FAM49A 3.04373 ADAMTS5 -4.27239
AQP1 3.03761 TM4SF18 -4.24862
PDGFRB 3.02402 CYP24A1 -4.20666
B3GNT1 3.00978 DPY19L2P2 -4.20305
MAOA 2.98823 KLHL9 -4.19991
CERCAM 2.98504 LGR5 -4.14646
RASSF5 2.97825 CDC37L1 -4.14413
TGM2 2.95568 PGM5 -4.13192
TTC39A 2.95362 AFAP1 -4.12776
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Table 4.2.4: Similarities in genes regulated by E2-WT and E2-Brd4. Human exon 
array analysis was used to generate lists of genes regulated by HPV16 E2-WT. 
Pawel Herzyk carried out Partek analysis to sort the raw data into lists of genes 
that had a fold-change (F.C) of ≥ 1.5 and a p-value of ≤0.05. The table lists the top 
50 +/- E2-WT regulated genes ≥ 2-fold. Similarities between the top 50 +/- E2-WT 
and E2-Brd4 regulated genes are highlighted in grey. Genes up and down regulated 
by both E2-WT and E2-Brd4 ≥ 2-fold in the top 50 genes are highlighted in green. 
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Table 4.2.5 
Network Associated network functions 
1 Cellular Movement, Cancer, Endocrine System Disorders 
2 Cellular Movement, Immune Cell Trafficking, Hematological System Development and Function 
3 Cell Cycle, Tissue Development, Organ Morphology 
4 Dermatological Diseases and Conditions, Hereditary Disorder, Lipid Metabolism 
5 Cellular Growth and Proliferation, Connective Tissue Disorders, Inflammatory Disease 
 
Table 4.2.5.: Top 5 16E2-WT regulated pathways from Ingenuity Pathway anal-
ysis (array 2). The top 100 E2-WT regulated genes (≥ 2-fold) were subjected to IPA 
and 5 networks of genes were identified. The table lists the predicted functions 
with the IPA generated networks. (Genes associated with this table are shown 
in Supplementary Table S.4 and p-values associated with functions can be 
found in Supplementary Table S.13). 
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Table 4.2.6 
Network Associated network functions 
1 Gene Expression, Protein Synthesis, Digestive System Development and Function 
2 Cancer, Cellular Movement, Cellular Development 
3 Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking 
4 Amino Acid Metabolism, Molecular Transport, Small Molecule Biochemistry 
5 Dermatological Diseases and Conditions, Drug Metabolism, Lipid Metabolism 
 
Table 4.2.6.: Top 5 16E2-Brd4 regulated pathways from Ingenuity Pathway 
analysis (array 2). The top 100 E2-Brd4 regulated genes (≥ 2-fold) were subjected 
to IPA and 5 networks of genes were identified. The table lists the predicted func-
tions with the IPA generated networks. (Genes associated with this table are 
shown in Supplementary Table S.6 and p-values associated with functions 
can be found in Supplementary Table S.13). 
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4.2.7 Regulation of cell motility by E2-Brd4 
As previously described in Chapter 4.1.4, E2-WT regulates cellular movement. We 
decided to test the role of Brd4 in E2 regulated cellular movement by carrying 
out would healing assays (as previously seen in Figure 4.1.2). The E2-Brd4 mutant 
expressing cells was slower than non-E2 expressing cells and faster than E2-WT at 
wound closing. The wound is more visible at the 12 hour time point and after 24 
hours the cells covering the wound are less dense than the non-E2 cell condition. 
As demonstrated before, the E2-WT expressing cells fail to fully heal the wound 
after 24 hours (Figure 4.2.3). This difference in movement is not due to differ-
ences in cell growth (Figure 4.2.2b). This suggests a partial phenotype therefore 
the interaction between E2 and Brd4 is required, in part, for the regulation of all 
movement. 
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Figure 4.2.4 
 
 
 
 
 
 
Figure 4.2.4: Wound healing and cell movement of HPV16 E2-Brd4. 5x104 cells 
were seeded into cell chambers and grown for 24 hours. 24 hours after seeding 
the chambers were removed and movement of E2 expressing cells vs non E2-ex-
pressing cells was monitored by microscopy and images were collected at 0, 16 
and 24 hour time points (as described in Methods section 2.2.2.4). Both No E2 
and E2-Brd4 clones have closed the gap by the 24 hour time point. E2-Brd4 is 
slightly slower at closing the wound however, and you can see that the cells cover-
ing the wound are less dense than in the non-E2 cell condition. 
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 The role of TopBP1 in E2 regulation of host genes 
Due to the novel finding that Brd4 is not required for E2’s down-regulation of 
host genes, we wanted to ask how TopBP1 is involved in HPV16 E2 regulation of 
the host genome. 
4.3.1 E2-TopBp1 is compromised in activating transcription in U20S 
cells 
As demonstrated previously for E2-Brd4 (Figure 4.2.1), the ability of the E2-TopBP1 
mutant to activate transcription in U20S cells was tested. The ability of E2-TopBP1 
to activate transcription compared to E2-WT is compromised (Figure 4.3.1). At 
10ng of E2-TopBP1 input DNA transcription is approximately 11% of E2-WT. This in-
creases to 22% with 1000ng of DNA input. These results in U20S cells mirror those 
previously seen in 293T and C33a cells in Chapter 3. 
4.3.2 Generation of U20S cells expressing 16 E2-TopBP1 
Cells that stably express E2-TopBP1 were generated in U20S cells for use in human 
exon array analysis (as described in Methods section 2.2.2.2). Expression of po-
tential clones was tested using western blot analysis as seen in Figure 4.3.2a. 
The growth of these cells was also monitored by conducting a growth curve, 
which showed that the cells containing the E2-TopBP1 mutation grew slower than 
E2-WT or no E2 cells (Figure 4.3.2b).  
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Figure 4.3.1 
 
Figure 4.3.1: 16 E2-TopBP1 Transcription activation in U20S cells. Transcription 
assays were carried out in U20S cells with input levels of 10ng, 100ng and 
1000ng, along with an E2 reporter containing 6E2 DNA binding sites upstream 
from a tk promoter driving luciferase (Vance, Campo et al. 1999). Cells were har-
vested and luciferase and protein assays carried out (as described in Methods 
section 2.2.1.5 and 2.2.1.13). The results are normalised to protein levels in each 
sample and are represented as fold increase over ptk6E2 levels in the absence of 
E2. The results are representative of three independent experiments done in dupli-
cate. Bars represent standard error. Fold activation in transcription over that ob-
tained when no E2 was co-expressed is shown in the table below. 
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Figure 4.3.2 
 
Figure 4.3.2: Generating and characterising stably expressing E2-TopBP1 
clones. 
a) Potential E2-TopBP1 expressing clones were screened by making lysates for 
western blot analysis (as described in Methods section 2.2.1.11). Actin control is 
shown for equal loading. 
b) 4x105 cells were seeded and counted every 3 days, growth curves were gener-
ated from the numbers of cells from each count (as described in Methods section 
2.2.2.3). The growth curve displays no difference in the growth rate between the 
E2 and non-E2 expressing clones, but E2-TopBP1 grows slightly slower. This was 
done in two individual clones. Only one clone is graphed as the growth of the two 
clones was similar. 
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4.3.3 Identifying differentially expressed host genes induced by 
E2-TopBP1 
Human exon array analysis in the U20S model was carried out as previously de-
scribed, to compare E2-WT and E2-TopBP1 regulation of host genes. This was the 
first set of microarray analysis that we set out to do in the U20S model (“array 
1”). It should be noted the results for E2-Brd4 were done in a separate human 
exon array experiment (“array 2”). As the number of genes regulated ≥ 2-fold by 
E2-WT was smaller in array 1 it was decided to look at all of the genes regulated 
by E2-WT ≥ 1.5-fold. 16 E2-WT regulates 267 genes ≥ 1.5-fold, out of the 267 genes, 
130 are up-regulated and 137 are down-regulated by E2-WT. Comparatively, the 
E2-TopBP1 mutant regulates 1380 genes ≥ 1.5-fold, 683 are up-regulated and 697 
are down-regulated. As described before for E2-Brd4 mutant, E2-TopBP1 regulates a 
large subset of genes. (Supplementary Table S.7 displays full list of genes reg-
ulated by 16 E2-TopBP1 ≥ 1.5-fold). 
4.3.4 Validation of E2-WT and E2-TopBP1 genes 
Fifteen genes were chosen for validating the array, 10 down-regulated genes and 
5 up-regulated genes. The 15 genes fall into three distinct groups; genes regu-
lated by E2-WT only (validation in Table 4.1.2), genes regulated by both E2-WT and 
E2-TopBP1 (validation of E2-WT Table 4.1.2), and genes regulated only by E2-TopBP1. 
Using SYBR green qPCR to validate genes with a fold-change ≥ 2, and a p-value 
≤0.05, the validation agreed with the initial array analysis, genes that were up 
or down-regulated followed the same trend (Table 4.3.1). 5 out of 5 of the up-
regulated genes (up-regulated by both E2-WT and E2-TopBP1) validated in the E2-
TopBP1 expressing cells. 4 out of 5 of the down-regulated E2-TopBP1genes validated 
successfully, confirming our array results. 
4.3.5 Similarities in genes regulated by E2-WT and E2-TopBP1 
As Brd4 was shown to not be involved in the down-regulation of many genes that 
E2 regulates, the role of TopBP1 in E2’s regulation of host genes was also investi-
gated. Table 4.3.2 displays the top 50 +/- regulated genes by E2-WT, and addi-
tionally highlights the genes that are regulated in a similar way by both E2-WT 
and E2-TopBP1. In the top 50 E2-WT up-regulated genes, 18% of these were similarly 
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regulated by E2-TopBP1. In the top 50 E2-WT down-regulated genes 16% were simi-
larly regulated by E2-TopBP1. The number of genes regulated in a similar manner 
increased to 64% for up-regulated, and 46% for down-regulated E2-WT genes when 
genes not in the top 50 were also included.  
Additionally, IPA analysis was carried out to investigate the pathways regulated 
by the sets of genes found from the analysis of the second array, for both 16E2-WT 
and E2-TopBP1. Tables 4.2.4 and 4.3.3 display the top 5 biological functions associ-
ated with the top 100 genes regulated by E2-WT and E2-TopBP1 respetively. The only 
similarity in the top 5 associated network functions of E2-WT and E2-TopBP1 regu-
lated genes is cancer. The regulation of the host genome is altered when E2 can-
not bind to TopBP1. 
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Table 4.3.1 
Gene 
Name 
Fold-change in Ar-
ray 
Fold-change clone 
1 
Fold-change clone 
2 
MAGEC1 59.28 344.32 ± 308.96 528.93 ± 522.29 
ENG 7.22 16.42 ± 9.31 29.9 ± 11.79 
FAR2 6.07 6.43 ± 2.53 2.79 ± 1.28 
APBA2 5.25 29.69 ± 16.37 35.7 ± 33.27 
SH3PXD2B 2.33 2.08 ± 0.29 7.93 ± 4.43 
ADAMTSL1 -2.83 -133.70 ± 90.51 -32.38 ± 18.49 
COL6A3 -8.7 1.55 ± 0.76 2.03  ± 0.74 
MFAP5 -13.21 -16.37 ± 1.16 -81.42 ± 18.49 
ATP8B1 -14.43 -65.87 ± 57.71 -547.79 ± 540.70 
DHRS2 -27.01 -26.99 ± 6.77 -275.74 ± 140.47 
 
Table 4.3.1: Validation of genes regulated by HPV16 E2-TopBP1. Table displays 5 
up-regulated and 5 down-regulated genes fold-change in the microarray analysis. 
5 genes are up-regulated by both E2-WT and E2-TopBP1 and 5 are down-regulated 
exclusively by E2-TopBP1. Genes are validated in two E2-TopBP1 expressing clones in 
triplicate, standard error shown. Sybr Green qPCR validation is described in Meth-
ods section 2.2.1.12. 
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Table 4.3.2 
 
Up-regulated by E2 Fold-change Down-regulated by E2 Fold-change
HIST1H2BM 71.9508 GTSF1 -302.705
HIST1H3H 70.7304 NFE4 -24.794
MAGEC1 40.1869 TMPRSS15 -11.624
SLN 14.5889 SLC14A1 -5.94492
HOXB2 10.631 C1orf85 -4.48436
TNFAIP6 4.86318 CD33 -4.1363
ENG 4.85397 CLIC2 -3.9316
GNG11 4.11702 FBXL13 -3.60857
FAR2 3.70124 PTGFR -3.59376
ZNF788 3.3983 CSTA -3.49077
APBA2 2.99782 NLRP5 -3.33859
SERPINA3 2.74046 DNAJC18 -3.31614
C10orf72 2.5905 BMPER -3.27652
GFPT2 2.53867 HBE1 -3.07671
SH3PXD2B 2.50361 RNF144B -3.04874
FAP 2.47498 GDF15 -2.98979
LRRCC1 2.36516 LOC79015 -2.97446
ARHGDIB 2.35827 HSD17B8 -2.75366
SNTB1 2.25035 HIST1H3E -2.69962
EML1 2.23335 MLH3 -2.64666
ARHGAP11A 2.23306 NLRP4 -2.60899
CCDC99 2.16172 TRIML2 -2.55713
FGD4 2.1616 CD68 -2.47599
ZNF271 2.15217 ACYP1 -2.43839
MTMR10 2.11787 PSG9 -2.41357
CALHM2 2.11199 HLA-DPA1 -2.38118
HNMT 2.09265 GNGT2 -2.37174
GOLGA8B 2.08224 FST -2.35479
AQR 2.05191 GCNT2 -2.3148
NFIA 2.02545 GRAMD3 -2.29601
ZNF770 2.02363 PGAP2 -2.20441
ZADH2 2.01373 RPL23 -2.20367
RTKN2 2.00087 IL1RAPL1 -2.18097
CLEC2B 1.98705 OR10A3 -2.14773
RAB27B 1.97895 GPR65 -2.14222
MYO5B 1.97609 AURKC -2.13613
TMEM55A 1.96272 ZNF300P1 -2.10876
IMPACT 1.92209 ME3 -2.06315
ZNF738 1.90705 ADRB2 -2.05351
TRPS1 1.88341 PSG4 -2.04519
TTC39C 1.87129 ZFP90 -2.02583
ATPBD4 1.86744 DPYSL4 -1.9764
FAN1 1.86327 TOX -1.96981
B4GALNT3 1.85095 LTBP2 -1.96341
STK38L 1.83674 IL6 -1.95904
ZNF365 1.82942 CARS -1.90807
CASC5 1.81003 EIF2B2 -1.89313
FAM60A 1.79363 AOC2 -1.88615
C8orf40 1.79137 MDGA2 -1.88515
NUP210 1.78893 WNT2B -1.87542
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Table 4.3.2: Similarities in genes regulated by E2-WT and E2-TopBP1. Human 
exon array analysis was used to generate lists of genes regulated by HPV16 E2-WT 
and E2-TopBP1. Pawel Herzyk carried out Partek analysis to sort the raw data into 
lists of genes that had a fold-change (F.C) of ≥ 1.5 and a p-value of ≤0.05. The ta-
ble lists the top 50 +/- E2-WT regulated genes ≥ 1.5-fold. Similarities between the 
top 50 +/- E2-WT and E2-TopBP1 regulated genes are highlighted in grey. Genes reg-
ulated in a similar way not in the top 50 genes are highlighted in green.  
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Table 4.3.3 
Network Associated network functions 
1 Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral Metabolism 
2 Cancer, Tumour Morphology, Hereditary Disorder 
3 Inflammatory Disease, Inflammatory Response, Respiratory Disease 
4 Cellular Development, Cellular Growth and Proliferation, Hematological System Development and Function 
5 Cardiovascular Disease, Connective Tissue Disorders, Developmental Disorder 
 
Table 4.3.3.: Top 5 16E2-TopBP1 regulated pathways from Ingenuity Pathway 
analysis (array 2). The top 100 E2-TopBP1 regulated genes (≥ 2-fold) were sub-
jected to IPA and 5 networks of genes were identified. The table lists the predicted 
functions with the IPA generated networks. (Genes associated with this table 
are shown in Supplementary Table S.8 and p-values associated with func-
tions can be found in Supplementary Table S.13). 
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4.3.6 Regulation of cell motility by E2-TopBP1 
As E2-WT was shown to be involved in cellular movement, it was decided to see if 
TopBP1 plays a role in this by testing the E2-TopBP1 mutant in wound healing as-
says. Wound healing assays demonstrate that E2-TopBP1 is defective in cellular 
movement in a similar manner to E2-WT (Figure 4.3.3). This would suggest that 
TopBP1 is not required for E2 regulation of cellular movement.  
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Figure 4.3.3 
 
Figure 4.3.3: Wound healing and cell movement of HPV16 E2-TopBP1. 5x104 
cells were seeded into cell chambers and grown for 24 hours. 24 hours after seed-
ing the chambers were removed and movement of E2 expressing cells vs non E2-
expressing cells was monitored by microscopy and images were collected at 0, 16 
and 24 hour time points (as described in Methods section 2.2.2.4). Both E2-WT 
and E2-TopBP1 clones clearly show a defect in movement and their ability to close 
the gap in the 24 hour time period. 
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4.4 Wildtype 18E2 regulates host genes 
As this analysis focused only on HPV16 E2 regulation of the host genome we de-
cided to extend our studies to investigate how HPV18 E2 regulates host gene ex-
pression. As discussed in Chapter 1, HPV16 and 18 are the two most common 
high-risk HPV types, although HPV18 demonstrates a more severe outcome in 
cervical cancer than HPV16, adenocarcinoma versus squamous cell carcinoma. 
Perhaps there are key changes in virus-host gene regulation contributing to this 
phenotype.  
The comparison between 16 E2-WT and 18 E2-WT was carried out in the second hu-
man exon array, “array 2”. 16 E2-WT regulates 879 genes ≥1.5-fold, 407 up-regu-
lated genes and 472 down-regulated genes. 18 E2-WT regulates 745 genes ≥ 1.5-
fold, 469 up-regulated and 276 down-regulated.  An overlap of 362 genes were 
regulated in the same direction in both HPV16 and 18, showing E2 of these two 
high-risk types must regulate a subset of the same host genes. (Supplementary 
Table S.9 displays full list of genes regulated by 18 E2 wildtype ≥ 1.5-fold). 
7 up and down-regulated genes were validated in two separate clones for 18E2-
WT in triplicate. All 7 genes validated in both clones (Table 4.4.2). Validation of 
16 E2-WT genes can be found in Table 4.2.1.  
Similarities between the top 50 up and down-regulated genes in 16 E2-WT and 18 
E2-WT are set out in Table 4.4.3. 16 and 18 E2-WT share a large overlap in the 
genes they down-regulate in the host genome. 88% of the top 50 16 E2-WT down-
regulated genes are similarly down-regulated by 18 E2-WT. Also, 60% of the top 50 
16 E2-WT up-regulated genes are also similarly regulated in 18 E2-WT.  
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Table 4.4.1 
Gene 
Name 
Fold-change in  
array 
Fold-change clone 
1 
Fold-change clone 
2 
MAGEC1 35.05 442.6 ± 122.44 1927 ± 671.13 
ENG 2.67 8.7 ± 4.61 16 ± 6.37 
APBA2 2.28 15.2 ± 1.82 60.4 ± 31.48 
ATP8B1 -2.28 -2.8 ± 0.58 -2.9 ± 0.38 
ADAMTSL1 -4.93 -5.6 ± 0.67 -9.4 ± 1.18 
TMPRSS15 -7.4 -2317 ± 1148 -400 ± 100 
GTSF1 -291.81 -3174 ± 3174 -62421 ± 62421 
 
Table 4.4.1: Validation of genes regulated by HPV18 E2-WT. Table displays the 
fold-change of 3 up-regulated and 4 down-regulated genes in the microarray anal-
ysis. Genes are validated in two clones in triplicate, standard error shown. Sybr 
Green qPCR validation is described in Methods section 2.2.1.12. 
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Table 4.4.2 
Net-
work 
Associated network functions 
1 Cellular Movement, Cancer, Organ Morphology 
2 Cell Cycle, Cellular Development, Embryonic Development 
3 Cellular Development, Cellular Growth and Proliferation, Hair and Skin Development and Function 
4 Cell-to-cell Signaling and Interaction, Hematological System Development and Function, Immune Cell Traffick-
ing 
5 Neurological Disease, Cell Signaling, Embryonic Development 
 
Table 4.4.2.: Top 5 18E2-WT regulated pathways from Ingenuity Pathway anal-
ysis (array 2). The top 100 18E2-WT regulated genes (≥ 2-fold) were subjected to 
IPA and 5 networks of genes were identified. The table lists the predicted functions 
with the IPA generated networks. (Genes associated with this table are shown 
in Supplementary Table S.10 and p-values associated with functions can be 
found in Supplementary Table S.13). 
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Table 4.4.3 
 
Up-regulated by E2 Fold-change Down-regulated by E2 Fold-change
HIST1H3H 90.7546 GTSF1 -219.713
HIST1H2BM 46.231 NFE4 -33.2709
MAGEC1 30.2533 BGN -22.9955
SLN 20.2274 KCNIP1 -21.732
HOXB2 9.13427 MIR31 -18.8279
C6orf15 7.1056 MGP -18.0495
FAM198B 7.06128 KRT75 -17.2035
CLDN4 6.71694 FGF5 -14.8293
LRRC15 6.61625 RIMS1 -14.4025
SERPINA1 5.93304 SEMA3A -12.5742
LRRC17 5.67212 SULT1B1 -12.5642
CXCL14 5.30661 ESM1 -12.2765
CDK15 4.91096 IL1RL1 -9.54772
SPTLC3 4.61896 CCL2 -8.46037
IL2RB 4.54159 HHIP -8.32544
LIPH 4.41975 PDCD1LG2 -7.53008
TRIM16 4.35329 CD274 -7.42495
PLAC8 4.3376 MC5R -7.17821
MGST1 4.26395 DCHS2 -7.10103
UNC13D 4.13402 SEMA3E -6.75657
CA12 4.07438 ADAMTSL1 -6.52013
SLC12A8 4.00346 KRTAP4-12 -6.49334
LUM 3.96639 ST6GALNAC3 -6.15485
LIMCH1 3.91481 TMEM154 -6.04587
3.67791 TMPRSS15 -6.0099
LCP1 3.51652 CLDN1 -5.66267
CALHM2 3.42559 MTAP -5.63307
IGFBP5 3.42263 SLITRK6 -5.55367
KCNJ8 3.41959 VLDLR -5.38956
GFPT2 3.38769 RAB38 -5.2863
KLK6 3.33344 LPAR1 -5.20042
PAGE2 3.29191 KIAA1797 -5.17872
GPR56 3.26354 KITLG -4.94164
SPP1 3.22762 KRT34 -4.93765
CDO1 3.20934 FBXL13 -4.75785
PTP4A3 3.20919 FAM180A -4.7544
TNNC1 3.16845 KCNB2 -4.63984
SERPINF1 3.14816 KIAA1432 -4.60797
GPR45 3.12373 EGLN3 -4.43062
KRT86 3.09044 DENND4C -4.40059
RASD2 3.0506 AK3 -4.38385
FAM49A 3.04373 ADAMTS5 -4.27239
AQP1 3.03761 TM4SF18 -4.24862
PDGFRB 3.02402 CYP24A1 -4.20666
B3GNT1 3.00978 DPY19L2P2 -4.20305
MAOA 2.98823 KLHL9 -4.19991
CERCAM 2.98504 LGR5 -4.14646
RASSF5 2.97825 CDC37L1 -4.14413
TGM2 2.95568 PGM5 -4.13192
TTC39A 2.95362 AFAP1 -4.12776
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Table 4.4.3: Similarities in genes regulated by 16 E2-WT and 18 E2-WT. Human 
exon array analysis was used to generate lists of genes regulated by HPV18 E2-
WT. Pawel Herzyk carried out Partek analysis to sort the raw data into lists of genes 
that had a fold-change (F.C) of ≥ 1.5 and a p-value of ≤0.05. Numbers of genes up 
and down-regulated by each are shown. The table lists the top 50 +/- 16 E2-WT 
regulated genes ≥ 2-fold. Genes similarly up or down-regulated by 18 E2-WT are 
highlighted in grey if they are in the top 50 16 E2-WT genes table. Genes regulated 
by 18 E2-WT in a similar way which are not in the top 50 16 E2-WT genes are high-
lighted green. 
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Results demonstrate that 18E2 can regulate cellular genes and that there are 
overlapping, but also distinct, gene sets regulated by 16 and 18 E2. To investi-
gate the similarities and differences between 16 and 18, Ingenuity Pathway Anal-
ysis (IPA) was used to analyse gene data sets (fold-change of ≥ 1.5) highlighted 
by microarray analysis (Tables 4.2.4 and 4.4.2) (as described in Methods sec-
tion 2.2.3.2). Cell movement and cancer both came up as the number one bio-
logical functions in IPA anaylsis for HPV16 E2 and HPV18 E2. Additionally, both 16 
and 18E2 are involved in pathways regulating the cell cycle, immune cell traf-
ficking and cellular growth and proliferation. These functions may be essential 
for successful HPV infection. Yet, there are also distinct differences between the 
two high-risk types. (Supplementary file S.10 lists genes associated with 
HPV18 E2 functions). 
4.5 Wildtype 16E2 regulates host gene expression in epi-
thelial cells 
The study was then extended into human keratinocytes (NTERT cells) as they of-
fer a mechanism to study a more realistic disease profile, as we want to identify 
changes with therapeutic relevance. NTERT are epithelial cells immortalised by 
telomerase (not transformed). NTERT cells were infected with E2 retroviruses as 
described in the following paper (White, Sowa et al. 2012). 
In NTERT cells 16E2 regulates 115 genes, 48 are up-regulated ≥1.5 fold and 67 
are down-regulated ≥1.5 fold (Table 4.5.1). (Supplementary Table S.11 dis-
plays full list of genes regulated by 16 E2 wildtype ≥ 1.5-fold in NTERT cells). 
8 genes were selected for further validation of the array, 4 of which successfully 
validated (Table 4.5.2). This is most likely due to the low fold-changes gained 
from the human exon array. 
Using Ingenuity Pathway Analysis (as described in Methods section 2.2.3.2), 
networks involved in infection, inflammation and cancer were all identified in 
the keratinocyte cells (Table 4.5.3). 24 of the down regulated genes are known 
interferon stimulated genes (ISG). (IFIH1, IFI35, DDX58, OAS2, CD14, IFITM1, 
IFIT3, OAS1, IL8, MX1, IFIT1, IFI44L, IFI27, IFNK, EGR1, KCNMA1, PTGS1, 
SERPING1, RSAD2, OAS3, DUSP10, DSC1, CLU and ZFP36). 
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Therefore, E2 potentially interferes with the host innate immune response to 
promote survival of the infected cell. 14 interferon genes were selected for fur-
ther validation using qPCR. 10 out of the 14 genes validated when qPCR analysis 
was carried out in triplicate for these genes (Table 4.5.4).  
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Table 4.5.1 
 
Up-regulated by 16E2 Fold-change Down-regulated by 16E2 Fold-change
HAS2 2.5879 CLCA4 -3.78519
NR1D2 2.54635 RSAD2 -3.73351
SULT1E1 2.47792 IFNK -3.56724
CXCL14 2.35527 IFI27 -2.94607
TNFSF4 2.16465 IFI44L -2.84101
PAPSS2 2.05552 IFIT1 -2.68203
GLIPR1 2.03416 MX2 -2.61854
ANO1 1.92593 MX1 -2.43196
TREM2 1.90045 ANPEP -2.37873
NEFL 1.89273 TXNIP -2.28848
RPL35A 1.86539 PBX1 -2.18485
ITGA4 1.84288 CYP1A1 -2.1258
IGFL1 1.80728 SEMA6D -2.12395
ANGPTL4 1.7995 IL8 -2.08927
BICC1 1.78966 OAS1 -2.0712
SLC1A4 1.77383 IFIT3 -2.06189
FHL1 1.76745 GPR1 -2.03442
IL7R 1.7665 USP18 -2.02222
PHGDH 1.74329 EPHA4 -2.01517
IRAK2 1.73158 HIST1H3F -1.98992
MMP1 1.72778 HCP5 -1.93073
SPRR2A 1.72519 ABI3BP -1.92131
MCOLN3 1.71764 IGFL3 -1.90776
DYNC1I2 1.69744 IFITM1 -1.88955
COL12A1 1.69613 CYP3A5 -1.84336
NR1D1 1.68872 TIMP2 -1.83115
SLC10A6 1.68781 FDXACB1 -1.8294
SCG5 1.65218 DDX60 -1.79865
RFTN1 1.65047 ORAI3 -1.78824
SACS 1.64492 NRCAM -1.78006
DDAH1 1.62976 APCDD1 -1.76576
PLA2G7 1.62757 CD14 -1.76431
IL1F9 1.62607 EPHB3 -1.75591
RAB3B 1.62468 OAS2 -1.75209
SLC9A7 1.61464 DSC1 -1.71474
PI3 1.59609 PARP9 -1.70928
ANXA6 1.5744 EGR1 -1.69221
CLDN7 1.57251 DLX3 -1.69023
ADAMTS6 1.57225 KCNMA1 -1.68519
NUAK1 1.56993 OAS3 -1.66597
CACHD1 1.55891 SLC47A2 -1.64974
SERPINB1 1.5581 DDX58 -1.6428
GSTM3 1.5552 DUSP10 -1.63187
MICALCL 1.54376 ARNTL -1.62456
IL24 1.53432 ZNF323 -1.62158
MCOLN2 1.53374 PART1 -1.62011
ZC3HAV1L 1.51812 GCET2 -1.60773
FLI1 1.51029 IFI35 -1.60568
RPS10P7 -1.59981
ECM1 -1.59722
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Table 4.5.1 16E2 NTERT array gene regulation. Human exon array analysis was 
used to generate lists of genes regulated by HPV16 E2 in epithelial cells. Pawel 
Herzyk carried out Partek analysis to sort the raw data into lists of genes that had 
a fold-change (F.C) of ≥ 1.5 and a p-value of ≤0.05. Numbers of genes up and 
down-regulated by each are shown. 
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Table 4.5.2 
 
Gene 
Name 
Fold-change in ar-
ray 
Fold-change valida-
tion 
NR1D2 2.54 3.82 ± 0.15 
ANO1 1.92 -4.48 ± 0.34 
IGFL1 1.8 2.26 ± 0.12 
SPRR2A 1.72 -1.43 ± 0.02 
EPHA4 -2.01 2.75 ± 0.25 
SEMA6D -2.12 40.86 ± 1.84 
PBX1 -2.18 -2.48 ± 0.28 
TXNIP -2.28 -10.84 ± 0.71 
 
 
Table 4.5.2: Validation of genes regulated by HPV16 E2 in epithelial cells. 
The table displays the fold-change of 4 up and 4 down-regulated genes that were 
regulated by 16 E2-WT in the human exon array.  Validation was done in triplicate, 
and fold-change calculated relative to POZN vector control.  Standard error is 
shown. Sybr Green qPCR validation is described in Methods section 2.2.1.12. 
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Table 4.5.3 
 
Network Associated network functions 
1 Dermatological Diseases and Conditions, Antimicrobial Response, Inflammatory Response 
2 Organismal Injury and Abnormalities, Respiratory Disease, Cellular Growth and Proliferation 
3 Cancer, Cellular Development, Cellular Growth and Proliferation 
4 Cellular Movement, Embryonic Development, Organ Morphology 
5 Gene Expression, Cardiovascular System Development and Function, Organismal Development 
 
Table 4.5.3: Top 5 16E2 NTERT regulated pathways from Ingenuity Pathway 
analysis. The 115 E2-WT regulated genes (≥ 1.5-fold) were subjected to IPA and 5 
networks of genes were identified. The table lists the predicted functions with the 
IPA generated networks. (Genes associated with this table are shown in Sup-
plementary Table S.12 and p-values associated with functions can be found 
in Supplementary Table S.13). 
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Table 4.5.4 
Gene 
Name 
Fold-change in ar-
ray 
Fold-change valida-
tion 
IFIH1 -1.57941 -1.6 ± 0.05 
IFI35 -1.60568 -2.11 ± 0.15 
DDX58 -1.6428 -4.98 ± 0.41 
OAS2 -1.75209 -8.58 ± 0.67 
CD14 -1.76431 83.22 ± 6.28 
IFITM1 -1.88955 -2.01 ± 0.2 
IFIT3 -2.06189 -15.62 ± 1.14 
OAS1 -2.0712 -4.58 ± 0.41 
IL8 -2.08927 -1.49 ± 0.09 
MX1 -2.43196 -18.72 ± 2.25 
IFIT1 -2.68203 -8.61 ± 0.81 
IFI44L -2.84101 -2.28 ± 0.13 
IFI27 -2.94607 1.31 ± 0.14 
IFNK -3.56724 -2.01 ± 0.2 
 
 
Table 4.5.4: Validation of interferon genes regulated by HPV16 E2 in epithe-
lial cells. The table displays the fold-change of 14 interferon genes that were reg-
ulated by 16 E2-WT in the human exon array.  Validation was done in triplicate, and 
fold-change calculated relative to POZN vector. Standard error is shown. Sybr 
Green qPCR validation is described in Methods section 2.2.1.2. 
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4.6 Summary and discussion 
As well as trying to gain a better understanding how the viral protein E2, and E2 
mutants, regulates the HPV genome for the continuation of the viral life cycle, 
the question of how E2 regulates the host genome was addressed. Previous stud-
ies of how E2 regulates the host genome to aid progression of the viral life cycle 
have focused on determining the effects of E2 on specific promoters and biologi-
cal processes. There is a gap in our understanding of how E2 regulates cellular 
processes on a global scale. Additionally, these studies have used cell types that 
do not tolerate E2 expression well, which in turn will be reflected in any results 
gained. Due to the toxicity of E2 in most cell types, previous microarray studies 
have relied on over expression of E2, usually through delivering the E2 protein 
via viruses or plasmid over expression to investigate the regulation of cellular 
genes (Vosa, Sudakov et al. 2012, Ramirez-Salazar, Centeno et al. 2011). These 
studies have been carried out transiently as the cells are destined for growth in-
hibition or cell death, and this method of E2 protein delivery adds additional 
toxicity to the cell. Therefore, the U20S model offers the first study of host gene 
regulation by physiologically tolerated levels of E2 proteins; therefore, the tar-
get genes identified are not related to E2 induced apoptosis or growth arrest. 
Our model system has also allowed us to answer questions about how E2 regu-
lates the host genome in conjunction with TopBP1 and Brd4. 
E2 is essential for viral genome replication and maintenance and needs to carry 
out this function without causing any damage to the host.  E2 binds to 12bp DNA 
motifs (ACCGN4CGGT) or E2 binding sites (E2BS) within the virus genome. In 
HPV16 there are four specific E2 binding sites within the long control region 
(LCR), to which E2 binds as a dimer (Androphy, Lowy et al. 1987). This interac-
tion is essential for the transcriptional regulation of HPV. E2 is responsible for 
the transactivation of the early PV promoter through interactions with transcrip-
tion regulatory factors such as CBP, p/CAF,BRCA1, Brm and Brd4 (Schweiger, You 
et al. 2006, Lee, Hwang et al. 2002, Lee, Lee et al. 2000, McPhillips, Oliveira et 
al. 2006, Kim, Lee et al. 2003, Kumar, Naidu et al. 2007).E2 is also known to re-
press viral transcription by blocking transcription factor binding to the early pro-
moter and recruiting chromatin modifying factors (Tan, Leong et al. 1994, 
Schweiger, Ottinger et al. 2007, Wu, Lee et al. 2006a, Smith, White et al. 2010). 
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As previously mentioned, there have been various studies of E2’s interaction 
with the host genome. A study by Vosa et al looked at the location and function 
of these E2BS within the host genome, using both computational methods and 
ChIP. They show that there are over 3,300 E2BSs in the human reference genome 
and E2 binds to E2BS within active chromatin regions. Interestingly, they made a 
link between E2 binding to sequence specific DNA and an interaction between 
Brd4, are both thought to be important for E2 binding to consensus sites (Vosa, 
Sudakov et al. 2012). 
Jang et al show that in C33a cells both E2 and Brd4 are located at transcription-
ally active promoters. However, binding of E2 did not correlate to the E2 con-
sensus binding sites within these promoters. The interaction of E2 at active nu-
clear regions enables the virus to evade transcriptional silencing (Jang, Shen et 
al. 2014). So these E2 binding sites are not an indicator of where E2 will bind to 
in the host genome. 
Another study in C33a cells shows that E2 regulates cellular gene expression in-
dependently of the other viral genes, using a recombinant adenoviral vector to 
overexpress HPV16 E2. They suggest that the cellular processes that E2 regulates 
in this microarray experiment would indicate that E2 expression allows for a con-
venient environment for the replication of HPV (Ramirez-Salazar, Centeno et al. 
2011). There is no overlap in their set of up and down regulated genes in C33a 
cells with our U20S data set. This may be due to cell type differences or their 
method for expressing E2 in these cells.  
It was originally thought that the regulation of cellular genes when E2 protein is 
expressed in cervical carcinoma derived cells may be due to the repression of 
the expression of the two viral oncogenes, E6 and E7 (Hamid, Brown et al. 2009, 
Gammoh, Isaacson et al. 2009) (Lagunas-Martinez, Madrid-Marina et al. 
2010)(Thierry 2009). However, the work of Vosa (Vosa, Sudakov et al. 2012), 
Ramirez (Ramirez-Salazar, Centeno et al. 2011) and the work described in this 
thesis all show that E2 induces changes in the expression of cellular genes, inde-
pendently of the regulation of E6 and E7. 
E2-WT results from “array 2”, 881 genes are regulated by E2-WT ≥1.5 fold, 408 
were up-regulated and 473 were down-regulated. E2 is known to suppress the 
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activity of papillomavirus promoters by binding to low affinity binding sites, 
leading to the displacement of cellular proteins (Tan, Leong et al. 1994, Oldak, 
Smola et al. 2004, Stubenrauch, Leigh et al. 1996, Tan, Gloss et al. 1992). 
It is reasonable to propose that protein-protein interactions could be more sig-
nificant for E2 mediated transcriptional regulation of cellular genes. E2 proteins 
from several papillomavirus types interact with a variety of cellular regulatory 
transcription factors, including Sp1, C/EBP, CBP/p300 and p53 (Steger, Schnabel 
et al. 2002, Hadaschik, Hinterkeuser et al. 2003, Massimi, Pim et al. 1999, 
Kruppel, Muller-Schiffmann et al. 2008, Wang, Naidu et al. 2009). E2 is also 
known to interact with Brd4 and TopBP1, which previous studies and the work 
presented in this thesis shows that they are vital for viral transcription and repli-
cation. Brd4 is an important transcriptional co-factor for E2 transcription activa-
tion (Wu, Lee et al. 2006a, Schweiger, You et al. 2006, McPhillips, Oliveira et al. 
2006). Brd4 is a BET family member that binds to acetylated histones with two 
conserved bromodomains and remains associated with chromosomes during mito-
sis (Dey, Chitsaz et al. 2003). The transactivation domain of most PV E2 proteins 
interact with the CTD of BRD4 protein (McPhillips, Oliveira et al. 2006). It still 
remains unclear whether HPV16 E2 binds to Brd4 on mitotic chromosomes. Brd4 
binding can increase E2 protein stability and may play a role in viral replication, 
(my results in Chapter 3 confirm this role) (Gagnon, Joubert et al. 2009).  
TopBP1 has been shown to interact in vitro and in vivo with E2 and can regulate 
the ability of E2 to control transcription and replication (Boner, Taylor et al. 
2002). TopBP1 has been proposed to play a role as a transcriptional regulator. If 
TopBP1 is overexpressed it co-activates transcription with the HPV16 E2 protein 
when E2 is bound to target promoters (Boner, Taylor et al. 2002). TopBP1 has 
also been implicated as being a transcriptional repressor; as TopBP1 can interact 
with the chromatin modification complex proteins Brg1 and repress transcrip-
tional and apoptotic function of E2F1 (Liu, Luo et al. 2004). A feedback loop is 
formed as E2F1 positively regulates the TopBP1 promoter (Yoshida, Inoue 2004). 
TopBP1 is proposed to be the mitotic chromatin acceptor for HPV 16 E2, the as-
sociation of E2 with chromatin may play a key role in mediating genome segrega-
tion and DNA replication function of the E2 protein (Donaldson, Boner et al. 
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2007). An absence of TopBP1 results in a redistribution of HPV16 E2 into an al-
ternative cellular protein complex, resulting in enhanced affinity for chromatin. 
This does not significantly alter the ability of E2 to either activate of repress 
transcription. TopBP1 may also be the mitotic chromatin receptor for HPV16 E2 
as it was shown to co-localise on chromatin at late stages of mitosis (Donaldson, 
Boner et al. 2007). 
 
Based on this information, E2’s regulation of the human genome may rely on its 
successful interactions with host proteins, such as TopBP1 and Brd4. The array 
results (“array 2”) highlighting the genes regulated by E2 when it is not in com-
plex with Brd4 (E2-Brd4 mutant) show that E2 is now regulating a larger set of 
genes than it did previously when it was interacting with Brd4. This mutant regu-
lated 2814 genes ≥ 1.5 fold, 1885 up-regulated and 929 down-regulated. So the 
other point to note is that the nature of E2’s regulation of the host genome has 
switched, there is now a greater up-regulation of genes.  
A comparison of the top 50 up/down-regulated genes both regulated by E2-WT 
and E2-Brd4 indicated that Brd4 is not involved in the down-regulation of the ma-
jority of the top 50 E2-WT targets. This is an interesting finding as previous re-
ports have suggested that E2 repression of the LCR is Brd4 related (Schweiger, 
Ottinger et al. 2007). We show that down regulation of highly regulated genes by 
E2 is largely independent of Brd4. However, many of the E2-WT genes that are 
up-regulated are not regulated due to failure to bind Brd4. 
Perhaps this suggests these proteins are required in a complex for efficient tran-
scriptional regulation of host genes, and if either of those proteins unable to in-
teract with the complex the quality of E2s transcriptional regulation may be 
compromised or result in a loss of control. The results from Chapter 3 for both of 
these mutants indicate that this occurs, especially for E2-Brd4, which has the most 
compromised transcription activation (Figure 3.4). 
Cellular movement came up as one of the main pathways affected by E2 (in “ar-
ray1”). Some of the genes regulated by E2 involved in cellular movement are 
SH3PXD2B, FGD4, FAP and ARGIDIB. To test how E2 affects cellular migration I 
employed wound healing assays to evaluate whether cells expressing E2 vs non-
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E2 expressing showed any differences in movement. From this work it was clear 
that E2 expressing cells fail to heal wounds like non-E2 expressing cells, despite 
growth rates being similar. Movies following the movement of E2 and non-E2 ex-
pressing cells over a 24 hour time period (can be found in supplementary files in 
publication) clearly showed that E2 expressing cells have defective movement, 
and struggle to migrate. This provides a phenotype to match the pathways regu-
lated in the microarray. 
Morison et al demonstrated that in HeLa cervical cancer cells, E2 expressing 
cells had increased motility. However, this is not a good model to investigate the 
role of E2 in cellular movement as these cells have a background of HPV, and 
this increase in movement cannot be solely contributed to viral E2 alone (Morri-
son, Morreale et al. 2011). In cervical cancer, the HPV genome becomes inte-
grated and results in the loss of E2 expression (Mair, Kubicek et al. 2014)(zur 
Hausen 2009). As discussed in Chapter 1, the loss of E2 results in the increase of 
expression of E6 and E7 as their promoters are no longer repressed by E2; this 
may lead to genomic instability and the transformed phenotype associated with 
cancer. In transformed cells where E2 is no longer expressed, cell movement 
may reflect the non-E2 expressing cells condition in the wound healing assays. 
The faster movement of cells may be more reflective to those in a cancerous 
state. The loss of E2 control on cellular movement could be mediated by the ab-
sence of regulation of gene splicing (as mentioned in publication (Gauson, Win-
dle et al. 2014), or due to altered gene regulation. 
When performing this same experiment with the two E2 mutants,it was found 
that the E2-TopBP1 had a similar defect to E2-WT, but E2-Brd4 expressing cells dis-
played a partial phenotype. This suggests that TopBP1 is not responsible for E2s 
movement defect, and Brd4 is perhaps only partially involved. Other proteins 
that interact with E2 are controlling E2 regulation of genes whose products are 
involved in cellular movement. 
Overall this study suggests that when the E2-TopBP1-Brd4 complex is defective, 
the interaction of the viral E2 protein with the host genome is altered. An inter-
esting follow up to this experiment would be to see the effect of the E2 mutant 
that fails to bind both TopBP1 and Brd4; does this lead to a loss of control of the 
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regulation of host genes? As the viral life cycle is closely linked to the differenti-
ation of host cells, and the regulation of which, is also linked to interactions 
with host proteins, perhaps not binding TopBP1-Brd4 and the non-specific regu-
lation of the host genome may be related to the quality of viral transcription and 
replication of the viral genome or transcriptional control of the host genome. 
HPV18 E2 also regulated similar pathways to HPV16 E2, although there were sim-
ilarities between the two high-risk HPV types there were also differences. IPA 
analysis showed that both of these high-risk HPV types are involved in cellular 
movement, cellular assembly and organisation and cellular development func-
tions. No movement assays were carried out for HPV18 E2, although, it is ex-
pected they would demonstrate a similar phenotype due to the pathways the 
genes are involved in. These findings complement the functional assay results 
gathered in Chapter 3, which also show that these two HPV types have differ-
ences. This highlights the fact that studies between HPV types are not compara-
ble when looking at processes such as replication.  
Genes altered by HPV16 E2 in the U20S cell model were also shared with genes 
regulated in clinical samples of HPV infected cells (found in 3 separate microar-
ray studies). Genes changed in low grade and high grade cervical squamous in-
traepithelial lesions compared to a normal cervix were investigated, as well as 
comparisons of genes changed between high grade cervical squamous intraepi-
thelial lesions, cervical squamous cell carcinomas, and normal cervix. 
20 genes out of 74 from “array 1” were found to be regulated in a similar way to 
at least one of the data sets probed. This suggests that E2 may reprogram the 
host genome during infection and could leave epigenetic marks to continue E2 
regulation of genes, even after E2 expression is lost after integration of the viral 
genome. It could be speculated that some of the changes of E2 gene regulation 
of the host could be epigenetically inherited, and despite E2 being lost in trans-
formed cells, E2’s influence on the genome may still be active. Equally, a sub-
set of the genes that were found to be regulated by E2 in the array may not still 
be regulated upon transformation. Further experiments to determine what hap-
pens epigentically with E2’s regulation of the host genome in patient tumour 
samples is required to elucidate the key changes that are responsible for the 
progression to cancer. Where does E2 locate in host chromatin? Is this different 
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in transformed and non-transformed cells? Is this location on host chromatin 
linked to the interaction with the E2-TopBP1-Brd4 complex? If yes, can we target 
these proteins to make antiviral therapies? 
Chromatin modifications at E2 regulated promoters could be responsible for the 
alterations in gene expression. A better understanding of these chromatin modi-
fications is required in order to reverse the control that E2 has on the cellular 
genome. This is important as we have shown E2 manipulates the host genome 
and this likely contributes to the viral life cycle. Ultimately, reversing the ef-
fects of E2 on the genome may affect HPV transformed cells and we could utilise 
pre-existing therapeutics that target chromatin-modifying enzymes and epige-
netic regulators to reverse the effect of E2. Using resources such as TCGA and 
ENCODE could offer to be useful tools to progress this element of research.  
The U20S model is not the most suitable to answer this question. Future work 
will focus on NTERTs/NOKS and even looking directly at patient samples. The 
preliminary results in the E2 expressing NTERT cells suggest that E2 is regulating 
interferon genes to promote viral infection, and evade immune response. Future 
RNA-seq and ChIP-seq experiments will be carried out in epithelial cells that sta-
bly express E2.
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Chapter 5 – Conclusions and Future Work 
Despite the availability of prophylactic vaccines against HPV16/18/6/11, the 
battle against HPV related cancers is not over (Schiller, Castellsague et al. 
2012).The need to develop novel antiviral therapies still remains. The vaccine 
only protects against the two most prevalent types of HPV and cannot clear pre-
existing HPV infection. It is possible that other high-risk oncogenic HPV types 
may become more prevalent after the introduction of this vaccine. Small mole-
cule inhibitors that block the interaction of the viral replication factors, E1 and 
E2, are not effective across all HPV types due to slight differences between E1-
E2 interactions in different HPV types (White, Titolo et al. 2003). However, the 
interaction between TopBP1 is confirmed in BPV1 E2 which suggests that the in-
teraction is conserved across all PV types, which makes this interaction an excel-
lent candidate for viral therapy (Donaldson, Boner et al. 2007). It is likely that 
the interaction between the viral proteins and that of the host is more con-
served across HPV types. 
From Chapters 3 and 4 we have established that E2 forms a complex with the 
host proteins TopBP1 and Brd4, and this complex is essential for the initiation of 
viral replication, as well as the regulation of the host genome, in both HPV16 
and 18. This complex offers a good target for anti-viral therapies for HPV related 
cancers. However, TopBP1 may prove to be the better pan-type specific target 
as it is required in both HPV16 and 18 viral replication and transcription, 
whereas HPV18 E2 does not require Brd4 for replication function. Perhaps HPV18 
E2 interacts with a different set of proteins for this regulation, and may explain 
why the disease outcome is different between these two high-risk types.  
Inhibiting the interaction between E2 with TopBP1, or disrupting TopBP1 func-
tion, is a promising target for the following reasons: 
1. TopBP1 is essential for optimum E2 mediated DNA replication, and has 
been shown to be required for replication initiation. 
2. TopP1 is a candidate mitotic chromatin receptor for HPV16 E2. 
3. TopBP1 helps E2 regulate the host genome. 
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4. There are known enzymes that target TopBP1 
TopBP1 is both phosphorylated and acetylated by other host proteins, such as; 
Akt and SIRT1. These modifications act as a switch to regulate the many func-
tions of TopBP1, and these modifications can be altered using enzymes that tar-
get TopBP1. Three Akt inhibitors which are in clinical trial include; perifosine 
(KRX-0401, Aeterna Zentaris/Keryx), MK- 2206 (Merck), and GSK-2141795 (Glax-
oSmithKline)(Pal, Reckamp et al. 2010). There are also a number of SIRT1 inhibi-
tors such as; Suramin (Trapp, Meier et al. 2007), Sirtinol (Grozinger, Chao et al. 
2001), Tenovin-1 (Lain, Hollick et al. 2008), Salermide (Lara, Mai et al. 2009), 
and Cambinol (Heltweg, Gatbonton et al. 2006). Here, how TopBP1 and E2 modi-
fications may benefit the viral life cycle and why these inhibitors could be useful 
in future studies will be discussed. 
Lysine acetylation has been found in a diverse range of organisms, from bacteria 
to humans which would suggest that the regulatory functions of acetylation are 
well conserved (Kim, Yang 2011, Soufi, Soares et al. 2012). This would allow the 
virus a mechanism to alter the host regulation of multiple cellular processes. 
Acetylation regulates nucleic acid-protein interactions and also protein-protein 
interactions. Acetylated lysines act as docking sites for proteins that contain 
acetyllysine recognition domains, such as bromodomains  (Zeng, Zhou 2002, 
Zeng, Zhang et al. 2010). Lysine acetylation is regulated by three types of pro-
teins: bromodomain (BRD) proteins (Filippakopoulos, Knapp 2014, Barneda-
Zahonero, Parra 2012), histone acetyltransferases (HATs), histone deacytalses 
(HDACs) and sirtuins (SIRTs) (Dhalluin, Carlson et al. 1999, Seto, Yoshida 2014, 
Chen, Fu et al. 2014, Anand, Brown et al. 2013). These proteins all regulate ly-
sine acetylation in different ways. BRD proteins bind to acetylated lysine and 
therefore act as readers for the state of lysine acetylation. HATs affect lysine 
acetylation acting as writers. Finally, HDACs and SIRTs remove acetyl groups and 
are erasers (Anand, Brown et al. 2013). 
TopBP1 and Treslin cooperate in the loading of Cdc45 onto replication origins 
(Kumagai, Shevchenko et al. 2010, Zegerman, Diffley 2007, Zegerman, Diffley 
2010). Lui et al have shown that the acetylation of TopBP1 regulated by SIRT1 is 
essential for the TopBP1-Treslin interaction and DNA replication (Liu, Lin et al. 
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2014), and propose that this offers to be a mechanism to regulate DNA replica-
tion under normal and stress conditions. TopBP1 is normally acetylated in S 
phase, allowing for TopBP1 to bind to Treslin and in turn initiation of replica-
tion. However, in unfavourable nutrient deprived conditions, the activity of 
SIRT1 is up-regulated (Canto, Auwerx 2009, Cohen, Miller et al. 2004, Escande, 
Chini et al. 2010) and TopBP1 acetylation is decreased, resulting in a decrease of 
TopBP1-Treslin interaction and the activation of metabolic checkpoint. Treslin is 
also a target for S phase Cdk2 or possibly E2(Johansson, Graham et al. 2009). 
Therefore, it is possible that the E2-TopBP1 interaction could also be regulated 
by phosphorylation and acetylation pathways. 
Several proteins are known to be phosphorylated upon entry into S-phase which 
are involved in DNA replication. Proteins are phosphorylated by kinases such as 
Cdk2 and this is essential for replication function (Aleem, Berthet et al. 2004). 
The increase of Cdk2 activity in early S phase is known to promote the loading of 
proteins onto the viral origin of replication such as Cdc45 for the initiation of 
replication. Additionally, phosphorylation of the viral E1 protein by Cdk2 is es-
sential for the initiation of viral replication (Ma, Zou et al. 1999). 
The work of Johansson et al shows that E2 is stabilised in S-phase of the cell cy-
cle and this may be associated with an increase in phosphorylation of E2 protein. 
Phosphorylation of E2 may be essential for optimum viral DNA replication (Jo-
hansson, Graham et al. 2009). In Lorna Macintosh’s thesis work (Figure 28- ac-
cessible though Glasgow Libraries), E2 is shown to have a preferential interac-
tion with TopBP1 in S-phase, phosphorylated E2 and TopBP1 peak in S-phase. 
The E2-TopBP1 mutant does not show this increase in S-phase. The E2 mutant may 
not be a substrate of Cdk2, and hence is not phosphorylated.  
Another kinase which may phosphorylate E2 is Cdc7. Cdc7 is a serine-theronine 
kinase which is essential for the initiation of S-phase. If Cdc7 is inhibited in can-
cer cells it prevents the progression into S-phase, accumulating DNA damage, 
followed by the induction of p53-independent cell death (Yoshizawa-Sugata, Ishii 
et al. 2005, Im, Lee 2008, Kim, Kakusho et al. 2008, Montagnoli, Tenca et al. 
2004). However, if Cdc7 is inhibited in normal cells it does not significantly af-
fect cell viability. Cdc7 inhibitors are non-toxic and causes cell death preferen-
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tially in only cancer cells. Many Cdc7 inhibitors, first were identified by at Nervi-
ano Medical Sciences Srl by high throughput screening using biochemical kinase 
assay (Montagnoli, Valsasina et al. 2008, Vanotti, Amici et al. 2008, Jackson 
2008). Due to their low toxicity, Cdc7 inhibitors may be a good tool to reduce E2 
phosphorylation, and therefore, blocking E2-TopBP1 interaction, without being 
toxic to cells. 
HPV infection has also been linked to increased Akt activity (Pim, Massimi et al. 
2005)(Menges, Baglia et al. 2006). Akt stimulates cell survival signalling path-
ways and inhibits DNA damage checkpoint response (King, Skeen et al. 2004, 
Tonic, Yu et al. 2010, Xu, Hegarat et al. 2010). Akt is a protein kinase which is 
known to phosphorylate TopBP1 at the Ser-1159 residue, which in turn induces 
oligomerisation of TopBP1 through its 7th and 8th BRCT domains. This phosphory-
lation event is crucial for TopBP1 to interact with and repress E2F1(Liu, Paik et 
al. 2006). The repression of E2F1 by TopBP1 is mediated by TopBP1s recruitment 
of the Brg1-Brm chromatin –remodelling complex (Liu, Luo et al. 2004).  Liu et al 
show that oligomerisation effects TopBP1 function in checkpoint activation by 
preventing its recruitment to chromatin and subsequent binding to ATR upon 
replicative stress, as well as, it induces the interaction with E2F1. Therefore, 
they propose that Akt may function as a switch for the function of TopBP1, 
switching between checkpoint activation to transcriptional regulation (Liu, 
Graves et al. 2013). Akt inhibitors inhibit TopBP1 oligomerisation and result in its 
function to switch back to checkpoint activation and no longer promote cell sur-
vival. 
TopBP1 is also a known mediator for the oncogenic gain-of-function activities of 
mutant p53 (mutp53) in cancer (Chowdhury, Lin et al. 2014). A drug capable of 
blocking TopBP1 oligomerisation and p53 binding is Calcein AM. This drug has sig-
nificant anti-tumour activity in a wide range cultured cancer cells harbouring 
high levels of TopBP1 (Chowdhury, Lin et al. 2014). The activity of this drug re-
sults in the re-activation of E2F1-dependent apoptosis and blockade of mutp53 
gain-of-function. Therefore, proving that this drug has potential for targeting 
TopBP1 for cancer therapy (Chowdhury, Lin et al. 2014).  
Brd4 may also be a valuable target for novel antiviral therapies. In the field of 
cancer research, epigenetic deregulation of transcription is now appreciated to 
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be as important for carcinogenesis as genetic mutation. Bromodomain-containing 
proteins are of substantial biological interest, as components of transcription 
factor complexes and determinants of epigenetic memory (Filippakopoulos, 
Knapp 2014, Rosner, Hengstschlager 2012, Simo-Riudalbas, Esteller 2014). The 
bromodomain and extraterminal domain (BET) family of proteins are known to 
play an essential role in regulating transcription by RNA polymerase II (Pol II) 
(Dey, Ellenberg et al. 2000). Bromodomain proteins are chromatin “readers”; 
they recruit chromatin-regulating enzymes, including “writers” and “erasers” of 
histone modification, to target promoters and regulate gene expression (Rosner, 
Hengstschlager 2012). 
Brd4 is recognised as a critical mediator of normal and disease functions through 
its interactions with both cellular and viral factors (Wu, Chiang 2007a), and is 
now known to be a promising target for many cancers (acute myeloid leukemia, 
multiple myeloma, Burkitt’s lymphoma, NUT midline carcinoma, colon cancer) 
because of its fundamental role in transcriptional processes (French, Miyoshi et 
al. 2003, Crawford, Alsarraj et al. 2008, Zuber, Shi et al. 2011, Mertz, Conery et 
al. 2011, Rodriguez, Huidobro et al. 2012). Brd4 promotes transcription by re-
cruiting the transcriptional elongation factor, p-TEFb, to promoters to enhance 
phosphorylation of the C-terminal tail (CTD) of RNA polymerase II promoters, 
and additionally by directly phosphorylating the RNA polymerase II CTD (Wu, 
Chiang 2007a, Devaiah, Lewis et al. 2012). Brd4 is also known to remain bound 
to transcriptional start sites of gene expression during M1/G transition, influenc-
ing mitotic progression (Yang, He et al. 2008, Dey, Nishiyama et al. 2009).  
Hence, Brd4 recruits P-TEFb to mitotic chromosomes resulting in increased ex-
pression of growth promoting genes. Brd4 has also been identified as an essential 
protein for viral transcription in HPV as well as many other viruses (Wu, Chiang 
2007a). Brd4 is an essential transcriptional co-activator for all E2 proteins, and is 
found ubiquitously in all proliferating cells (Houzelstein, Bullock et al. 2002), 
therefore blocking the interaction of the host protein with viral E2 is a viable 
target for HPV related cancers. 
There are currently a number of clinical trials investigating the targeting of BET 
family proteins. These include RVX-208, I-BET 762, OTX 015, CPI-0610 and TEN-
010. Results from the trial of OTX 015 has shown promising results for the treat-
ment hematologic malignancies (Boi, Gaudio et al. 2015, Ito, Umehara et al. 
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2011, Chung, Coste et al. 2011, Zeng, Li et al. 2005). Two groups have reported 
inhibitors of BET bromodomains, JQ1 and I-BET, which have high affinity for all 
bromodomains of the BET family. Both JQ1 and I-BET engage the bromodomain 
pocket in a manner that is competitive with acetylated peptide binding, which in 
turn causes the displacement of all four BET proteins from chromatin in cells 
upon exposure to these compounds (Ceribelli, Kelly et al. 2014). 
Initial studies on cellular model systems of viral infections have demonstrated 
that bromodomain inhibitors have promising efficacy, but more detailed mecha-
nistic studies are needed to understand the complex mechanisms that control vi-
ral replication and regulation of viral latency in vivo. 
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Figure 5.1 
 
 
 
 
Figure 5.1: E2 is phosphorylated by Cdk2 to facilitate an interaction with 
TopBP1 to initiate viral replication. Mutant E2-TopBP1 is not a substrate of Cdk2 
and cannot be phosphorylated. TopBP1 is not able to interact with E2-TopBP1 and 
cannot initiate replication.
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Future directions 
E2 is phosphorylated by Cdk2 to facilitate an interaction with TopBP1 which is 
required for initiation of viral replication (Figure 5.1). The E2-TopBP1 mutant may 
not be a substrate of Cdk2, and the lack of phosphorylation may prevent the 
binding of TopBP1 (Figure 5.1), hence the defect in replication seen in Chapter 
3 (Figure 3.3 and 3.5). The E90V mutation in E2 lies between two possible phos-
phorylation sites (Figure 1.7), which may be responsible for a lack of phosphory-
lation by Cdk2 or Cdc7 kinases, resulting in impaired interaction between E2 and 
TopBP1. As the E2-TopBP1 mutant is not completely null in replication, E2-TopBP1 
may utilise interactions with other host proteins to carry out viral replication, 
although not as efficiently. Results from Chapter 3 (Figure 3.8.1 and 3.8.2) 
clearly show that TopBP1 is required for the initiation of replication and for the 
formation of replication foci. Under normal conditions, HPV activates the ATM-
dependent DNA damage response to induce viral genome amplification upon epi-
thelial differentiation. Gillespie et al have shown that homologous DNA recombi-
nation factors are localised to viral replication foci, and suggest that HPV acti-
vates the ATM pathway to recruit these repair factors to foci to aid in HPV repli-
cation (Gillespie, Mehta et al. 2012). If replication foci fail to form, proteins in-
volved in homologous DNA recombination may not co-localise together to facili-
tate replication. In the absence of replication foci, replication can still occur, 
although, the quality of the replication may be severely compromised. Perhaps 
the mechanism the virus uses to replicate may also change when E2 fails to bind 
to TopBP1.Additonally, the results from the U20S microarray show that when E2 
fails to bind TopBP1, it regulates the expression of an increased number of 
genes. Perhaps, these are interactions that E2 uses to compensate for the roles 
TopBP1 fulfils within the viral life cycle. Future work should focus on making a 
phosphorylation mutant of E2 to test in viral life cycle models.  
It is possible that acetylated TopBP1 may bind to one of Brd4’s bromodomains at 
one side, and to E2 on the other. Brd4 would still free to interact with both the 
host chromatin and transcription factors, perhaps bringing the E2-TopBP1 com-
plex to open sites of chromatin and the promoters of host genes for their regula-
tion. This is a perfect environment for the virus to conduct viral transcription 
and replication as it has everything it needs. TopBP1 may also bind to host chro-
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matin. Previous work suggests that TopBP1 may be the mitotic chromatin accep-
tor for HPV16 E2, and could play a role in mediating genome segregation and 
DNA replication functions of the E2 protein (Donaldson, Boner et al. 2007). 
Perhaps Brd4 and TopBP1 chaperone E2 to the viral origin to initiate replication 
as the result from the ChIP assays in Chapter 3 (Figure 3.6) show that E2 does 
not locate to the origin independently of E1. Alison McBride’s group did a ChIP-
on Chip experiment to investigate where E2 binds to in the host genome, they 
found that E2 did not locate to E2 binding sites, but instead there was an over-
lap between E2 and Brd4 on chromatin (Jang, Kwon et al. 2009a). 
Drugs that target Brd4 and TopBP1 could be used in future studies. There are no 
inhibitors of E2-Brd4 or E2-TopBP1. Inhibiting the function of TopBP1 or Brd4 
with FDA approved drugs could affect viral replication. 
Inhibitors could be offered to vulnerable groups such as, pregnant women, trans-
plant patients, HIV infected individuals, and women in third world countries. The 
treatment could potentially be offered in a similar manner to the treatment pro-
gram currently offered to those with HSV-2 infection, to dampen down the pro-
duction of infectious virus particles. If one of the discussed inhibitors could be 
given at sub-toxic doses it offers to be a potential therapeutic. 
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Supplementary data 
S.1: Vec vs E2-WT (array 1) 
S.2: E2-WT IPA (array 1) 
S.3: Vec vs E2-WT (array 2)  
S.4: E2-WT IPA (array 2) 
S.5: Vec vs E2-Brd4 (array 2)  
S.6: E2-Brd4 IPA (array 2)  
S.7: Vec vs E2-TopBP1 (array 1) 
S.8: E2-TopBP1 IPA (array 1)  
S.9: Vec vs 18E2 (array 2)  
S.10: 18E2 IPA (array 2) 
S.11: NTERT 16E2 (array 3) 
S.12: NTERT 16E2 IPA (array 3) 
S.13: IPA gene function p-values 
All supplementary files can be found on the accompanying disc. 
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